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GREAT EXPECTATIONS: PHOSPH(ON)ATE PRODRUGS IN DRUG
DESIGN—OPPORTUNITIES AND LIMITATIONS
Victoria C. Yan, A.B.
Advisory Professor: Florian L. Muller, Ph.D.

ABSTRACT
Phosphate and phosphonates are chemical moieties with historical precedence in anticancer and
antiviral nucleotide analogues. Synchronous to modern efforts identifying novel therapeutic
targets in cancer, such chemical moieties are being investigated in the design of novel inhibitors
with antineoplastic potential. A central challenge to the delivery of phosph(on)ate-containing
drugs is their anionic character at physiological pH, which portends poor membrane permeability.
This limitation has been successfully overcome through the use of prodrugs. When attached to the
phosph(on)ate moiety, prodrugs mask the negative charge and easily enable cell permeability.
Upon cellular entry, the promoieties are enzymatically or environmentally cleaved to unveil the
active pharmacophore. A secondary and conventionally overlooked function of prodrugs is their
ability to mediate cell- and tissue-specific drug localization. This arises from the intrinsically
different enzymatic expression or environmental conditions specific to certain cell or tissue types.
Here, I explore the challenges associated with phosph(on)ate prodrugs at the synthetic, in vitro,
and in vivo levels first through the lens of a phosphonate-containing enolase inhibitor and then
more broadly to other phosphate prodrugs such as cyclophosphamide, sofosbuvir, and remdesivir.
The findings of this work have resulted in 1.) the development of a novel phosph(on)ate amidation
reaction, 2.) the discovery of a novel promoiety, 3.) the synthesis of novel enolase inhibitor
prodrugs with diverse mechanisms of bioactivation, and 4.) ongoing efforts to advance the parent
nucleoside of remdesivir to the clinic for the treatment of COVID-19. Together, this work
epitomizes the necessity of considering model-specific limitations at the in vitro and in vivo levels
for successful implementation of prodrugs in the clinic.
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CHAPTER 1. INTRODUCTION
Part of this chapter has been published in (permission granted)
Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham
CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R,
Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W,
Marszalek JR, DePinho RA, Muller FL. 2020. An enolase inhibitor for the targeted treatment of ENO1deleted cancers. Nat Metab 2:1413–1426

1.1 Overview of Collateral Lethality and the ENO1/2 Paradigm
The phosphate moiety is prevalent in biology,
serving structural, functional, and regulatory roles
(1). Nucleotides are an example of phosphatecontaining biomolecules that have historically
been of interest for the development of
chemotherapeutic and antiviral agents (2). In
ongoing

precision

oncology

therapeutic

development, one class of phosphate-containing
biomolecules
includes

that

have

metabolic

implicated

in

garnered

intermediates

cancer-specific

attention
that

are

metabolic

aberrations (3). Collateral lethality is an example
of

an

emerging

therapeutic

strategy

that

Figure 1. Collateral lethality paradigm
applied to ENO1/2. Small molecule
targeting of ENO2 is selective for ENO1deleted cancers.

capitalizes on cancer-specific metabolic vulnerabilities conferred by passenger deletion of
metabolic enzymes neighboring tumor suppressor genes (4, 5). A pioneering example of this
paradigm encompasses homozygous deletion of the 1p36 tumor suppressor locus, which accounts
for the collateral deletion of the glycolytic enzyme enolase 1 (ENO1) in cancers such as
glioblastoma multiforme (GBM). Enolase is a cell-essential enzyme that catalyzes the conversion
of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP) in the penultimate step of glycolysis.
Cancers harboring homozygous deletion of ENO1 are exceptionally sensitive to inhibition of its
redundant paralogue, enolase 2 (ENO2) (4, 6). In contrast, normal, ENO1-wildtype (WT) tissue
remain unperturbed, which enables selective toxicity against ENO1-deleted cancer cells with a
sufficient therapeutic window (Figure 1). Independent validation by shRNA (4) and public domain
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CRISPR data evidenced the therapeutic viability of ENO2 inhibition under this paradigm. Though
a non-specific, pan-enolase inhibitor was initially found to demonstrate 50-fold selectivity against
ENO1-deleted glioma cells compared to ENO1-WT cells in vitro (6), non-specific enolase
inhibition is therapeutically prohibited due to on-target inhibition of ENO1 in red blood cells
(RBCs) (7, 8). As ENO1 is the sole isoform expressed in RBCs, pan-enolase inhibition results in
anemia, which is consistent with human Mendelian data. By conducting structure-activityrelationship (SAR) studies, our lab conceived of a phosphonate-containing enolase inhibitor,
termed HEX, that demonstrates 4-fold specificity for ENO2 over ENO1 (Figure 2). As a substratecompetitive enolase inhibitor bearing structural resemblance to 2-PG, HEX is anionic at
physiological pH, which hinders its cell and tissue permeability.

Figure 2. Structures of HEX and previous enolase inhibitor tool compounds.

1.2 Overview of Phosph(on)ate Prodrugs
Prodrugs attached to the phosph(on)ate moiety of drugs primarily serve to enhance membrane
permeability by masking their negative charge and increasing lipophilicity. Due to the polyprotic
nature of phosph(on)ates, two prodrug moieties must be attached to render the molecule net neutral
(9). Historically, there have been two broad classes of phosph(on)ate prodrugs: 1.) bis-esters (10)
and 2.) McGuigan (ProTide) prodrugs (11, 12). Common to these two classes of prodrugs is their
reliance on esterases for bioactivation. Both classes have been successfully applied to FDAapproved antiviral nucleotide analogues such as anti-HIV agent tenofovir disoproxil (Viread®) (13)
and the anti-HCV agent sofosbuvir (Sovaldi®) (14), respectively. A third class of prodrugs that has
been the subject of more recent development efforts can be broadly characterized by the avoidance
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of esterase-mediated bioactivation (15, 16); as a result, a considerable amount of structural
diversity exists within this class. Ongoing development of novel phosph(on)ate prodrugs housed
within this class has made the field privy to the relationship between cell- and tissue-specific
expression of enzymes (in a given pathology) and prodrug structure. In other words, the field is
becoming increasingly aware of the ability for prodrug identity to influence tissue localization of
the active drug (15, 17, 18). A more detailed description of each class of prodrug follows in the
sections below.

1.2.1 Class 1: Bis-ester prodrugs

Figure 3. Examples of various bis-ester prodrugs. Left: adefovir dipivoxil is an example of a
bis-POM prodrug. Middle: tenofovir disoproxil is an example of a bis-POC prodrug. Right: ESB2
is an example of a bis-SATE prodrug of HEX.

Bis-ester phosph(on)ate prodrugs are characterized by the addition of two identical ester groups
onto the phosph(on)ate moiety of the drug. Three common bis-esters commonly employed include
the pivaloyloxymethyl (POM; Farquhar prodrugs), isopropyloxycarbonyloxymethyl (POC), and
the S-acyl-2-thioethyl (SATE) prodrugs (Figure 3) (10, 16, 19). Notably, the synthesis and utility
of the POM ester as a phosph(on)ate prodrug moiety was first reported by David Farquhar, a
former professor at MD Anderson (10, 20). Bis-ester prodrugs are cleaved or bioactivated via
esterases (21). Where the first POM or POC ester is initially cleaved by a class of enzymes known
as carboxylesterases (20), the first SATE ester is the initially cleaved by a class of enzymes known
as thioesterases; the first SATE ester can also be cleaved by carboxylesterases (22). The second
POM, POC, or SATE ester, is cleaved by phosphodiesterases (22). Examples of successful, FDAapproved bis-ester prodrugs include the anti-HIV drug tenofovir disoproxil (Viread®) (13) and the
anti-HBV drug adefovir dipivoxil (Hepsera®) (23), which use POC and POM prodrugs,
respectively. In the case of HEX, our lab initially attempted to immediately resolve the issue of
poor membrane permeability and provide initial in vivo proof-of-concept of the collateral lethality
paradigm by attaching POM esters onto the phosphonate moiety of HEX (Figure 2).
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Bis-ester phosph(on)ate prodrugs were designed for intracellular, bioreversible delivery of
monophosphate nucleotide analogues, which are anionic and poorly cell permeable (10). A major,
well-documented issue with bis-ester prodrugs in vivo is the tendency for one ester moiety to be
prematurely cleaved in the bloodstream prior to crossing the cell membrane due to the presence of
serum esterases (24) capable of removing ester groups on net neutral, but not anionic substrates.
If the subsequently released molecule is a phosphate monoester, it can then be subject to
dephosphorylation by phosphatases or nucleosidase (if the substrate is a nucleotide analogue) (25,
26). However, if the subsequently released molecule is a phosphonate monoester,
dephosphorylation is prohibited due to the inability for hydrolases to cleave C-P bonds. For bisester phosphonate prodrugs, the poorly permeable free phosphonate is often predominant species
that circulates in vivo (27–29). Differential expression of serum esterases across model species
greatly influences the half-life (T1/2) and pharmacokinetic properties of bis-ester phosph(on)ate
prodrugs, which is a persistent challenge for developing this class of prodrugs (29, 30).

1.2.2 Class 2: McGuigan prodrugs
McGuigan (ProTide) prodrugs are characterized by the presence of phenol and L-amino acid ester
groups attached to the phosph(on)ate and were first described by Christopher McGuigan while he
was at the University of Southampton (Figure 4) (31). McGuigan prodrugs are bioactivated
through the following sequence of enzymes: 1.) carboxylesterase 1 (CES1)/cathepsin A (CTSA)
and 2.) histidine triad nucleotide-binding protein 1 (HINT1; Figure 5) (32, 33). In contrast to bisester prodrugs, attachment of McGuigan prodrugs turns the phosphorous atom into a stereocenter
due to the presence of four unique substituents. Bioactivation of McGuigan prodrugs occurs in a

Figure 4. FDA-approved McGuigan prodrugs. Promoieties are indicated in blue. Interestingly,
they are all Gilead compounds.
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stereospecific manner, with the Sp having greater potency than the Rp isomer ((32–36). There are
currently 3 FDA-approved drugs that employ McGuigan prodrugs: the anti-HCV drug sofosbuvir
(Sovaldi®) (14) the second-generation anti-HIV agent, tenofovir alafenamide (Vemlidy ®) (37), and
the anti-SARS-CoV-2 drug remdesivir (Veklury®) (38). Similar to the in vivo outcome of bis-ester
prodrugs, however, the inclusion of an esterase-labile moiety in the McGuigan prodrug results in
premature hydrolysis and formation of the intermediate L-alanyl metabolite (Figure 5) (39–41) in
plasma. Similar to formation of the phosphate mono-ester intermediate for bis-ester prodrugs,
formation of the L-Ala phosphoramidate intermediate in plasma can also result in
dephosphorylation by phosphatases or nucleosidases (if the substrate is a nucleotide analogue;
Figure 5) (40–42). However, formation of the L-Ala phosphonoamidate intermediate in plasma
mainly results in de-amidation rather than dephosphorylation due to the inability for enzymes to
cleave P-C bonds (43, 44). Evidently, the resulting free phosphonate has poor cell permeability.

-

Figure 5. General bioactivation mechanism of McGuigan prodrugs. Promoieties are
indicated in blue. Grey circle indicates a generic pharmacophore.

1.2.3 Class 3: Alternate prodrugs
A broad, emerging class of phosph(on)ate prodrugs
attempts to forgo esterase bioactivation and harness
enzymatic or environmental features unique to a
given pathology. Due to the polyprotic nature of
phosph(on)ates, two prodrug moieties are required
to render the molecule neutral (9). Of the two
promoieties, only one is required to be “directing
group” that enables selective bioactivation of the
drug at the site of pathology. Inevitably, this class

Figure 6. Examples of alternative prodrugs.
Promoieties are indicated in blue. Evofosfamide
is an example of a nitroheterocyclic prodrug.
VCY27 is an example of a cycloSal prodrug.
Brincidofovir is an example of a lipid prodrug

of prodrugs is structurally diverse because the identity of the “directing group” can be tailored to
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enzymatic or environmental distinctions of the pathology (45). One example of a Class 3 prodrug
strategy capitalizes on the tendency for many solid tumors to exhibit hypoxia (46) by attaching a
nitroheterocyclic promoiety to a phosphoramidate nitrogen mustard (Figure 6) (15). It has been
proposed that, in hypoxic environments, a class of enzymes known as nitroreductases are
expressed and capable of facilitating 2-electron reduction of the nitroheterocycle for removal (47).
Another example of a Class 3 prodrug strategy forgoes enzymatic activation altogether and instead
relies on local alkalinity or more broadly, the presence of nucleophiles, for bioactivation. The most
advanced form of these nucleophilicity-activated promoieties uses salicylic alcohol derivatives to
protect the phosph(on)ate and are generally known as cycloSal prodrugs (Figure 6) (48). In general,
Class 3 prodrugs largely remain in preclinical development.

1.3 Overview of Case Study 1: HEX and POMHEX
To realize the potential of the collateral lethality paradigm (4, 5), our laboratory has focused on
developing a small molecule inhibitor of ENO2 for selective targeting of cancers harboring
homozygous deletion of ENO1. There are 3 isoforms of enolase: ENO1, ENO2, and ENO3. ENO3
is found exclusively in striated muscle tissue (49, 50). In all cell types except for muscle, ENO1 is
the predominant isoform of enolase; ENO2 is expressed at about 1-10% the level of ENO1 in most
cell types (Human Protein Atlas: ENO1, ENO2, ENO3). Even though ENO2 is often referred to
as neuronal enolase, ENO1 is still the dominant isoform in the neuroendocrine tissue (51).
Therapeutic targeting of ENO2 in ENO1-deleted cancers is possible because most tissues solely
express ENO1/2: cancers harboring deletions of ENO1 are entirely reliant on ENO2 to catalyze
the penultimate step of glycolysis (4).

Enolase is a glycolytic enzyme that facilitates the conversion of 2-PG to PEP. Much like other
glycolytic intermediates, both 2-PG and PEP are highly polar metabolites; unsurprisingly, the
transition state between 2-PG and PEP are also highly polar. Initial efforts to design a small
molecule inhibitor of enolase centered on the development of an active site transition state
analogue. Mechanistic biochemical experiments conducted in the 1980s showed that a
phosphonate-containing tool compound (phosphoacetohydroxamate; PhAH, Figure 2) acts as a
transition-state analogue that inhibits enolase with nanomolar affinity (52, 53). Because PhAH
does not exhibit sufficient selectivity for ENO2 over ENO1 (6), structure activity relationship
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(SAR) studies were conducted. Achieving selectivity for ENO2 over ENO1 is challenging because
the two isoforms share at least 70% identity, with even greater similarity at the active site (6, 29).
It was hypothesized forming a cyclic version of PhAH would increase specificity for ENO2
because its active site is slightly more spacious compared to that of ENO1. This hypothesis resulted
in the discovery of SF2312, a 5-membered ring natural product, as a noncompetitive inhibitor of
enolase (6). Despite exhibiting low nanomolar affinity for enolase, SF2312 lacked sufficient
specificity for ENO2. Synthesis and in vivo testing of a cell-permeable, bis-POM ester prodrug of
SF2312 resulted in hemolytic anemia in mice due to on-target inhibition of ENO1 in red blood
cells (RBCs), which is the only isoform of enolase expressed in RBCs (6, 29). Pan-enolase
inhibition is thus therapeutically prohibited due to induction of hemolytic anemia (7, 8),
reinforcing the need to identify a core pharmacophore with sufficient specificity for ENO2.

Figure 7. Structures of POMHEX, HemiPOMHEX, and HEX with corresponding bioactivation
mechanism in vivo. HEX is a phosphonate-containing drug that is anionic at physiological pH,
hampering membrane permeability. POMHEX was designed as a membrane permeable bis-ester
prodrug. However, rapid extracellular hydrolysis of the first POM group reveals a negative charge
(HemiPOMHEX), hindering membrane permeability.

Further expanding the backbone resulted in the generation of a cyclic, 6-membered ring version
of PhAH that we termed HEX (Figure 2) (29). HEX is a substrate competitive inhibitor of enolase
that demonstrates approximately 4-fold specificity for ENO2 over ENO1 (Ki=64 nM versus 232
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nM, respectively) (29). Against cancer cells in culture, HEX showed preferential killing of ENO1deleted glioma cells compared to ENO1-WT or isogenic-rescued cell lines at micromolar
concentrations. As a phosphonate-containing inhibitor, HEX is negatively charged at physiological
pH, which impedes its membrane permeability and explains its micromolar-range IC50 against
ENO1-deleted cells in culture despite possessing a nanomolar Ki for ENO2. To improve membrane
permeability, a bis-POM ester prodrug of HEX, termed POMHEX, was generated (Figure 7).
Compared to HEX, POMHEX demonstrated superior potency against ENO1-deleted glioma cells
in culture while maintaining a wide therapeutic window against ENO1-WT or isogenic rescued
cell lines at nanomolar concentrations. Consistent with the robust body of literature demonstrating
the poor stability of bis-ester POM prodrugs in biological fluids (13, 23), POMHEX exhibited poor
stability in mouse and human plasma ex vivo and was undetectable after administration to mice in
vivo. Again, this is due to the presence of plasma esterases (24). As the core pharmacophore (HEX)
contains a phosphonate (rather than a phosphate), premature hydrolysis of the first POM ester on
POMHEX results in the formation of the HemiPOMHEX monoester in plasma without further
ester hydrolysis.

While both HEX and POMHEX have their sets of shortcomings, both were still tested in
xenografted orthotopic tumors harboring deletion of ENO1 in mice to provide immediate in vivo
proof-of-principle of the collateral lethality paradigm (29). Both compounds were capable of
eradicating ENO1-deleted gliomas in vivo; HEX was dosed at 150 mg/kg IV + 100 mg/kg IP for 5
days while POMHEX was dosed at 10 mg/kg IV + 10 mg/kg IP for 5 days. Evidently, poor
membrane permeability of the free phosphonate HEX was sufficiently overcome at high doses.
The highly polar nature of HEX amidst its ability to cause on-target regression of tumors implanted
in the brain (29) strongly suggests that it reaches the brain through the blood-CSF barrier, rather
than the blood-brain-barrier (BBB). Importantly, efficacy was demonstrated even in GBM mouse
xenograft models with an intact BBB; these data are particularly promising, considering that GBM
is typically characterized by a breached BBB. This would concur with the latter’s preference for
lipophilic compounds (29) and the ability for similar, low molecular weight (MW) phosphonate
compounds, such as fosfomycin, to reach the brain through the blood-CSF barrier (54, 55). The
antineoplastic effects of POMHEX at much lower drug concentrations than HEX, despite its poor
PK, can be rationalized by the combinatorial effects of HemiPOMHEX and HEX (released from
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cells) through the blood-CSF barrier. A significant limitation with POMHEX is that rapid
hydrolysis of the first POM ester results in a steep, diminishing concentration gradient of intact
POMHEX and a tandem increasing concentration gradient of HemiPOMHEX away from the
initial site of injection (29). As a result, a high concentration of HemiPOMHEX accumulates in
the heart, which could potentially be quite detrimental. Thus, we seek to identify novel prodrugs
with improved PK properties for optimal, low dose delivery of the active pharmacophore to
gliomas.

1.4 Overview of Case Study 2: Cyclophosphamide
Cl

Cyclophosphamide (Figure 8) is a DNA-alkylating agent of the
nitrogen mustard class. It is a classical chemotherapeutic agent
that was initially approved by the FDA in the 1950s for use

N

against cancers such as malignant lymphomas, among others
(56). It is often used as part of various chemotherapy regimens,

Cl

O H
N
P
O

such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, Figure 8. Structure of
vincristine, prednisone) (57). As a DNA damaging agent, one cyclophosphamide.
Promoiety is indicated in blue.
might expect that cyclophosphamide would be far too toxic to
rapidly proliferating tissues, which oftentimes have higher proliferation indices than many cancers,
to exert any meaningful therapeutic effects on cancerous tissue (45). While it is true that
cyclophosphamide is toxic to many prolific tissues, it is still able to achieve a sufficient—albeit
narrow—therapeutic window to impart its therapeutic effects by capitalizing on differential
expression of aldehyde dehydrogenase (ALDH) between normal and cancer cells (58, 59).

1.5 Overview of Case Study 3: Sofosbuvir
Sofosbuvir (SOF) is a prodrug nucleotide analogue of the McGuigan class (Figure 9) designed for
the treatment of HCV (42). The molecule was developed by Pharmasset, Inc. (later bought by
Gilead Sciences) (34), but the parent nucleoside of SOF was initially developed by Roche (14).
While the active nucleoside triphosphate (NTP) is a somewhat potent inhibitor the NS5B
polymerase, with a Ki of 0.42 ± 0.04 µM (14, 60, 61), the nucleoside of sofosbuvir (RO2433,
uridine analogue) is inefficiently phosphorylated by intracellular nucleoside kinases
(deoxycytidine kinase dCK, uridine kinase UCK, or thymidine kinase TK) to the corresponding
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monophosphate (Figure 6) (61). SOF was thus designed as an orally bioavailable prodrug that
would efficiently deliver the intracellular nucleoside monophosphate analogue to bypass the initial
phosphorylation reaction (34, 60). Interestingly, sofosbuvir was the not the first anti-HCV
nucleotide analogue to utilize the McGuigan prodrug strategy (62). However, it is one of the few
anti-HCV phosphoramidate prodrugs

that reached clinical trials (63, 64) and subsequently

received approval by the FDA (42). As described in Section 1.2.2, McGuigan prodrugs such as
sofosbuvir are bioactivated through CES1/CTSA and HINT1. As a result, sofosbuvir experiences
hydrolysis of its L-Alanine ester promoiety in plasma (42, 65), which eventually results in release
of the essentially inactive nucleoside RO2433. Inactivation of the intact prodrug to the parent
nucleoside RO2433 is offset by the first-pass effect arising from oral administration of sofosbuvir,
which enables high loading of sofosbuvir and its corresponding NTP in the liver. Again, this is
because McGuigan prodrug activating enzymes are highly expressed in the liver (more in Chapter
5). For a liver-specific pathology such as hepatitis, this paradigm is ideal as any remaining release
of RO2433 is essentially innocuous due to its inability to be efficiently converted to the bioactive
NTP in visceral organs.

Figure 9. Bioactivation of SOF. SOF is orally administered and subject to significant hepatic
extraction during first pass metabolism.

1.6 Overview of Case Study 4: GS-441524 and remdesivir
Remdesivir (RDV) is another prodrug nucleotide analogue of the McGuigan class that was initially
designed for the treatment of HCV by Gilead Sciences (66), later investigated for the treatment of
EBOV (67), and now FDA-approved for the treatment of COVID-19 (38, 68). In contrast to the
many pyrimidine analogues that were being investigated as NS5B inhibitors (34), the nucleobase
of RDV (and its corresponding nucleoside core, GS-441524) is a purine (adenine) analogue
(Figure 10). Compared to the sofosbuvir NTP, the RDV NTP (GS-443902) had much lower
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affinity for the NS5B polymerase (Ki ~5 µM (35)) , which could explain its failure to advance as
an anti-HCV drug. The decision to attach McGuigan prodrugs onto GS-441524 was borne out of
a similar rationale as that applied for sofosbuvir: because the sofosbuvir nucleoside (RO2433) was
inefficiently phosphorylated by nucleoside kinases, the McGuigan prodrug approach was pursued.
While no matched biochemical studies with GS-441524 supported the notion of completely
inefficient phosphorylation of the nucleoside, the McGuigan prodrug strategy was nonetheless
pursued to generate RDV.

Figure 10. In vitro versus in vivo metabolism of RDV. (A) The ideal bioactivation of remdesivir
predominately occurs in vitro. (B) The presence of serum enzymes in vivo predominately results
in premature hydrolysis of the phosphate prodrugs, followed by dephosphorylation to the
nucleoside, GS-441524. Other factors, including the influence of hepatic extraction and trapping
of the L-Ala intermediate in RBCs, account for significant differences between in vitro and in
vivo metabolism.

It should be noted that a 2’ methylated ribose derivative of RDV, GS-6620 (32, 69), was actually
the compound that Gilead Sciences elected to advance to clinical trials for HCV (63). In contrast
to RDV, which has only been clinically administered IV, GS-6620 was evaluated as an oral agent
in patients with chronic genotype 1 HCV (63), which is concurrent with liver-specific delivery of
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McGuigan prodrugs. While GS-6620 was well-tolerated in the phase 1 trial when administered as
450 mg BID or 900 mg BID tablets or as a 450 mg solution, a central issue that Gilead encountered
was high PK/PD variability (63, 69). Poor predictability of GS-6620 partly resulted in its
discontinued investigation. It is speculated that a central reason for discontinued investigation of
GS-6620 and similar 2’ methylated ribose compounds was that a similar anti-HCV purine analogue,
BMS-986094 (formerly INX198), was cardiotoxic and resulted in the death of a patient in a phase
2b trial (70–72).
Unlike GS-6620, RDV does not have a 2’ methyl substituted ribose (Figure 10) and was
synthesized as part of the family of compounds as GS-6620 that were initially developed for HCV
(73). After what can essentially be considered clinical failure of GS-6620, initial clinical
experience with RDV was for the treatment of the EBOV (68). Following an interim analysis in a
phase 3 trial, RDV was less effective compared to competing treatments MAb114 and REGN-EB3,
two monoclonal antibodies, which prompted the data safety and monitoring board to recommend
that patients be re-assigned to one of the latter two treatments—ending further development of
RDV for the treatment of EBOV. Having already cleared early-stage clinical trials for EBOV
(NCT02818582), RDV was immediately evaluated for its anti-COVID-19 efficacy in phase 3 trials
beginning in early 2020 (74).

The family of compounds that includes RDV and its parent nucleoside, GS-441524, are broadspectrum, direct-acting antivirals with activity against several RNA viruses (66, 73, 75). Thus,
while RDV and GS-441524 were not specifically designed to inhibit the RNA-dependent RNA
polymerase (RdRp) of SARS-CoV-2, the active triphosphate, GS-443902, has high affinity for the
SARS-CoV-2 RdRp, with a Km of approximately 8.9 nM (76), which happens to be lower than for
the HCV NS5B polymerase (Km ~5 µM) (35, 66) . Since its initial report in 2016 (67, 77), a vast
body of literature on the biochemical and pharmacological properties of RDV have accumulated
on its broad-spectrum antiviral activities in vitro (35, 75, 76, 78–81) and in vivo (39, 40, 82–84).
One outstanding theme prevalent in all in vivo studies on RDV conducted to-date is its remarkably
short T1/2 in both preclinical species (39, 40, 67) and in patients administered RDV IV (41, 85, 86).
This is similar to PK parameters of other esterase-labile phosphate prodrugs of the McGuigan class
(see Section 1.2.2), including GS-6620 (63), GS-9148 (experimental NRTI) (87), and most
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prominently, SOF (42, 88). However, unlike the multiple studies demonstrating the inactivity of
the SOF parent nucleoside, RO2433 (34, 60, 61), studies with the parent nucleoside of RDV, GS441524, showed that it was able to exert broad spectrum antiviral activity across multiple cell lines
(66, 75, 81, 84, 89). These data indicate that, unlike RO2433, GS-441524 can be efficiently
phosphorylated by nucleoside kinases (likely adenosine kinase, ADK). Because McGuigan
prodrugs such as RDV are preferentially activated in the liver (see Section 1.2.2), I have proposed
that GS-441524 would be superior for the treatment of non-liver-centric pathologies such as
COVID-19 (17, 90, 91). Efforts to evaluate the anti-SARS-CoV-2 activity of GS-441524 in vitro
and in vivo are ongoing (18, 92–94). A detailed discussion on the merits of GS-441524 over RDV
in non-liver-specific pathologies is presented in Chapter 5.

1.7 Current approaches towards the synthesis of mixed phosph(on)ate
prodrugs
Note: In this section, I introduce the terms phosphoric acid and phosphonic acid. Both terms refer
to the protonated counterparts of phosphate and phosphonate (Figure 11), respectively. I refer to
the protonated forms when discussing reactions occurring in organic solvents.

The attachment of non-identical, mixed, promoieties
(e.g. Class 2 and 3) onto phosph(on)ates has
traditionally been logistically challenging for three
general reasons: 1.) the reactivity of phosp(on)ates is
less well-characterized compared to their carboxylic
acid counterparts and 2.) classical techniques readily
employed in organic chemistry, such as silica-based

Figure 11. Structures of a phosphate
(left) versus phosphonate (right).
R=aliphatic, aromatic, benzylic

chromatography, are poorly suited to oxyphosphorous compounds such as phosphate- and
especially phosphonate-containing compounds. This is primarily due to the highly polar nature of
the phosphorous-oxygen bond and the high affinity of silicon for oxygen. As a result, attempts to
run phosph(on)ate-containing compounds on silica results in compound streaking and poor
separation; the former is particularly true for phosphonate compounds. Another obstacle related to
the synthesis of mixed promoieties is the need to consider chiral resolution of the phosph(on)ate
product because the phosphorous atom becomes a stereocenter. While stereochemistry at
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phosphorous does not appear to significantly alter bioactivity of some promoieties (95–98), isomer
purification is especially important for McGuigan prodrugs, as it has been repeatedly demonstrated
that hydrolysis by CES1/CTSA is more efficient for the Sp rather than the Rp configuration (14,
32, 34). Below is a brief overview of some considerations that should be kept in mind when
pursuing phosph(on)ate chemistry. This is not an exhaustive an account but rather a portrait of
general themes intended to parse the nuances of phosphate and phosphonate chemistry. A
comprehensive survey of synthetic approaches towards phosph(on)ate prodrugs was written in
2014 by Pradere et al. in Chemical Reviews (16).
The synthesis of mixed phosph(on)ate prodrugs is
also technically challenging and differs from
considerations made when working with their
carboxylic acid counterparts (9, 16). There are 3 main
challenges that must be considered when synthesizing
such promoieties: 1.) hazardous reagents and highly
water-sensitive intermediates, 2.) propensity for
phosph(on)ates to dimerize with traditional coupling
reagents, and 3.) different reactivity profile of the
starting

phosph(on)ate

phosph(on)ate

and

the

intermediate

ester

or

Figure 12. Dimerization of BnHEX
benzylamine during an Sn2 reaction.
BnHEX benzylamine is a benzyl-protected
synthetic intermediate we use in prodrug
synthesis.

phosphonoamidate/phosphoramidate. A key example
of how phosphonic and phosphoric acids differ from their carboxylic acid counterparts is in the
formation of anhydrides. Dimerization readily occurs under typical coupling conditions
(halogenation, peptide-like couplings) for all three chemical moieties. However, unlike anhydrides
formed from carboxylic acids, which are susceptible to aqueous hydrolysis, phosphoanhydrides
formed from phosphonic and phosphoric acids are highly stable in water provided they are anionic.
This is because the negative charge repels incoming nucleophilic attack by water. If the
phosphoanhydride is esterified and thus uncharged, the molecule is more susceptible to aqueous
hydrolysis. This would explain Nature’s use of phosphate dimers in the form of ATP (and di- and
triphosphates) as energy storage molecules. While dimerization of phosphonic and phosphoric
acids is seemingly not discussed in the phosph(on)ate chemistry community, it nonetheless is a
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pervasive issue that underpins most coupling reactions. In our experience, even large CROs have
struggled with overcoming the issue of phosphonate dimerization.

1.7.1 Considerations for phosphate prodrug synthesis
Unlike phosphonate prodrugs, phosphate prodrugs can be (but does not necessarily have to be)
assembled using standardized, convergent synthetic approaches in which the phosphate prodrug
fragment and pharmacophore (usually a nucleoside) are first prepared separately and then coupled
together. Common techniques to couple the prodrug fragment and parent pharmacophore include
P(III)-based phosphoramidite and oxidation (99) and nucleophilic phosphoryl substitution of
phosphoryl chlorides and corresponding alcohols (16). Though commonly employed in the
synthesis of nucleotide prodrug analogues (16, 35, 69, 100), this fragment-based, convergent
synthesis can be applied to a wide variety of structurally diverse parent pharmacophores that
contain a free alcohol for attachment (101–103).

It should be noted that the approaches discussed below (Section 1.7.2) for the synthesis of
phosphonate prodrugs can also be applied to phosphate prodrug synthesis. However, such methods
are not commonly used to generate phosphate prodrugs due to the challenges associated with the
subsequently described methods (16).

1.7.2 Considerations for phosphonate prodrug synthesis
Phosphonate prodrugs cannot be formed using a standardized approach as described for phosphate
prodrugs. This is because, unlike phosphate prodrugs in which the alcohol of the parent
pharmacophore is linked with the phosphate promoiety, the phosphonate promoiety is
characterized by a P-C bond linkage, where the C can be alkyl, benzyl, or aryl. Fragment-based,
convergent syntheses of phosphonate prodrugs are possible under specific circumstances. Two
instances where the phosphonate moiety has been installed onto the parent pharmacophore is in a
synthesis of the acyclic nucleotide analogues, adefovir dipivoxil (ADV) and tenofovir disoproxil
(TDF) (104). Here, convergent synthesis is possible due to the presence of an oxygen atom beta
to the phosphonate, which can be tosylated or mesylated and then linked via Sn2 with the N9 ethyl
alcohol on the nucleobase (104–106). While this convergent synthesis unites the phosphonate
component and the nucleobase portions of ADV or TDF, it is notable that the phosphonate
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fragment is not the fully prepared, final promoiety as observed in the convergent synthesis of
phosphate prodrugs. This is likely because the Sn2 reaction between the ADV or TDF nucleobase
and the tosylated or mesylated phosphonate fragment proceeds under basic conditions, which
contrasts the acidic or mildly alkaline conditions used for O-phosphorylation reactions joining the
phosphate promoiety and the parent pharmacophore (35, 69). In the cases of ADV and TDF, which
are phosphonate ester prodrugs (Class 1 in Section 1.2.1), the bis-ester moieties would likely
hydrolyze under the harsh, alkoxide-catalyzed conditions of the Sn2 reaction (105, 106). Thus, for
the preparation of ADV and TDF, a fragment-based approach can be used to attach the free
phosphonate; however, esterification of the phosphonate is accomplished subsequently (104–106).
Similar concerns of promoiety hydrolysis during the Sn2 reaction are also relevant in the synthesis
of the Class 2 (see Section 1.2.2) relative of TDF, tenofovir alafenamide (TAF). Similar to the
ester moieties on ADV and TDF, the phenol moiety on TAF is alkaline-labile and prevents
assembly of the McGuigan phosphonate promoiety before Sn2 reaction with the nucleobase (106).
Thus, due to the reaction condition incompatibilities—even in cases that are amenable to a
fragment-based approach (ADV, TDF, TAF)—attachment of promoieties onto phosphonates
typically occurs after the phosphonate is installed on the parent molecule. As a result, reactivity of
functional group(s) on the parent molecule must be considered to avoid unwanted cross reactivity
with the activating agent, coupling agent, or nucleophile.

Attachment of commonly used
Farquhar prodrug esters can
proceed via Sn2 displacement
of

the

electrophilic

alkyl

halide esters and the free
phosphonic acid nucleophile,
as in the cases of ADV and
TDF (104–106). However,
attachment

of

non-

halogenated,

nucleophilic

promoieties, such as those
containing

an

alcohol

or

Atherton-Todd reaction (in situ chlorination)
O
R1 P OR2
H

amine or alcohol
CCl4

O
R1 P OR2
NR3R4

O
or R1 P OR2
OR2

Chlorination, then nucleophilic displacement
O
R1 P O
OH

cat. DMF
SOCl2 or (COCl)2

O
amine or alcohol
R1 P Cl
Cl

O
O
R1 P NR3R4 or R1 P OR2
OR2
NR3R4
+ Dimer

Peptide-like couplings
O
R1 P O
OH

amine or alcohol
EDC (or DCC)

R1

O
P O
NR3R4

or

O
R1 P OR2
OR2

+ Dimer

Figure 13. Common synthetic approaches towards
phosph(on)ate prodrug synthesis. The Atherton-Todd reaction
may also form a dimer, but I have no personal experience with this
and have not encountered reports in the literature on this. R 1, R2,
R4=O, aliphatic, benzylic, aromatic. R3=aliphatic, H
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amine, requires activation of the phosphonic acid to increase its electrophilicity and enable
nucleophilic phosphoryl substitution reactions or variants thereof (Figure 13). Activation of the
phosphonic acid and nucleophilic displacement can occur by either stepwise or concerted
mechanisms.

Stepwise syntheses involve halogenation (typically chlorination) of the phosphonic acid. The
resulting phosphoryl halide, though highly susceptible to hydrolysis in the presence of trace
amounts of water, can be isolated. Commonly used reagents pairs to activate the phosphonic acid
include thionyl chloride (SOCl2)/catalytic dimethyl formamide (DMF), oxalyl chloride
(COCl)2/catalytic DMF, and phosphorus oxychloride (POCl3); such reagents are commonly used
in the synthesis of acyl chlorides from carboxylic acids. However, unlike carboxylic acids, which
only have one free -OH that can be halogenated, phosphonic (and phosphoric) acids have two free
-OHs. While a dichlorinated phosphonic acid is amenable to reaction with nucleophilic
promoieties to form the corresponding bis-ester prodrug, it is more difficult to generate mixed
phosphonate prodrugs (Class 2 and Class 3 prodrugs as described in Section 1.2.2 and Section
1.2.3) under such conditions. Nevertheless, mixed phosphonate prodrugs have been generated
using this approach with highly variable yields (~25-60%) (107–109). In addition to experimental
variability (e.g. degree of dryness of reagents and glassware), different reactivity profiles between
the dichloride and mono-adduct could partly explain inconsistency in yields—especially when the
mixed phosphonate prodrug contains both a P-O and P-N bond. As I will explain in greater depth
in Chapter 2, phosphonate monoesters and phosphonoamidates exhibit different reactivity profiles.
One seemingly uncommon approach to exert better control over formation of the final mixed
phosphonate is by forming the monochlorinated product first and adding the first promoiety, then
using a second reaction to add the next promoiety (Figure 10). Monochlorination of phosphonic
acids can be accomplished using POCl3, rather than SOCl2 or (COCl)2 with catalytic DMF (110);
nonetheless reactions must be carefully monitored to avoid forming the dichlorinated product.

Concerted syntheses involve the use of coupling reagents in addition to the nucleophilic
promoieties. In contrast to stepwise syntheses, in which the activated phosphonic acid can be
isolated and the nucleophiles can be added sequentially, the activated phosphonic acid is often too
unstable and transient to be isolated. Coupling reagents include those commonly used in peptide

17

synthesis:

N,

N′-dicyclohexylcarbodiimide

(DCC)

and

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide (EDC) (16). Another less commonly used concerted addition
is the coupling of nucleophiles under Mitsunobu conditions (triphenyl phosphine, PPh 3; and an
azo reagent such as diisopropyl azodicarboxylate, DIAD). Reactions using DCC or Mitsunobu
conditions have typically been used with alcohol nucleophiles to generate the corresponding
mono- or di-ester (16) while reactions using EDC conditions have typically been used with amine
nucleophiles to generate the corresponding monoamidate (111). While concerted syntheses are
generally attractive for their use of less hazardous, milder conditions, a challenge associated with
the aforementioned coupling conditions is the propensity for phosphonic acids to dimerize (112)
more frequently than observed in stepwise syntheses (described in greater detail in Chapter 2), as
it can act both as the nucleophile and the electrophile.

Another complicating factor for phosph(on)ate prodrugs that is exacerbated during the synthesis
of phosphonate prodrugs of the McGuigan class is that chirality at phosphorous influences the
efficiency of enzymatic removal by CTSA and CES1, with the Sp configuration often exhibiting
slightly greater potency against the target cell population in vitro (32, 33, 35, 100). Unlike
phosphate McGuigan prodrugs, in which a fragment approach can be taken to generate the
McGuigan fragment with the desired stereochemistry, such an approach cannot be readily applied
to phosphonate McGuigan prodrugs for reasons described earlier. Chiral resolution of the desired
stereoisomer is typically achieved after the racemic phosphonate-containing parent compound is
generated (Figure 13) (113). This is not ideal, as the undesired stereoisomer formed cannot be
recycled and is essentially a dead-end product. Efforts to optimize the diastereomeric excess (d.e.)
or select for the desired diastereomer include selective recrystallization, altering the salt form,
altering reaction parameters (113), introducing catalysts (114), and chromatographic techniques
(115, 116). There are comparatively few examples of phosphonate McGuigan prodrugs, with the
best described example TAF. Currently, the Sp isomer of TAF is obtained via simulated moving
bed chromatography followed by recrystallization (115).

Overall, there are several challenges associated with phosph(on)ate prodrug synthesis. In general,
difficulties encountered during phosphate prodrug synthesis are exacerbated in phosphonate
prodrug synthesis, which is largely because the latter is oftentimes not amenable to convergent
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synthesis. Differences in reactivity between the starting phosphoric or phosphonic acid and the
initial prodrug adduct, introducing chirality at phosphorous, the use of hazardous reagents, and the
propensity for phosph(on)ates to dimerize are obstacles that differentiate phosphoric and
phosphonic acids from their carboxylic acid counterparts.

1.8 Conclusions and Foreword
Currently, prodrugs comprise less than 20% of all FDA-approved drugs (9). Within this subset,
six drugs are phosph(on)ate prodrugs that are specifically designed to improve cellular
permeability, as opposed to simply improving the water solubility of a hydrophobic drug. Among
the six FDA-approved phosph(on)ate prodrugs designed for enhanced intracellular delivery, two
are Class 1 prodrugs (Section 1.2.1; ADV, TDF), 3 are Class 2 prodrugs (Section 1.2.2; SOF, TAF,
RDV), and one is a Class 3 prodrug (Section 1.2.3; cyclophosphamide). With the exception of
cyclophosphamide, all FDA-phosph(on)ate prodrugs intended for improved intracellular delivery
are direct-acting antivirals. Despite comprising a small fraction of all FDA-approved drugs,
phosph(on)ate prodrug development is a promising area of development for two reasons: 1.)
phosph(on)ate prodrugs have historically been quite effective either alone or in combination with
other drugs and 2.) with the popularity of metabolomics in cancer metabolism research, one could
therapeutically actionize on cancer-specific metabolic aberrations by designing competitive
inhibitors (or activators) of phosphorylated metabolites. Due to the tunability of the two
promoieties phosph(on)ate prodrugs are highly amenable to cell- and tissue-specific drug delivery
and could thus serve as a valuable mechanism to realize the aims of precision medicine. Thus far,
only two phosph(on)ate prodrug strategies have been heavily explored: Farquhar prodrugs (Class
1, Section 1.2.1) and McGuigan prodrugs (Class 2, Section 1.2.2). The latter strategy has been
applied liberally in pre-clinical research and seemingly without careful consideration of the
relationship between promoiety identity and cell- and tissue-specific bioactivation and while
perhaps not acknowledging some key limitations associated with in vitro assays and PK/PD
evaluations in model species.

Here, I consider the successes, shortcomings, and opportunities of phosph(on)ate prodrug
development against the backdrop of the prodrug structure-bioactivation paradigm. The breadth of
this body of work was inspired by lessons that I have learned from my own work on generating
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novel prodrugs of our laboratory’s enolase inhibitor, HEX, and in recognition that the GS441524/remdesivir paradigm—sprung onto the world’s center stage by COVID-19—is
emblematic of the core challenges associated with phosph(on)ate prodrug development. Through
the 5 case studies I present herein, I attempt to answer the question “what makes a phosph(on)ate
prodrug successful in the clinic?” while identifying shortcomings related to phosph(on)ate prodrug
synthesis and overreliance on certain preclinical models to project clinical success. The lessons
crystalized in this discussion can provide guidance for designing more precise phosph(on)ate
prodrugs that have better localization to the tissue and cell type of interest of a given pathology.

20

CHAPTER 2. DISCOVERY OF A NOVEL REACTION FOR EXPEDIENT
MONO-AMIDATION OF PHOSPH(ON)ATES
This chapter has been published in (permission granted)
Yan VC, Pham C-D, Muller FL. 2020. Expedient Method for Direct Mono-amidation of
Phosphonic and Phosphoric Acids. ChemRxiv https://doi.org/10.26434/chemrxiv.12073131.V1.

2.1 Abstract

Phosphoramidate or phosphonoamidatecontaining prodrugs contribute to the
vastly

delivery

of

phosphate

and

phosphonate-containing anti-viral/cancer
nucleotide analogues (16, 117, 118).
However, synthetic approaches towards
their

formation

are

often

harsh,

unreliable, or generate water-soluble
byproducts that can be difficult to
separate

from

the

anionic

phosphoramidate or phosphonoamidate
product
difficulties

(111).
could

These

technical

impede

the

identification of novel, more effective
amine prodrugs. In this chapter, I show

Scheme 1. Strategies for mono-amidation of
phosphates and phosphonates

that direct mono-amidation of structurally complex phosphonic and phosphoric acids may be
accomplished in as quickly as seconds under modified Mitsunobu conditions. Unlike traditional
Mitsunobu couplings, where the triphenylphosphine oxide (TPPO) byproduct is often cited as a
vulnerability (119), I use its formation as an asset. Juxtaposing the anionic nature of the generated
mono-amidated product with the hydrophobicity of the oxide, the desired product may be isolated
with a single water extraction. Compared to state-of-the-art strategies towards phosphoramidates
and phosphonoamidates (16), this approach is mild, reliable, and enables access to a variety of
aliphatic and benzylic amines for prodrug attachment.
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2.2 Introduction
Phosphoramidates and phosphonoamidates are characterized by a single P(V)-N bond and are
chemical moieties with high therapeutic relevance (120, 121). From TAF (44), to SOF (42), to
RDV (38) phosphoramidates permeate the antiviral prodrug landscape. Yet for all their importance
in improving the delivery of phosph(on)ate drugs, current mono-amidation strategies are subverted
by their harsh reaction conditions, challenging purifications, and inconsistent yields (16) (Scheme
1). Two examples of common mono-amidation approaches include stepwise chlorination and
concerted peptide-like couplings (Section 1.2.7). The former method not only requires the use of
hazardous reagents, but also demands great precaution for handling the resulting phosphoryl
dichloride, which is highly susceptible to hydrolysis. A similar variation on direct monochlorination is Atherton-Todd reaction (122), wherein reaction of dialkyl phosphite in CCl4
produces a highly reactive mono-chlorinated intermediate that may be reacted with amines to
generate the phosphoramidate. In addition to the hazardous solvent requirements, the AthertonTodd conditions must be applied onto dialkyl phosphites (H-phosphonates) and cannot be applied
directly onto phosphates or phosphonates. Finally, another set of methods include peptide
couplings, which are challenged by the propensity for phosph(on)ates to dimerize, requiring vast
excesses of amine and coupling reagent and/or dilute conditions to obtain the mono-amidated
product (16, 123). Here, I show that direct mono-amidation of phosphonic or phosphoric acids
may be accomplished using modified Mitsunobu conditions to quickly generate structurally
diverse phosphonoamidates and phosphoramidates. In contrast to conventional Mitsunobu
couplings, we use the resulting hydrophobicity of the TPPO byproduct as an asset, rather than a
historically perceived vulnerability (124), enabling isolation of the anionic mono-amidate with a
single water extraction. The mild and expedient nature of our reaction conditions enables simple
attachment of various benzylic and aliphatic amines for exploration into their prodrug activity (98).

2.3 Results and Discussion
I first discovered the reaction while synthesizing mixed phosphonoamidate prodrugs of our
laboratory’s phosphonate-containing enolase inhibitor, HEX (29). A benzyl-protected precursor,
BnHEX, was reacted with benzylamine, PPh3, and DIAD in CH2Cl2 (Figure 14a, entry 1). After
1 hour, the desired phosphoramidate was obtained in moderate yields (~50%). While I was initially
pleased that I was able to generate the desired phosphoramidates under such expedient conditions,

22

I found that this often resulted in a notable amount of phosphonate dimer, as noted by a doublet at
~10 ppm by 31P NMR spectroscopy. Unsatisfied with this inadvertent dimerization, I decided to
first form the betaine (125) by combining PPh3 (2 equiv.) and DIAD (2 equiv.) in CH2Cl2 at 0°C
for 30 minutes. Thereafter, we prepared a solution of BnHEX (1 equiv.), and amine (2 equiv.) in
CH2Cl2, which was then added dropwise to the betaine solution. After 30 minutes of reaction, we
found that the desired mono-adduct was efficiently formed (~50-70% yield, Figure 14a) as
indicated by a singlet at ~18 ppm by

31P

NMR spectroscopy, with minimal phosphonate

dimerization (~10 ppm). These initial results show preferential reaction with benzylic amines, with
the most effective reaction being with 2-picolylamine (Table 1, Figure 14, entry 2).

Having established the general reaction parameters for phosphonic acids, I sought to examine the
reaction efficiency when using phosphoric acids. Using 1-naphtyl phosphate as a test compound,
we screened a variety of aromatic and aliphatic amines (Table 2, Figure 14b, entries 1-11).
Compared to our reactions with BnHEX, we found that pre-formation of the betaine solution was
not necessary to prevent phosphate dimerization. Sequential addition of the phosphoric acid (1
equiv.), amine (1.5 equiv.), PPh3 (1 equiv.), and DIAD (1 equiv.) in NMP at room temperature was
all that was required for the desired phosphoramidate to be generated instantaneously (Figure 12).
These optimized conditions are notably lower than that required for efficient mono-amidation of
phosphonic acids (1 equiv. of acid to 2 equiv. of all other starting reagents). This can likely be
attributed to the significantly faster rate of the reactions with phosphoric acids (Figure 12),
compared to phosphonic acids. Given the expedience of the reaction with phosphoric acids, we
then sought to test the limits of our reaction’s exclusivity for phosphates by reacting amines
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Table 1. Test reactions between BnHEX and 2-picolylamine. All reactions were performed
with 5 mg BnHEX in 500 μL solvent. Yields were calculated via

31

P NMR spectroscopic
†

analysis of the crude reaction mixture, using TPPO as an internal standard. Products were not
detected by LCMS or the reaction resulted in phosphonate dimer formation, as indicated by a
31

P NMR chemical shift at ~10 ppm in 20% CDCl3.

directly with fludarabine monophosphate (dihydrogen, Figure 14b, entries 12-15). Fludarabine
monophosphate is a highly functionalized mononucleotide analogue of adenine with an acidic N1nitrogen (pKa ~4.2) and C6-amine (pKa ~9.8); its ribose sugar also contains two potentially
reactive secondary alcohols. Yet even with these structural vulnerabilities, which often demand
protecting groups (126), coupling with an amine solely occurred with the phosphate (Figures 13,
14).
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Table 2. Test reactions between 1-naphthyl phosphate and benzylamine. All reactions were
31

performed with 5 mg 1-naphthyl phosphate in 500 μL solvent. Yields were calculated via P NMR
spectroscopic analysis of the crude reaction mixture, using triphenylphosphine oxide as an internal
†

standard. Reactants were insoluble.

Between my reactions with phosphonic acid BnHEX and phosphoric acids, I found that
structurally diverse amines were much more amenable to being attached onto the latter. In an
attempt to increase the efficacy of our reactions with phosphonic acids, we screened various base
additives (Table 1). Coincidentally, I discovered that the strong, non-nucleophilic base 1,8diazabicyclo[5.4.0]undec-7-ene (DBU) is capable of greatly improving coupling efficiencies
between phosphonic acids and amines. Returning to our reaction setup for BnHEX, we added the
(DBU, 2 equiv.) to our solution containing BnHEX and amine, which was then added dropwise to
the betaine solution. Indeed, we found that this allowed attachment of previously inaccessible
aliphatic amines to BnHEX at remarkable yields (Figure 11a, entry 1). It is
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Figure 14. Reaction scope with phosphonic and phosphoric acids. Yields were calculated via 31P
NMR spectroscopic analysis of the crude reaction mixture, using formation of TPPO as an internal
standard. (A) Reaction scope between a model phosphonic acid (BnHEX) and various amines. Yield
(1) was obtained without the addition of DBU, while yield (2) was obtained with the addition of 2
equiv. of DBU. (B) Reaction scope between model phosphoric and amines Top: 1-naphtyl phosphate;
yield (1) was obtained without the addition of DBU in NMP while yield (2) was obtained with the
addition of 0.75 equivalents of DBU in CH2Cl2. Bottom: Fludarabine monophosphate reactions in
NMP. *Asterisked yields indicate the addition of 1.5 equiv. Et3N to neutralize the HCl salt. Fludarabine
monophosphate was insoluble in the CH2Cl2 even with the addition of 0.75-5 equiv. of DBU. (C)
Examples of other therapeutically relevant molecules are selectively amidated at P(V).
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reasonable to conclude that the addition of
DBU to any of the amine couplings described
will greatly improve reaction yields.
Seeking to test the limits of our reaction even
further, I applied these coupling conditions to
other therapeutically relevant molecules such
as adefovir phosphonate and tenofovir
phosphonate. From reactions with BnHEX, it
had become apparent that phosphonic acids
were poorly suited to coupling with amines
in highly polar solvents such as NMP and
DMF (Table 1), preferring non-polar solvent
such as CH2Cl2 and CHCl3. Indeed, pilot
reactions in NMP with these phosphonic
acids and the most amenable amine, 2picolylamine, proved unfruitful. However,
with the discovery that DBU can facilitate
the couplings between BnHEX and aliphatic
amines, I proceeded to conduct with our
reactions with adefovir phosphonate and
tenofovir phosphonate using the same
procedure as we had done for BnHEX. To

Figure 15. Mono-amidation of phosphoric acids
31

occurs instantaneously. P NMR spectroscopy
scans were taken at 121 MHz in 80% NMP, 20%
CDCl3. (A) 1-naphthyl phosphate, (B) 1-naphthyl
phosphate + PPh3, (C) 1-naphthyl phosphate +
PPh3 + BnNH2. Mitsunobu coupling between 1naphthyl phosphate and benzylamine was
monitored over 60 minutes. Chemical shifts are as
follows (left to right, ppm): TPPO, +24.6;
phosphoramidate product, +1.3; PPh3, -6.8; 1naphthyl phosphate, -6.9.

our surprise, the addition of 2 equivalents of
DBU was able to dissolve these phosphonic acids in CH 2Cl2 and CHCl3 and the coupling product
with 2-picolylamine occurred in moderate yields (Figure 14c). Extending this logic, we then
decided to test whether HEX could be coupled using the DBU/CH2Cl2 procedure. Much like
adefovir phosphonate and tenofovir phosphonate, HEX was only soluble in highly polar organic
solvents, precluding mono-amidation prior to discovering the effects of DBU. Indeed, we found
that even HEX with its reactive hydroxamic acid could be effectively coupled with 2-picolylamine
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with the addition of 2 equivalents
of DBU (Figure 16c) in CH2Cl2.
The stark contrast in reactivity for
this panel of phosphonic acids
under these modified conditions
supports the finding that this type
of amidation with phosphonic
acids must occur in non-polar
solvents for optimal efficiency. To
test the unlikely possibility that
DBU, rather than solvent choice,
was the predominant reason for
the reaction’s improved efficacy,
we also performed the coupling
between

BnHEX

and

2-

picolylamine using 2 equivalents
of DBU in NMP. After forming
the betaine and reacting with the
BnHEX/2-picolylamine/DBU
mixture for 40 minutes, the acid
and amine remained unreacted.
These data further highlight the
necessity for phosphonic acidamine couplings to occur in nonFigure 16. Reaction between benzylamine and fludarabine
monophosphate occurs exclusively with the phosphate.
31
Top: Reaction monitoring by
P NMR. A=PPh3,
B=fludarabine phosphate, C=fludarabine phosphate + PPh3,
D=fludarabine phosphate +PPh3 + BnNH2. Bottom: reaction
monitoring by UPLC-MS; ELSD is at indicated timepoints.

polar solvents.

Prompted by the finding that the
dissolution of and reaction with
phosphonic acids in non-polar

solvents can be facilitated by addition of DBU, I sought to examine whether similar observations
could be made for phosphonic acids. Based on conventional
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Figure 17. 1H-31P HSQC supports that coupling between fludarabine phosphate and
benzylamine occurs at phosphate. O2P=8, gpz2=32.4, cnst2=20, sw=8. Resonances correspond to
protons that are, at most, J3 to the phosphorous.

Mitsunobu couplings, we anticipated that the mono- and dibasic phosphates would not readily
couple under these conditions, as an acidic proton is necessary for protonation of the betaine in the
opening steps of the reaction mechanism (127). Indeed, I found that, even with the addition of
DBU (0.75-2 equivalents), mono- and dibasic phosphates were essentially insoluble in CH2Cl2 and
CHCl3. However, for fully protonated phosphoric acids, such as 1-naphthyl phosphate (dihydrogen,
Figure 17b), 0.75 equivalents of DBU was the minimum amount required for dissolution in either
CH2Cl2 or CHCl3 after light vortexing. Overall, reaction with various benzylic and aliphatic amines
proved more effective in these non-polar solvents compared to those performed in NMP without
DBU (Figure 17b, yield 1 versus yield 2). This suggests that, even for phosphoric acids, monoamidation likely occurs more readily in non-polar solvents compared to highly polar ones. We note
that 1-naphtyl phosphate served as a very user-friendly compound to make these observations as
it was capable of dissolving in the aforementioned solvent systems. In contrast, fludarabine
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monophosphate was essentially insoluble in
DBU/CH2Cl2. Here, comparison of reaction
efficiencies in different solvent systems was
not possible. Thus, to ensure that these
solvent-specific effects were not unique to 1naphtyl phosphate, we also coupled phenyl
dihydrogen phosphate with benzylamine in
either NMP or DBU/CH2Cl2. Consistent with
our observations with 1-naphthyl phosphate,
we found that reaction efficiency was
improved in the latter, non-polar solvent
system (Figure 17c).
Irrespective of whether coupling occurred
with a phosphonic or phosphoric acid,
removal of the TPPO byproduct and isolation
of the mono-amidate could be obtained with
a single water extraction by capitalizing on
the contrasting hydrophobicities of TPPO and
the

anionic

product

(Figure

18).

Figure 18. Mono-amidates can be isolated
with a single water extraction. Top: 31P NMR
spectrum of the crude reaction (CDCl3) and of
the isolated phosphoramidate after 1 water
extraction (D2O). Bottom: 1H-31P HSQC of the
extract.

Phosphoramidates and phosphonoamidates are typically synthetic intermediates towards the
synthesis of prodrug moieties (47, 98, 117) and thus require further esterification (or amidation,
etc.) before becoming cell-permeable, therapeutically relevant entities. Due to the slight excess of
amine added in these reactions, some amine contaminant may carry over, depending on its
hydrophilicity. However, this has not problematic in subsequent reactions (98). This simple
isolation approach starkly contrasts that required for conventionally used reactions (Scheme 1),
which generate hydrophilic byproducts that can interfere with subsequent reactions. Using this
workflow, various benzylic and aliphatic amines can be easily attached on to phosphate- or
phosphonate-containing drugs for rapid screening of novel amine prodrug moieties (98). To
emphasize the magnitude with which this workflow eases the pipeline from synthesis to cell-based
screening: we are now able to generate over 20 mono-amidate prodrugs of HEX in two weeks (98)

30

rather than taking at least two weeks of reaction optimization for a single amine using other
approaches (Scheme 1a-c), underscoring the highly consistent and versatile nature of our monoamidation method (98).

Finally, I sought to gain some mechanistic insight into our reaction. While the PPh 3/DIAD redox
pair is synonymous with Mitsunobu couplings, examination of the classical Mitsunobu reaction
mechanism (127) proves to be incompatible with our transformation. In canonical Mitsunobu
couplings with alcohols, oxidation of PPh3 to TPPO occurs due to formation of the alcohol-PPh3
complex, followed by an Sn2 attack on the alcoholic carbon—resulting in the oxygen transfer from
the alcohol to the phosphine to form the oxide (127). In this case, there is no such alcohol oxygen
to perform this transfer to generate TPPO. We thus propose an amidation mechanism wherein the
phosphonic or phosphoric acid acts as the pro-electrophile, rather than its traditional role as the
pro-nucleophile (Figure 19a). Within our model, oxidation of the phosphine occurs through
oxygen transfer from the phosphoric or phosphonic acid, as no other likely oxygen donors are
present amongst the starting reagents. To gain insight into our proposed reaction mechanism, I
prepared bis-18O-labeled 1-naphthyl phosphate, which was then HPLC-purified to remove any
residual H218O. The labeled phosphate was then reacted it with (R)-(-)-α-methylbenzylamine
(Figure 19b). Compared to the unlabeled control reaction, we found a significantly greater
proportion of

18O-labeled

TPPO (Figure 19c, M+1 = 281.29 expected, 281.27 found), which

coincided with the majority of the mono-18O-labeled phosphoramidate product (Figure 19c, M+1
= 330.32 expected, 330.34 found). We do note the strong 279.26 mass peak, corresponding to
unlabeled TPPO. This reaction was performed with 2 equivalents of amine, PPh 3, and DIAD; the
dominant unlabeled mass peak can most likely be explained by the propensity for PPh3 and DIAD
to oxidize to the corresponding TPPO even in the absence of other starting reagents. Nonetheless,
the height of the peak corresponding to the 18O-labeled TPPO peak at 281.27 vastly overshadows
that observed in the unlabeled reaction (Figure 19c). These observations strongly support our
proposed mechanism of oxygen transfer to the phosphine, thereby strengthening the role of the
phosphoric or phosphonic acid as the pro-electrophile in our mono-amidation reactions.
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Figure 19. Proposed mechanism where phosphoric or phosphonic acids act as proelectrophiles. (A) Proposed reaction mechanism with a generic amine and 18O-labeled
phosph(on)ate. (B). Labeled reaction with possible reaction product masses. (C) Mass spectrometry
chromatograms of the labeled (top) and unlabeled reaction products (bottom). The peak for 18Olabeled TPPO is significantly higher in the labeled compared to unlabeled reaction. The unlabeled
residual is from unreacted 1-naphtyl phosphate in the initial isotope labeling experiment.

2.4 Conclusions
In sum, I have discovered a novel mono-amidation reaction that modifies traditional Mitsunobu
conditions but differs in employing the acid as the pro-electrophile, rather than pro-nucleophile.
This reaction enables expedient, direct mono-amidation of highly functionalized phosphate- or
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phosphonate-containing species. In contrast to other coupling procedures (16), this modification
on the Mitsunobu coupling is fast, reliable, and occurs under exceptionally mild conditions.
Fundamentally, this reaction turns the formation of TPPO—a historically perceived inconvenience
(124)—into an asset: one water extraction is all that is required for its removal and to obtain the
mono-amidated product at sufficient purity to proceed with the next reaction. That our reaction is
exquisitely selective for phosphates or phosphonates enables direct reaction onto highly
functionalized nucleotide analogues for prodrugging efforts. Given the interest in discovering
novel phosphoramidate-based prodrugs (117), this reaction is well-suited to rapidly screening a
number of biologically labile amines. Taken together, our reaction not only expands the reaction
scope of the traditional Mitsunobu coupling (119) but also represents a significant addition to the
phosph(on)ate chemist’s toolkit.

2.5 Experimental
1H, 13C, 31P,

and 19F NMR spectra were recorded on a Bruker Avance 300 MHz spectrometer in

either CDCl3 or D2O, unless otherwise indicated. Chemical shifts were measured in ppm relative
to CDCl3 (δ=7.24 for 1H and δ=77.0 for 13C) or D2O (δ=4.80 for 1H). NMR characterizations are
reported in the following order: chemical shift, multiplicity (s = singlet, bs = broad singlet, d =
doublet, t = triplet, q = quartet, m = multiplet), and coupling constant (J, reported in Hertz). Where
appropriate, 2-dimensional experiments (HSQC) and decoupled NMR experiments ( 1H with 31P
decoupling) were used to support assignments. BnHEX was initially synthesized according to
previously published procedures1; subsequent syntheses were contracted to WuXi AppTec,
Shanghai, China. Fludarabine Monophosphate was purchased from Selleckchem. Other starting
materials were purchased at the highest commercial quality from Sigma Aldrich and were used
without additional purification. Centrifugations were performed using an Eppendorf Centrifuge
5810R. Mass spectra were obtained on a Waters Acquity UPLC H-Class PLUS System (A/B: A =
30% MeCN in water, B = 0.1% formic acid in water) using an electrospray ion source.

Synthesis of phosphoramidates from BnHEX. All coupling reactions described for BnHEX (1)
follow the same general procedure. Betaine formation: DIAD (2 equiv.) and triphenyl phosphine
(2 equiv.) were combined in anhydrous DCM at 0°C and allowed to stir to room temperature for
30 minutes. Separately, BnHEX (1 equiv.), and the indicated amine (2 equiv.) were dissolved in
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anhydrous DCM; in cases such as aliphatic amines where DBU was required, 2 equiv. of DBU
were added to this solution (specified if needed below). This was then added dropwise to the
betaine solution. The reaction was allowed to stir for 30 minutes. The crude reaction mixture was
then transferred to a 50 mL Falcon tube, where 1 volume of water was added. The reaction was
vortexed and centrifuged (4000 rpm, 4°C) for 2 minutes. The aqueous layer was then isolated and
lyophilized to a white powder, unless otherwise specified.

N-benzyl-P-(1-(benzyloxy)-2-oxopiperidin-3-yl)phosphonamidic acid (A1).

Following the

general procedure above, the following quantities were used: DIAD (68.17 μL, 350.59 μmol) and
triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL). BnHEX (1, 50 mg,
175.29 μmol) and benzylamine (38.30 μL, 350.59 μmol) in anhydrous DCM (1 mL). Yield: 40%.
Analysis by ESI+ (Expected [M+H]+ =375.38. Observed [M+H]+ = 375.35). 1H NMR (500 MHz,
D2O) δ 7.32-7.53 (m, 10 H), 4.91-4.96 (m, 2H), 4.02-4.11 (m, 2H)), 3.46-3.57 (m, 2H), 2.80-2.87
(dt, J=21.52 Hz, J=21.70 Hz, 1H), 2.07-2.13 (m, 1H), 1.92-1.98 (m, 2H), 1.72-1.79 (m, 1H). 13C
NMR (125.7 MHz, D2O) δ 167.97 (d, J=4.72 Hz, 1C), 141.25 (d, J=7.36 Hz, 1C), 134.52 (s, 1C),
129.92 (s, 2C), 129.15 (s, 1C), 128.73 (s, 2C), 128.60 (s, 2C), 127.59 (s, 1C), 127.00 (s, 1C), 75.54
(s, 1C), 50.11 (s, 1C), 45.28 (s, 1C), 43.64 (d, J=111.12 Hz, 1C), 22.33 (d, J=3.65 Hz, 1C), 21.65
(d, J=7.23 Hz, 1C). 31P NMR (202 MHz, D2O) δ 20.91.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(pyridin-2-ylmethyl)phosphonamidic acid (A2).
Following the general procedure above, the following quantities were used: DIAD (68.17 μL,
350.59 μmol) and triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 50 mg, 175.29 μmol) and pyridin-2-ylmethanamine (37.83 μL, 350.59 μmol) in
anhydrous DCM (1 mL). The product was lyophilized to an orange oil. Yield: 74%. Analysis by
ESI+ (Expected [M+H]+ = 376.36. Observed [M+H]+ = 376.35). 1H NMR (300 MHz, D2O) δ 8.38
(d, J=4.73 Hz, 1H), 7.83 (t, J=1.77, 1.92 Hz, 1H), 7.37-7.49 (m, 7H), 4.90 (d, J=2.02 Hz, 2H),
3.43-3.58 (m, 2H), 2.79-2.91 (dt, J=21.84 Hz, 1H), 2.06-2.14 (m, 1H), 1.91-1.99 (m, 2H), 1.701.81 (m, 1H). 13C NMR (75 MHz, D2O) δ 167.86 (s, 1C), 159.86 (d, J=7.28 Hz, 1C), 147.91 (s,
1C), 138.34 (s, 1C), 129.84 (s, 2C), 129.11 (s, 1C), 128.70 (s, 2C), 123.71 (s, 1C), 122.76 (s, 1C),
122.07, (s,1C), 71.16 (s, 1C), 50.04 (s, 1C), 46.42 (s, 1C), 43.18-44.65 (d, J= 111.72 Hz, 1C),
22.38 (d, J= 3.65 Hz, 1C), 21.54 (d, J=7.01 Hz, 1C). 31P NMR (121 MHz, D2O) δ 20.60.
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P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(pyridin-3-ylmethyl)phosphonamidic acid (A3).
Following the general procedure above, the following quantities were used: DIAD (68.17 μL,
350.59 μmol) and triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 50 mg, 175.29 μmol) and pyridin-3-ylmethanamine (37.83 μL, 350.59 μmol) in
anhydrous DCM (1 mL). Yield: 76% Analysis by ESI+ (Expected [M+H]+ = 376.36. Observed
[M+H]+ = 376.35). 1H NMR (300 MHz, D2O) δ 8.58 (d, J= 2.14 Hz, 1H), 8.38-8.40 (dd, J= 5.02
Hz, 1H), 7.92-7.95 (dt, J=7.90 Hz, 1H), 7.53-7.48 (m, 5H), 4.92 (s, 2H), 4.07-4.10 (d, J= 9.13 Hz,
2H), 3.47-3.55 (m, 2H), 2.76-2.88 (dt, J=21.88 Hz, 1H), 2.05-2.16 (m, 1H), 1.90-2.00 (m, 2H),
1.70-1.82 (m, 1H). 13C NMR (75 MHz, D2O) 167.84 (d, J= 4.44 Hz, 1C), 149.20 (s, 1C), 148.82
(s, 1C), 147.65 (s, 1C), 146.93 (s, 1C), 129.88 (s, 2C), 129.62 (s, 1C), 129.13 (s, 1C), 128.71 (s,
2C), 124.09 (s, 1C), 75.47 (s, 1C), 43.15-44.63 (d, J=110.71 Hz, 1C), 42.67 (s, 1C), 22.41 (d, J=
4.10 Hz, 1C), 2.53-2.63 (d, J=7.02 Hz, 1C), 21.14-21.17 (d, J=2.48 Hz, 1C).

31P

NMR (121 MHz,

D2O) δ 20.52.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(3-fluorobenzyl)phosphonamidic

acid

(A4).

Following the general procedure above, the following quantities were used: DIAD (86.98 μL,
441.74 μmol) and triphenylphosphine (115.86 mg, 441.74 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 63 mg, 220.87 μmol) and 3-fluorophenyl methanamine (50.39 μL, 441.74 μmol) in
anhydrous DCM (1 mL). Yield: 61%. Analysis by ESI+ (Expected [M+H] + = 393.37. Observed
[M+H]+ = 393.42). 1H NMR (300 MHz, CDCl3) δ 7.18-7.38 (m, 9 H), 4.87 (s, 2H), 4.03 (s, 2H),
3.27-3.38 (m, 2H), 2.62-2.74 (dt, J=22.20 Hz, J=6.9 Hz, 1H), 2.07-2.13 (m, 1H), 1.79-1.88 (m,
2H), 1.55-1.59 (m, 1H).

13C

NMR (75 MHz, CDCl3) δ 166.80 (d, J=4.50 Hz, 1C), 161.13 (d,

J=2.32 Hz 1C), 144.65 (d, J=7.36 Hz, 1C), 135.40 (s, 1C), 129.39 (s, 2C), 129.58 (s, 1C), 128.42
(s, 2C), 124.60 (d, J = 2.89 Hz, 1C), 122.83 (s, 1C), 115.95 (d, J = 21.89 Hz, 1C), 114.24 (d, J =
21.34 Hz, 1C), 75.48 (s, 1C), 50.52 (s, 1C), 45.47 (s, 1C), 42.70-43.64 (d, J=96 Hz, 1C), 23.12 (d,
J=2.84 Hz, 1C), 22.35 (d, J=8.16 Hz, 1C). 31P NMR (121 MHz, CDCl3) δ 19.30. 19F NMR (282
MHz, CDCl3) δ -112.30.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(4-fluorobenzyl)phosphonamidic

acid

(A5).

Following the general procedure above, the following quantities were used: DIAD (68.17 μL,
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350.59 μmol) and triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 50 mg, 175.29 μmol) 4-fluorophenyl methanamine (40.07 μL, 350.59 μmol) in
anhydrous DCM (1 mL). Yield: 64%. Analysis by ESI+ (Expected [M+H]+ = 393.37. Observed
[M+H]+ = 393.38). 1H NMR (300 MHz, D2O) δ 7.41-7.54 (m, 5H), 7.10-7.24 (m, 4H), 4.94 (s,
2H), 4.02 (d, J=8.76 Hz, 2H), 3.46-3.60 (m, 2H), 2.77-2.88 (dt, J=21.74 Hz, 1H), 1.90-2.00 (m,
2H), 2.07-2.16 (m, 1H), 1.77-1.83 (m, 1H). 13C NMR (75 MHz, D2O) δ 167.89 (d, J=4.16 Hz, 1C),
164.48 (s, 1C), 137.00-137.13 (dd, J=7.12 Hz, 1C), 134.52 (s, 1C), 130.95 (d, J=8.86 Hz, 2C),
129.90 (s, 2C), 129.15 (s, 1C), 128.73 (s, 2C), 114.89 (d, J=21.90 Hz, 2C), 75.51 (s, 1C), 50.09 (s,
1C), 42.95-44.41 (d, J=110.78 Hz, 1C), 22.31 (d, J=4.00 Hz, 1C), 21.59 (d, J=8.00 Hz, 1C), 21.34
(s, 1C). 31P NMR (121 MHz, D2O) δ 20.78. 19F NMR (282 MHz, D2O) δ -113.20.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(2,4-difluorobenzyl)phosphonamidic

acid

(A6).

Following the general procedure above, the following quantities were used: DIAD (96.64 μL,
490.82 μmol) and triphenylphosphine (128.74 mg, 490.82 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 70 mg, 245.41 μmol) and (2,4-difluorophenyl)methanamine (58.55 μL, 490.82 μmol)
in anhydrous DCM (1 mL). Yield: 61%. Analysis by ESI+ (Expected [M+H]+ = 411.12. Observed
[M+H]+ = 411.38). 1H NMR (300 MHz, CDCl3) δ 6.68-7.71 (m, 9H), 4.84 (m, 2H), 4.09 (s, 2H),
3.29 (m, 2H), 2.65 (m, 1H), 2.01 (m, 2H). 1.55 - 1.76 (2H, m); 13C NMR (75 MHz, CDCl3) δ
176.91 (s, 1C), 158.62-164.51 (dd, J1=11.92 Hz, J2= 150.9 Hz, 2C), 166.95 (d, J=4.42 Hz, 1C),
135.37 (s, 1C), 132.21 (s, 1C), 130.48 (dd, J1=9.60 Hz, J2= 150.28 Hz, 1C), 129.31 (s, 2C), 128.59
(s, 1C), 128.41 (s, 2C), 124.55-124.88 (d, J = 3.75 Hz, 1C), 118.25 (dq, J1 = 3.52 Hz, J2 = 14.70
Hz, 1C), 111.71 (dq, J1 = 3.52 Hz, J2 = 21.00 Hz, 1C), 103.44 (q, J1 = 25.12 Hz, 1C), 75.41 (s, 1C),
50.49 (s, 1C), 44.78-45.56 (d, J1 = 112.50 Hz, 1C), 39.14 (d, J=3.50 Hz, 1C), 36.06 (d, J=3.50 Hz,
1C), 23.19 (s, 1C), 22.35 (d, J=7.57 Hz, 1C). 31P NMR (121 MHz, CDCl3) δ 18.98. 19F NMR (282
MHz, CDCl3) -109.43 (d, J=7.86, 1F), δ -112.95 (d, J=6.86, 1F).

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(2,6-difluorobenzyl)phosphonamidic

acid

(A7).

Following the general procedure above, the following quantities were used: DIAD (96.64 μL,
490.82 μmol) and triphenylphosphine (128.74 mg, 490.82 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 70 mg, 245.41 μmol) and (2,4-difluorophenyl)methanamine (58.55 μL, 490.82 μmol)
in anhydrous DCM (1 mL). Yield: 61%. Analysis by ESI+ (Expected [M+H]+ = 411.12. Observed
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[M+H]+ = 411.38). 1H NMR (300 MHz, CDCl3) δ 6.68-7.71 (m, 9H), 4.84 (m, 2H), 4.09 (s, 2H),
3.29 (m, 2H), 2.65 (m, 1H), 2.01 (m, 2H). 1.55 - 1.76 (2H, m); 13C NMR (75 MHz, CDCl3) δ
176.91 (s, 1C), 158.62-164.51 (dd, J1=11.92 Hz, J2= 150.9 Hz, 2C), 166.95 (d, J=4.42 Hz, 1C),
135.37 (s, 1C), 132.21 (s, 1C), 130.48 (dd, J1=9.60 Hz, J2= 150.28 Hz, 1C), 129.31 (s, 2C), 128.59
(s, 1C), 128.41 (s, 2C), 124.55-124.88 (d, J = 3.75 Hz, 1C), 118.25 (dq, J1 = 3.52 Hz, J2 = 14.70
Hz, 1C), 111.71 (dq, J1 = 3.52 Hz, J2 = 21.00 Hz, 1C), 103.44 (q, J1 = 25.12 Hz, 1C), 75.41 (s, 1C),
50.49 (s, 1C), 44.78-45.56 (d, J1 = 112.50 Hz, 1C), 39.14 (d, J=3.50 Hz, 1C), 36.06 (d, J=3.50 Hz,
1C), 23.19 (s, 1C), 22.35 (d, J=7.57 Hz, 1C). 31P NMR (121 MHz, CDCl3) δ 18.98. 19F NMR (282
MHz, CDCl3) -109.43 (d, J=7.86, 1F), δ -112.95 (d, J=6.86, 1F).

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(3,4-difluorobenzyl)phosphonamidic

acid

(A8).

Following the general procedure above, the following quantities were used: DIAD (276.11 μL,
1.40 mmol) and triphenylphosphine (367.82 mg, 1.40 mmol) in anhydrous DCM (3 mL). BnHEX
(1, 200 mg, 245.41 μmol) and (3,4-difluorophenyl)methanamine (165.89 μL, 1.40 mmol) in
anhydrous DCM (1 mL). Yield: 52%. Analysis by ESI+ (Expected [M+H] + = 411.36. Observed
[M+H]+ = 411.42). 1H NMR (300 MHz, CDCl3) δ 7.21-7.25 (m, 8H), 4.77 (s, 2H), 3.91 (s, 2H),
3.21-3.35 (m, 2H), 2.50-2.62 (m, 1H), 1.90-1.92 (m, 1H). 1.75-1.79 (m, 1H), 1.46-1.50 (1H, m);
13C

NMR (75 MHz, CDCl3) δ 166.90 (s, 1C), 151.56-151.85 (m, 1C), 148.27-148.55 (m, 1C),

131.54-131.65 (dd, J1 = 3.75 Hz, J2 = 5.25 Hz, 1C), 129.28 (s, 2C), 128.69 (s, 1C), 128.46 (s, 2C),
125.51 (dd, , J1 = 3.75 Hz, J1 = 5.25 Hz, 1C), 118.33 (d, J1 = 17.25 Hz, 1C) 117.09 (d, J1 = 17.25
Hz, 1C), 75.41 (s, 1C), 50.39 (s, 1C), 44.05-45.55 (d, J1 = 112.5 Hz, 1C), 45.00 (s, 1C), 42.10 (s,
1C), 23.18 (s, 1C), 22.38 (d, J=8.25 Hz, 1C). 31P NMR (121 MHz, CDCl3) δ 18.95. 19F NMR (282
MHz, D2O) δ -137.06 (d, J=21.32 Hz, 1F), -138.22 (d, J=12.73, 1F).

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(cyclopropylmethyl)phosphonamidic acid (A9). To
a solution of triphenylphosphine (275.87 mg, 1.05 mmol) in DCM (15 mL), DIAD (204.50 μL,
1.05 mmol) were added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX
(150 mg, 525.88 mmol), cyclopropylmethanamine hydrochloride (74.80 mg, 1.05 mmol), and
DBU (156.98 μL, 1.05 mmol) in DCM (2 mL) was prepared and added dropwise to the betaine
solution. The reaction mixture was allowed to warm to room temperature over 30 minutes. Then,
1 volume of water was added to the crude mixture. After vigorous shaking and partitioning via
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centrifugation (2 min at 4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to a clear
solid. Analysis by ESI+ (Expected [M+H]+ =339.34. Observed [M+H]+ = 339.38). 13C NMR (125
MHz, MeOD) δ 168.57 (d, J=4.15 Hz, 1C), 137.09 (s, 1C), 130.78 (s, 2C), 129.82 (s, 1C), 129.64
(s, 2C), 76.30 (s, 1C), 51.36 (s, 1C), 48.07 (s, 1C), 44.16-45.59 (d, J=107.65 Hz, 1C), 24.07 (d,
J=4.02 Hz, 1C), 23.57 (d, J=6.85 Hz, 1C), 14.13 (d, J=9.99 Hz, 1C), 3.97 (d, J=12.30 Hz, 2C). 31P
NMR (202 MHz, MeOD) δ 19.54 ppm.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-cyclobutylphosphonamidic acid (A10).
To a solution of triphenylphosphine (919.56 mg, 3.51 mmol) in DCM (20 mL), DIAD (681.66 μL,
3.51 mmol) were added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX
(500 mg, 1.75 mmol), cyclobutylamine (299.34 μL, 3.51 mmol), and DBU (523.27 μL, 3.51 mmol)
in DCM (2 mL) was prepared and added dropwise to the betaine solution. The reaction mixture
was allowed to warm to room temperature over 30 minutes. Then, 1 volume of water was added
to the crude mixture. After vigorous shaking and partitioning via centrifugation (2 min at 4°C,
4000 rpm), the aqueous layer was isolated and lyophilized to a clear solid. Analysis by ESI+
(Expected [M+H]+ =339.34. Observed [M+H]+ = 339.41). 1H NMR (300 MHz, D2O) 7.45-7.55
(m, 5H), 4.96 (s, 1H), 3.26-3.30 (t, J=5.55, 6.01 Hz, 2H), 2.68-2.79 (dt, J=21.36 Hz, 1H), 2.19-.27
(m, 2H), 2.05-2.11 (m, 1H), 1.79-1.91 (m, 4H), 1.51-1.62 (m, 2H).

31P

NMR (121 MHz, D2O)

19.47 (s, 1P).

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(prop-2-yn-1-yl)phosphonamidic

acid

(A11).

Following the general procedure above, the following quantities were used: DIAD (68.17 μL,
350.59 μmol) and triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL).
BnHEX (1, 50 mg, 175.29 μmol) and propargylamine (16.84 μL, 262.94 μmol) in anhydrous DCM
(1 mL). Yield: 35%. Analysis by ESI+ (Expected [M+H]+ =323.30. Observed [M+H]+ = 323.39).
1H

NMR (300 MHz, D2O) δ 7.37-7.44 (m, 5H), 4.88 (s, 2H), 3.57-3.61 (dd, J=10.85 Hz, 2H),

3.43-3.49 (m, 2H), 2.84-2.96 (dt, J=22.10 Hz, 1H), 1.97-2.03 (m, 1H), 1.86-1.93 (m, 2H), 1.681.76 (m, 1H). 13C NMR (75 MHz, D2O) δ 167.64 (d, J=4.50 Hz, 1C), 134.50 (s, 1C), 129.95 (s,
2C), 129. 19 (s, 1C), 128.76 (s, 2C), 76.44 (s, 1C), 50.05 (s, 1C), 43.09-44.57 (d, 111.27 Hz, 1C),
30.07 (s, 1C), 22.24-22.29 (d, J=3.79 Hz, 1C), 21.69-21.79 (d, J=8.03 Hz, 1C); some tertiary and
quaternary carbons not visible under these running conditions. 31P NMR (121 MHz, D2O) δ 20.89
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P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-methyl-N-(2-(pyrrolidin-1-yl)ethyl
phosphoramidic acid (A12). Following the general procedure above, the following quantities
were used: DIAD (137.65 μL, 707.17 μmol) and triphenylphosphine (183.91 mg, 707.17 μmol) in
anhydrous DCM (5 mL). BnHEX (1, 100 mg, 350.59 μmol) and N-methyl-2-(pyrrolidin-1yl)ethan-1-amine (88.39 μL, 701.17 μmol) in anhydrous DCM (2 mL). Yield: 63%. Analysis by
ESI+ (Expected [M+H]+ = 396.44. Observed [M+H]+ = 396.51). 1H NMR (300 MHz, D2O) δ 7.477.54 (m, 5H), 4.99 (s, 2H), 3.59-3.63 (m, 2H), 2.99-3.04 (t, J=6.44, 7.03 Hz, 4H), 2.76-2.80 (dt,
J=10.9 Hz, 1H), 2.63 (s, 3H), 2.00-2.25 (m, 7H), 1.90-1.97 (m, 4H), 1.82-1.90 (m, 1H). 13C NMR
(75 MHz, D2O) δ 167.92 (d, J=4.57 Hz, 1C), 134.40 (s, 1C), 129.86 (s, 2C), 129.20 (s, 1C), 128.76
(s, 2C), 75.45 (s, 1C), 53.86 (s, 2C), 51.46 (s, 1C), 49.91-50.10 (d, J=15.22 Hz, 1C), 46.20 (s, 1C),
41.40-42.88 (d, J=111.54 Hz, 1C), 33.20-33.25 (d, J=4.18 Hz, 1C), 22.55-22.62 (d, J=5.52 Hz,
1C), 22.29-22.35 (d, J=4.28 Hz, 1C), 21.07 (s, 2C). 31P NMR (121 MHz, D2O) δ 22.00.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(cyclohexylmethyl)phosphonamidic acid (A13). To
a solution of triphenylphosphine (275.87 mg, 1.05 mmol) in DCM (6 mL), DIAD (204.50 μL,
1.05 mmol) were added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX
(150 mg, 525.88 mmol), cyclohexane methylamine (136.85 μL, 1.05 μmol), and DBU (157.29 μL,
1.05 mmol) in DCM (2 mL) was prepared and added dropwise to the betaine solution. The reaction
mixture was allowed to warm to room temperature over 30 minutes. Then, 1 volume of water was
added to the crude mixture. After vigorous shaking and partitioning via centrifugation (2 min at
4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to clear oil. Analysis by ESI+
(Expected [M+H]+ = 381.42. Observed [M+H]+ =381.50). 1H NMR (300 MHz, CDCl3) δ 7.377.44 (m, 5H) 3.61-3.65 (m, 2H), (m, 1H), 2.15-2.25 (m, 1H), 1.97-2.12 (m, 2H), 1.83-1.93 (m,
1H), 1.62-1.74 (m, 6H), 1.32-1.44 (m, 1H), 0.79-0.94 (m, 3H).

31 P

NMR (121 MHz, CDCl3)

δ17.41 (s, 1P).

N-dodecyl-P-(1-hydroxy-2-oxopiperidin-3-yl)phosphonamidic acid (A14). To a solution of
triphenylphosphine (96 mg, 350.59 mmol) in DCM (4 mL), DIAD (68.17 μL, 350.59 mmol) were
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added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX (50 mg, 175.29
mmol), dodecylamine (74.69 μL, 350.59 μmol), and DBU (52.33 μL, 350.59 mmol) in DCM (1
mL) was prepared and added dropwise to the betaine solution. The reaction mixture was allowed
to warm to room temperature over 30 minutes. Then, 1 volume of water was added to the crude
mixture. After vigorous shaking and partitioning via centrifugation (2 min at 4°C, 4000 rpm), the
aqueous layer was isolated and lyophilized to a white solid. 1H NMR (300 MHz, CDCl3) δ 7.377.44 (m, 5H), 3.55-3.63 (m, 2H), 2.85-2.93 (m, 4H), 2.12-2.17 (m, 1H), 1.96-2.03 (m, 2H), 1.761.81 (m, 2H), 1.56-1.66 (m, 2H), 1.41-1.51 (m, 2H), 1.18 (m, 36H), 0.79-0.83 (t, J=6.0 Hz). 31P
NMR (121 MHz, CDCl3) δ 31.14 (1P), 22.54 (1P).

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-methylphosphonamidic acid (A15). To a solution of
triphenylphosphine (183.91 mg, 701.17 mmol) in DCM (5 mL), DIAD (136.33 μL, 701.17 mmol)
were added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX (100 mg,
350.59 mmol), methylamine hydrochloride (47.34 mg, 701.17 mmol), and DBU (106.75 μL,
701.17 mmol) in DCM (1 mL) was prepared and added dropwise to the betaine solution. The
reaction mixture was allowed to warm to room temperature over 30 minutes. Then, 1 volume of
water was added to the crude mixture. After vigorous shaking and partitioning via centrifugation
(2 min at 4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to clear oil.

P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N,N-dimethylphosphonamidic acid (A16). To a
solution of triphenylphosphine (91.96 mg, 350.59 mmol) in DCM (2.5 mL), DIAD (68.17 μL,
350.59 mmol) were added with stirring at 0°C for 30 min. Separately, a solution containing
BnHEX (50 mg, 175.29 mmol), dimethylamine hydrochloride (28.59 mg, 350.59 mmol), and
DBU (53.37 mg, 350.59 mmol) in DCM (1 mL) was prepared and added dropwise to the betaine
solution. The reaction mixture was allowed to warm to room temperature over 30 minutes. Then,
1 volume of water was added to the crude mixture. After vigorous shaking and partitioning via
centrifugation (2 min at 4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to clear
oil.
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Synthesis of phosphoramidates from phosphates. For phosphate-containing compounds (1-naphtyl
phosphate, Fludarabine monophosphate), reagents were added in the following order: 1.)
phosphate starting material, 2.) DBU (0.75 equiv., for 1-naphtyl phosphate reactions only), 3.)
amine (1.5 equiv.), 4.) triphenyl phosphine (1 equiv.), 5.) DIAD (1 equiv.). After 1 second, the
reaction was transferred to a 5 mL Eppendorf tube and chloroform (2.5 mL), followed by water
(2.5 mL) were added to the reaction. The reaction was vortexed and centrifuged (4000 rpm, 4°C)
for 2 minutes. The aqueous layer was then isolated and lyophilized to a clear oil. For phosphate
reactions performed in DCM or CHCl3, DBU (0.75 equiv.) were added to the aforementioned
reagents, prior to the addition of DIAD.

Naphthalen-1-yl hydrogen benzylphosphoramidate (B1). Following the general procedure
above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol), benzylamine
(3.65μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol), triphenylphosphine (5.85 mg, 22.31 μmol),
and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL).Analysis by ESI+ (Expected [M+H]+ =314.29.
Observed [M+H]+ =314.32). 1H NMR (300 MHz, D2O) δ 8.10-8.13 (d, J=7.05 Hz, 1H), 7.95 (d,
J=6.77 Hz, 1H), 7.70-7.73 (d, J=8.54 Hz, 1H), 7.55-7.59 (m, 2H), 7.46-7.55 (t, J=7.79, 7.79 Hz,
1H), 7.38-7.41 (d, J=7.79 Hz, 1H), 7.22-7.28 (m, 5H), 4.05 (d, J=10.73 Hz, 2H). 13C NMR (125
MHz, D2O) δ 148.13 (d, J=7.70 Hz, 1C), 140.79 (d, J=6.73 Hz, 1C), 134.50 (s, 1C), 129.98 (s, 1C),
128.38 (s, 2C), 127.58 (s, 1C), 127.30 (s, 2C), 126.83 (s, 2C), 126.56 (s, 1C), 126.00 (d, J=3.70
Hz, 1C), 123.18 (s, 1C), 122.06 (s, 1C), 114.62 (d, J=3.68 Hz, 1C), 45.34 (s, 1C). 31P NMR (121
MHz, D2O) δ 5.11.

Naphthalen-1-yl hydrogen (pyridin-2-ylmethyl)phosphoramidate) (B2). Following the
general procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31
μmol), pyridin-2-ylmethanamine (3.45 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol),
triphenylphosphine (5.85 mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL).
Analysis by ESI+ (Expected [M+H]+ =315.28. Observed [M+H]+ =315.22). 1H NMR (300 MHz,
D2O) δ 8.56 (d, J= 5.07 Hz, 1H), 8.10 (d, J=5.15 Hz, 1H), 7.96-8.00 (d, J=8.67 Hz, 1H), 7.87-7.92
(t, J=7.82, 7.97 Hz, 1H), 7.81-7.84 (d, J=7.76 Hz, 1H), 7.59-7.62 (d, J=7.82 Hz, 1H), 7.35-7.52
(m, 4H), 7.13-7.15 (d, J=7.87 Hz, 1H), 4.11-4.15 (d, J=12.88 Hz, 2H). 13C NMR (125 MHz, D2O)
δ 158.38 (d, J=4.91 Hz, 1C), 149.18 (s, 1C), 147.88 (d, J=7.49 Hz, 1C), 138.40 (s, 1C), 134.34 (s,
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1C), 127.52 (s, 1C), 126.48 (s, 2C), 125.86 (d, J=1.37 Hz, 1C), 124.12 (s, 1C), 123.16 (d, J=0.89
Hz, 1C), 122.36 (s, 1C), 121.89 (s, 1C), 114.26 (d, J=3.48 Hz, 1C), 45.92 (s, 1C). 31P NMR (121
MHz, D2O) δ 4.59.

Naphthalen-1-yl hydrogen (4-fluorobenzyl)phosphoramidate) (B3). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol), 4fluorobenzylamine (3.82 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol), triphenylphosphine (5.85
mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL). Analysis by ESI+ (Expected
[M+H]+ =332.28. Observed [M+H]+ =332.29). 1H NMR (300 MHz, D2O) δ 8.06-8.09 (d, J=7.57
Hz, 1H), 7.91-7.94 (d, J=8.43 Hz, 1H), 7.68-7.70 (d, J=8.43 Hz, 1H), 7.44-7.58 (m, 3H), 7.12-7.25
(m, 4H), 6.87-6.90 (d, J=8.89 Hz, 1H), 3.99-4.03 (d, J=11.55 Hz, 2H).

13C

NMR (125 MHz, D2O)

δ 128.86-131.03 (dd, J=8.95, 9.04, 265.33 Hz, 2C), 127.52 (s, 1C), 126.52 (s, 1C), 125.92-125.5
(d, J=3.47 Hz, 1C), 123.08 (d, J=1.56 Hz, 1C), 122.03 (s, 1C), 114.60-116.03 (dd, J=162.43 Hz,
2C), 30.72-30.84 (d, J=15.39 Hz, 1C); quaternary carbons and some tertiary carbons not visible
under these running conditions. 31P NMR (121 MHz, D2O) δ 5.02. 19F NMR (282 MHz, D2O) δ
-113.24

Naphthalen-1-yl hydrogen (2,6-difluorobenzyl)phosphoramidate (B4). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
(2,6-difluorophenyl)methanamine (4.00 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol),
triphenylphosphine (5.85 mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL).
Analysis by ESI+ (Expected [M+H]+ =350.27. Observed [M+H]+ =350.25). 1H NMR (300 MHz,
D2O) δ 8.25-8.27 (d, J=6.64 Hz, 1H), 7.96-7.99 (d, J=7.01 Hz, 1H), 7.83-7.90 (m, 1H), 7.74-7.77
(d, J=8.23 Hz, 1H), 7.60-7.74 (p, J=2.10, 2.29, 3.84, 3.84 Hz, 2H), 7.49-7.51 (t, J=3.21, 3.65 Hz,
1H), 7.42-7.45 (d, J=7.64 Hz, 1H), 7.08-7.13 (t, J=8.02, 8.11 Hz, 2H), 4.13-4.18 (d, J=13.24 Hz,
2H). 13C NMR (125 MHz, D2O) δ 160.09-162.12 (dd, J=7.28, 246.98 Hz, 2C), 147.94 (d, J=7.15
Hz, 1C), 134.45 (s, 1C), 127.64 (s, 2C), 126.88 (s, 2C), 126.23 (s, 1C), 126.02 (d, J=1.52 Hz, 1C),
123.71 (d, J=1.32 Hz, 1C), 122.03 (s, 1C), 115.08 (d, J=3.20 Hz, 1C), 111.79-111.60 (dd, J=5.00,
5.00, 19.23 Hz, 1C), 33.04 (t, J=3.56, 3.78 Hz, 1C). 31P NMR (121 MHz, D2O) δ 3.99. 19F NMR
(282 MHz, D2O) δ -114.99.
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Isopropyl (hydroxy(naphthalen-1-yloxy)phosphoryl)-L-alaninate (B5). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
isopropyl L-alaninate hydrochloride (4.39 mg, 33.46 μmol), DBU (2 equiv., 6.67 μL, 44.62 μmol),
triphenylphosphine (5.85 mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500
μL).Analysis by ESI+ (Expected [M+H]+ =320.34. Observed [M+H]+ =320.33). 1H NMR (300
MHz, D2O) δ 8.25-8.28 (d, J=9.76 Hz, 1H), 7.96-7.99 (d, J=9.39 Hz, 1H), 7.75-7.77 (d, J=8.82 Hz,
1H), 7.60-7.64 (m, 2H), 7.50-7.55 (t, J=7.39, 7.86 Hz, 1H), 7.43-7.46 (d, J=7.86 Hz, 1H), 5.075.15 (m, 1H), 3.80-3.85 (m, 1H), 1.54-1.57 (d, J=7.20 Hz, 6H), 1.24-1.27 (d, J=7.42 Hz, 3H). 13C
NMR (125 MHz, D2O) δ 176.27-176.30 (d, J=4.29 Hz, 1C), 147.95-147.89 (d, J=7.13 Hz, 1C),
134.46 (s, 1C), 127.66 (s, 1C), 126.71 (s, 2C), 126.25 (s, 1C), 126.04 (d, J=1.41 Hz, 1C), 123.73
(d, J=1.11 Hz, 1C), 122.04 (s, 1C), 115.07-115.09 (d, J=3.14 Hz, 1C), 70.22 (s, 1C), 55.83 (s, 1C),
20.26 (s, 2C), 15.04 (s, 1C). 31P NMR (121 MHz, D2O) δ 2.66

Naphthalen-1-yl hydrogen (cyclohexylmethyl)phosphoramidate (B6). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
cyclohexane methylamine (4.35 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol), triphenylphosphine
(5.85 mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL). Analysis by ESI+
(Expected [M+H]+ =320.34. Observed [M+H]+ =320.33). 1H NMR (300 MHz, D2O) δ 8.33 (d, J=
4.52 Hz, 1H), 7.98 (d, J=4.96 Hz, 1H), 7.71-7.73 (d, J=8.16 Hz, 1H), 7.60-7.63 (m, 2H), 7.50-7.55
(t, J=7.81, 7.88 Hz, 1H), 7.44-7.45 (d, J=7.53 Hz, 1H), 2.61-2.66 (dd, J=10.82 Hz, 2H), 1.62-1.76
(m, 11H). 13C NMR (125 MHz, D2O) 148.73 (d, J=7.40 Hz, 1C), 134.41 (s, 1C), 127.54 (s, 1C),
126.17 (d, J=1.15 Hz, 1C) 126.06 (s, 1C), 125.95 (s, 2C), 122.35 (s, 1C), 114.72 (d, J=3.11 Hz,
1C), 51.93 (s, 1C), 37.79 (s, 1C), 25.49 (s, 1C), 24.95 (s, 2C), 21.05 (s, 2C); some quaternary
carbons not visible under these running conditions. 31P NMR (121 MHz, D2O) δ 6.27.

Naphthalen-1-yl hydrogen cyclopropylphosphoramidate (B7).

Following the general

procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
cyclopropylamine (2.32 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol), triphenylphosphine (5.85
mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL). Analysis by ESI+ (Expected
[M+H]+ =264.23. Observed [M+H]+ =264.21). 1H NMR (300 MHz, D2O) δ 8.31 (d, J=6.10 Hz,
1H), 7.97 (d, J=6.34 Hz, 1H), 7.73 (d, J=7.71 Hz, 1H), 7.61-7.64 (p, J=1.71, 1.76, 3.86, 3.89 Hz,

43

2H), 7.50-7.55 (t, J=7.84, 8.87 Hz, 1H), 7.44-7.47 (d, J=7.70 Hz, 1H), 2.3-2.45 (m, 1H), 0.85-0.88
(d, J=5.20 Hz, 2H), 0.51-0.54 (d, J=6.37 Hz, 2H). 13C NMR (125 MHz, D2O) δ 148.90 (d, J=7.20
Hz, 1C), 134.44 (s, 1C), 127.63 (s, 1C), 126.66 (s, 1C), 126.12 (s, 2C), 126.06 (d, J=1.36 Hz, 1C),
123.77 (d, J=1.61 Hz, 1C), 122.15 (s, 1C), 114.62 (d, J=3.28 Hz, 1C), 6.10 (s, 2C), 6.02 (d, J=5.39
Hz, 1C). 31P NMR (121 MHz, D2O) δ 5.0.

Naphthalen-1-yl hydrogen cyclobutylphosphoramidate (B8). Following the general procedure
above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
cyclobutylamine (2.86 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol), triphenylphosphine (5.85
mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL). Analysis by ESI+ (Expected
[M+H]+ =278.26. Observed [M+H]+ =278.87).

Naphthalen-1-yl hydrogen (Z)-octadec-9-en-1-ylphosphoramidate (B9). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
oleylamine (11.01 μL, 33.46 μmol), DBU (2.50 μL, 16.73 μmol), triphenylphosphine (5.85 mg,
22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL). Analysis by ESI+ (Expected
[M+H]+ =474.63. Observed [M+H]+ =474.91).

Naphthalen-1-yl hydrogen ((S)-1-phenylethyl)phosphoramidate (B10). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
(R)-1-phenylethan-1-amine

(4.26

μL,

33.46

μmol),

DBU

(2.50

μL,

16.73 μmol),

triphenylphosphine (5.85 mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL).
Analysis by ESI+ (Expected [M+H]+ =328.32. Observed [M+H]+ =328.36).

Naphthalen-1-yl hydrogen ((R)-1-phenylethyl)phosphoramidate (B11). Following the general
procedure above, the following quantities were used: 1-naphtyl phosphate (5 mg, 22.31 μmol),
(R)-1-phenylethan-1-amine

(4.26

μL,

33.46

μmol),

DBU

(2.50

μL,

16.73 μmol),

triphenylphosphine (5.85 mg, 22.31 μmol), and DIAD (4.34 μL, 22.31 μmol) in DCM (500 μL).
Analysis by ESI+ (Expected [M+H]+ =328.32. Observed [M+H]+ =328.36).
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((2S,3R,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxytetradihydroxyfuran-2yl)methyl hydrogen benzylphosphoramidate (B12). Following the general procedure above, the
following quantities were used: Fludarabine monophosphate (5 mg, 13.69 μmol), benzylamine
(2.24 μL, 20.54 μmol), triphenylphosphine (3.59 mg, 13.69 μmol), and DIAD (2.66 μL, 13.69
μmol) in NMP (500 μL). Analysis by ESI+ (Expected [M+H]+ =455.36. Observed [M+H]+
=455.48). 1H NMR (300 MHz, D2O) δ 8.26 (s, 1H), 7.42-7.47 (m, 5H), 6.20-6.22 (d, J=6.12 Hz,
1H), 4.59-4.63 (t, J=6.47, 6.71 Hz, 1H), 4.42-4.46 (t, J=6.86, 6.86 Hz, 1H), 4.01-4.07 (m, 3H),
3.84-3.87 (d, J=9.65 Hz, 2H). 13C NMR (125 MHz, D2O) δ 156.5-160.22 (d, J=255.64 Hz, 1C),
150.09-50.34 (d, J=18.85 Hz, 1C), 140.64-140.74 (d, J= 7.41 Hz, 1C), 129.17 (s, 2C), 128.60 (s,
1C), 128.28 (s, 2C), 128.08 (s, 1C), 116.31-116.36 (d, J=4.16 Hz, 1C), 82.84 (s, 1C), 80.95-81.07
(d, J=8.88 Hz, 1C), 75.39 (s, 1C), 73.26 (s, 1C), 62.86-62.93 (d, J=5.17 Hz, 1C), 44.93 (s, 1C). 31P
NMR (121 MHz, D2O) δ 8.70.

((2S,3R,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4 dihydroxytetradihydroxytetra
hydrofuran-2-yl)methyl hydrogen (pyridin-2-ylmethyl)phosphoramidate (B13). Following
the general procedure above, the following quantities were used: Fludarabine (5 mg, 13.69 μmol),
pyridin-2-ylmethanamine (2.12 μL, 20.54 μmol), triphenylphosphine (3.59 mg, 13.69 μmol), and
DIAD (2.66 μL, 13.69 μmol) in NMP (500 μL). Analysis by ESI+ (Expected [M+H] + =456.34.
Observed [M+H]+ =456.42). 1H NMR (300 MHz, D2O) δ 8.56-8.58 (d, J=4.88 Hz, 1H), 8.22 (s,
1H), 7.47-7.50 (d, J=8.38 Hz, 1H), 7.46-7.47 (t, J= 3.70, 3.90 Hz, 1H), 7.16-7.20 (t, J=6.61, 6.63
Hz, 1H), 6.16-618 (d, J=6.29 Hz, 1H), 4.58-4.63 (t, J=6.49, 6.95 Hz, 1H), 4.42-4.45 (t, J=6.95,
6.95 Hz, 1H), 4.04-4.13 (m, 3H), 3.99-4.02 (d, J=10.18 Hz, 2H).

13

C NMR (75 MHz, D2O) δ

151.47-154.72 (d, J=246.11 Hz, 1C), 149.18 (s, 1C), 147.18 (s, 1C), 141.16-141.20 (d, J=2.47 Hz,
1C), 138.52 (s, 1C), 123.09 (s, 1C), 122.42 (s, 1C), 82.72 (s, 1C), 80.79-80.90 (d, J=8.60 Hz, 1C),
75.36 (s, 1C), 73.09 (s, 1C), 62.87-62.93 (d, J=4.82 Hz, 1C), 45.77 (s, 1C); some quaternary
carbons not visible under these running conditions. 31P NMR (121 MHz, D2O) δ 8.38.

((2S,3R,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2yl)methyl hydrogen cyclopropylphosphoramidate (B14). Following the general procedure
above, the following quantities were used: Fludarabine monophosphate (5 mg, 13.69 μmol),
cyclopropylamine (1.34 μL, 20.54 μmol), triphenylphosphine (3.59 mg, 13.69 μmol), and DIAD
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(2.66 μL, 13.69 μmol) in NMP (500 μL). Analysis by ESI+ (Expected [M+H]+ =405.30. Observed
[M+H]+ =405.37). 1H NMR (300 MHz, D2O) δ 8.44 (s, 1H), 6.31-6.33 (d, J=6.08 Hz, 1H), 4.614.65 (t, J=6.29, 6.33 Hz, 1H), 4.46-4.50 (t, J=6.90, 6.80 Hz, 1H), 4.14-422 (m, 3H), 2.24-2.32 (m,
1H), 0.86-0.89 (m, 2H), 0.44-0.467 (m, 2H).13C NMR (75 MHz, D2O) δ 149.25-149.43 (d,
J=13.71 Hz, 1C), 141.07-141.10 (d, J=2.79 Hz, 1C), 83.40 (s, 1C), 80.09-81.11 (d, J=8.75 Hz, 1C),
75.51 (s, 1C), 73.16 (s, 1C), 63.15-63.18 (d, J=3.15 Hz, 1C), 22.92-23.00 (d, J=5.93 Hz, 1C), 6.11
(s, 2C); some quaternary carbons not visible under these running conditions. 31P NMR (121 MHz,
D2O) δ 7.97.

Isopropyl

((((2S,3R,4R,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-

dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)-D-alaninate

(B15).

Following the general procedure above, the following quantities were used: Fludarabine
monophosphate (5 mg, 13.69 μmol, 22), isopropyl L-alaninate hydrochloric acid salt (3.59 mg,
27.38 μmol), triethylamine (3.82 μL, 27.39 μmol), triphenylphosphine (3.59 mg, 13.69 μmol), and
DIAD (2.66 μL, 13.69 μmol) in NMP (500 μL). Analysis by ESI+ (Expected [M+H] + =479.37.
Observed [M+H]+ =479.50). 1H NMR (300 MHz, D2O) δ 8.14 (s, 1H), 5.99-6.00 (d, J=6.37 Hz,
1H), 5.09-5.17 (m, 1H), 4.61-4.65 (t, J=6.55, 6.67 Hz, 1H), 4.30-4.35 (t, J=7.99, 7.99 Hz, 1H),
4.09-4.20 (m, 3H), 3.61-3.71 (m, 1H), 1.57-1.59 (d, J=7.34 Hz, 3H), 1.28-1.30 (d, J=7.78 Hz, 6H).
13C

NMR (75 MHz, D2O) δ 176.77-176.83 (d, J=4.58 Hz, 1C), 156.41-156.67 (d, J= 18.94 Hz,

1C), 140.33-140.36 (d, J=2.61 Hz, 1C), 85.24 (s, 1C), 83.22-83.29 (d, J=5.37 Hz, 1C), 75.65 (s,
1C), 73.59 (s, 1C), 48.94 (s, 1C), 72.30 (s, 1C), 63.26-63.32 (d, J=4.66 Hz, 1C), 20.64 (s, 2C),
15.07 (s, 1C); some quaternary carbons not visible under these running conditions. 31P NMR (121
MHz, D2O) δ 6.37.

Preparation of

18 O-labeled

naphthalen-1-yl hydrogen for mechanistic studies.

18O-labeled

naphthalen-1-yl hydrogen was prepared using a modified version of a previously published
procedure (128). To neat SOCl2, 1-naphtyl phosphate (5 mg, 22.31 μmol) and DMF (20 μL) were
added. The reaction was allowed to proceed for 24 h. Then, the crude dichlorinated product was
concentrated under a stream of nitrogen and re-dissolved in anhydrous CHCl3 and cooled to 0C.
Then, H218O was added dropwise and the reaction was allowed to stir for 2 h. The reaction was
then concentrated under reduced pressure and purified via reverse-phase HPLC (Aligent G1361A
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1260 Infinity) using a stepwise gradient (1-60% Buffer B over 25 minutes, 60-100% Buffer B over
10 minutes, 100% Buffer B over 5 minutes, 100-0% Buffer B over 1 minute; Buffer A: dH2O with
0.1% TFA, Buffer B: CH3CN + 0.1% TFA). Product-containing fractions were combined and
lyophilized to a white solid.

NMR reaction monitoring assay.

31P

NMR scans were taken at 121 MHz in 80% NMP 20%

CDCl3 (500 μL). Reaction conditions were similar to those described for (B1). Briefly, 1-naphtyl
phosphate (5 mg, 22.31 μmol), triphenylphosphine (5.85 mg, 22.31 μmol), benzylamine (3.65μL,
33.46 μmol), and DIAD (4.34 μL, 22.31 μmol) were added sequentially. The reaction was
monitored (ns = 100) for 1 h.
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CHAPTER 3. ALIPHATIC AMINES ARE VIABLE PROMOIETIES IN
PHOSPHONOAMIDATE-CONTAINING DRUGS
A continuation of Case Study 1.
Part of this chapter has been published in (permission granted)
Yan VC, Pham CD, Arthur K, Yang KL, Muller FL. 2020. Aliphatic amines are viable pro-drug moieties
in phosphonoamidate drugs. Bioorganic Med Chem Lett 30:127656.

3.1 Abstract
Phosphate and phosphonates containing a single P-N bond are frequently used prodrug motifs to
improve cell permeability of these otherwise anionic moieties (16). Upon entry into the cell, the
P-N bond is cleaved by phosphoramidases to release the active agent (32, 33). Here, we apply a
novel mono-amidation strategy (129) to our laboratory’s phosphonate-containing glycolysis
inhibitor and show that a diverse panel of phosphonoamidates may be rapidly generated for in vitro
screening. We show that, in contrast to the canonical L-alanine or benzylamine moieties which
have previously been reported as efficacious prodrug moieties, small and long-chain aliphatic
amines demonstrate greater drug release efficacy for our phosphonate inhibitor. These results
expand the scope of possible amine prodrugs that can be used as second prodrug leave groups for
phosphate or phosphonate-containing drugs.

3.2 Hypothesis
Small, aliphatic amines may be more effective promoieties on phosphonoamidate prodrugs
compared to benzylamine due to their increased hydrophilicity.

3.3 Introduction
Phosphoramidates are structurally intriguing chemical moieties with high biological and
therapeutic relevance (16). Within the realm of drug development, the inclusion of a
phosphoramidate moiety has become an increasingly attractive prodrug strategy for anionic
phosphate- or phosphonate-containing drugs. Upon entering the cell, the P-N bond would
eventually be cleaved by a class of enzymes known as phosphoramidases (Section 1.2.2 (32, 33)).
From anti-viral drugs such as TAF (44), SOF (42), and RDV (38) to emerging prodrugs of
conventional chemotherapies such as gemcitabine (NUC-103, Accelerin (130)) and 5-fluorouracil
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(NUC-3373), the phosphoramidate-containing “ProTide” approach to delivering phosphate or
phosphonate drugs is a central theme in prodrug development. Common to these drugs is the
presence of an α-amino acid motif, especially the L-alaninate ester moiety, which is used as a
substrate for phosphoramidase cleavage. In most cases, the L-amino acid-conjugated
phosph(on)ate is preferentially cleaved by HINT1; rarely is the D-amino acid-conjugated
phosph(on)ate preferentially cleaved (131). To the best of our knowledge, the only other amine
that has been reported in the context of phosphoramidate or phosphonoamidate clinical candidates
is the benzylamine moiety found in IDX-184 (132). These observations would suggest that either
the L-alaninate or benzylamine moieties would be the most optimal amine substrates for release
by phosphoramidases. Fundamental biochemical studies have explored the relationship between
altering the amine on phosphoramidate versions of AMP rate of hydrolysis by the
phosphoramidases in vitro. These studies suggest that amines beyond L-alaninate esters and
benzylamine may also be used as second prodrug groups. Indeed, SAR studies for a couple of
aliphatic amines have been conducted for the nucleoside of IDX-184 (97). These aliphatic monoamidates (morpholine, isopropylamine) were prepared via Atherton-Todd reaction and exhibited
slightly decreased antiviral activity against HCV1b-infected MT4 cells in the subgenomic
luciferase replicon assay (97). Further investigation into the structural limits of optimal amine
leave groups in other contexts beyond nucleoside monophosphates have yet to be reported perhaps
due to the difficulty in preparing mono-amidated substrates, especially for phosphonate prodrugs
(Section 1.7). Current mono-amidation strategies are hampered by harsh reaction conditions,
hazardous reagents, challenging purifications, and inconsistent yields (16). We have reported the
development of a facile, convenient mono-amidation method based on the Mitsunobu coupling;
when applied to either phosphonic or phosphoric acids, the corresponding mono-amidate can be
generated in reliably in good yields (129). Here, we report the efficacy of various structurally
diverse amine prodrug groups in the context of our laboratory’s phosphonate inhibitor of the
glycolytic enzyme enolase, HEX. We validate the finding that benzylamine and other benzylic
amines may be used as second prodrug groups and also demonstrate that, in the context of HEX,
aliphatic amines are often superior delivery moieties. These results may prompt further
investigation into using aliphatic amines as prodrug moieties for phosphate or phosphonatecontaining drugs.
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3.4 Results and Discussion
We generated a diverse panel of phosphonoamidate prodrugs of HEX using a novel monoamidation reaction that we had previously discovered (129) while screening for amine promoieties
that could deliver HEX to treat cancers harboring homozygous deletions of ENO1 under the
collateral lethality paradigm (4, 5). To evaluate the relationship between our amine promoiety and
efficacy of drug delivery, we first esterified the other free hydroxyl on the phosphonic acid to
enable efficient cell permeability (Figure 20a). We chose the pivaloyloxymethyl (POM) group as
the first ester group due to its known susceptibility for hydrolysis by ubiquitously expressed
esterases (29). Importantly, our decision to employ the labile POM ester minimizes the
confounding effects of initial prodrug cleavage. This is because it has been established that the
POM ester is readily removed in vitro (29, 133). Thus, differences in potency for each
phosphonoamidate prodrug can be attributed to efficiency of P-N bond cleavage (Figure 20b).
Mono-amidated products generated from reactions with BnHEX were subject to POM
esterification, followed by hydrogenation to liberate the hydroxamate—an essential moiety for
Enolase active site inhibition (6, 134) . Esterified phosphonoamidates all demonstrated selective
activity against ENO1-deleted glioma cells (D423) compared to ENO1-rescued (D423 ENO1) and
ENO1-wildtype glioma cells (LN319) (Figure 20c). Given the focus on aryl and benzylic amines
as prodrug motifs in the literature, we were pleasantly surprised to find that aliphatic amines proved
to be more productively cleaved in our in vitro system. Cyclopropylmethanamine-protected HEX
exhibited 10-fold greater potency compared to benzylamine-protected HEX (IC50, D423 = 22 nM
versus 244 nM, Figure 18c). Direct comparison of benzylamine-protected HEX to its saturated
counterpart, cyclohexane methylamine, likewise showed greater potency of the latter (Figure 20c,
entry 3 vs. 11).

Among the panel of amines synthesized, one that was particularly intriguing was dodecylamine, a
long chain alkylamine (Figure 21, CDP22). Owing to its lipophilicity and structural resemblance
to a phospholipid (Figure 21), we found that esterification of the second phosphonate hydroxyl
was unnecessary to achieve good potency against D423 cells (Figure 21). In support of the
hypothesis that CDP22 may permeate cells due to the aforementioned properties, we performed a
head-to-head comparison between CDP22 and VCY33, the free phosphonoamidate counterpart to
VCY32 (Figure 21). Compared to VCY33, which required micromolar concentrations to exert
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meaningful activity against D423 cells (Figure 21), CDP22 demonstrated good activity at
approximately 24 nM.

Figure 20. Aliphatic amines offer superior drug delivery in vitro. (A) General workflow for the
synthesis and screening amidated pro-drugs. For BnHEX, POM esterification followed by de-benzylation
of the hydroxamate yields the final, cell-permeable pro-drug. For specific reaction conditions, see
Experimental (Section 3.6). (B) Proposed bioactivation mechanism for phosphonoamidate pro-drugs.
Phosphoramidases cleave P-N bonds on anionic molecules and can thus serve as second pro-drug
deprotecting enzymes. (C) The relationship between amine structure and pro-drug efficacy can be
evaluated in cell-based screening. (Left) Structures of amine pro-drugs of the Enolase inhibitor with logP
values (calculated from Molinspiration). (Middle) Crystal violet cell proliferation assay evidences greater
cell killing against D423 cells by aliphatic amine pro-drugs compared to benzylamine. Cells were
incubated with pro-drug inhibitor for 5 days. Then, cells were fixed and stained with crystal violet and
quantified spectroscopically. Cell density as measured by crystal violet were plotted as a function of
inhibitor. (Right) Comparison of the IC50 values between model aromatic (FLM37) and aliphatic (CDP18,
VCY32) pro-drugs. While all 3 pro-drugs are selective for ENO1-deleted cells, derivatizing from an
aromatic (FLM37) to an aliphatic amidate (CDP18) increased potency by 3-fold (IC50 = 81.1 nM versus
244 nM. VCY32 featuring a smaller amine exhibits 10-fold greater potency compared to FLM37 (IC50 =
22 nM vs 244 nM). *IC50s in reference to respective POMHEX controls (VCY32 IC50 = 22 nM vs.
POMHEX IC50 = 41.47 nM; VCY34 IC50 = 121.0 nM vs. POMHEX IC50 = 217.0 nM).
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Figure 21 A long-chain aliphatic phosphonoamidate efficiently delivers HEX in vitro. (A)
Proliferation assay evidences nanomolar cytotoxicity by the long-chain aliphatic amine prodrug
against ENO1-deleted cells (top rows, red diamond) compared to ENO1-intact cells (bottom rows,
grey triangle). (b) Dose-response relationship (nanomolar) between CDP22 and VCY33. While
VCY33 as a small negatively charged phosphonoamidate exhibits a dramatic loss of potency (IC 50
= 8,828 nM) compared to its esterified counterpart, VCY32 (IC 50 = 22 nM), CDP22 exerts good
activity despite its negative charge (IC50 = 23 nM).

Preliminary investigations into the mechanism by which these aliphatic and benzylic amines are
cleaved suggest a route different than that observed for L-amino acid esters in McGuigan prodrugs,
which are known to be removed via HINT1 (Section 1.2.2 (32, 33)). HAP1 cells with CRISPR
knockouts (KO) of either HINT1 or CES2 and treated with VCY32, CDP22, or POMHEX (Figure
21); HAP1 cells with KO of PAPSS (3’-phosphoadenosine-5’-phosphosulfate synthase) were used
as a control. Unlike D423 cells, HAP1 cells are ENO1 WT. Thus, while we did not anticipate low
nanomolar toxicity against any of the HAP1 KO cell lines as we had observed in D423 cells, we
hypothesized that, if HINT1 was the main enzyme responsible for cleaving aliphatic amines, then
we would observe less cytotoxicity against HINT1- cells. To our surprise, we found that
cytotoxicity with VCY32, CDP22, and POMHEX were essentially the same across all HAP1 KO
cell lines (Figure 22). Because there was no meaningful reduction in cytotoxicity against HAP1cells compared to PAPSS- cells for VCY32 and CDP22, these data suggest that HINT1 is unlikely
to be the main enzyme that cleaves aliphatic amines from phosphonates. Interestingly, we also
observed no meaningful differences in cytotoxicity when VCY32 or POMHEX were tested in
CES2- cells. As discussed in Section 1.1.1, it has been extensively established that POM esters are
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Figure 22. Aliphatic amines on phosphonates are not preferential substrates for HINT1. HAP1
cells containing CRISPR KO of either HINT1 (red), PAPSS (blue, CT), or CES2 (grey) were treated
with a serial dilution of either VCY32 (left), CDP22 (middle) or POMHEX (right) for 4 days.
-

-

-

Reduced cytotoxicity in either HINT1 or CES2 cells compared to CT cells (PAPSS ) was not
observed for any compounds.

highly susceptible to cleavage by esterases (29). The bisPOM prodrug enolase inhibitor, POMHEX, has a
transient T1/2 in mouse plasma due to the presence of
CES1 (Figure 23) (29); absence of CES1 in human
plasma renders a slightly prolonged T1/2 (24, 29, 39).
Such observations suggest that CES1, which is highly
expressed in the liver (Human Protein Atlas), is largely
responsible for cleaving the first POM ester on POMHEX
and related compounds such as VCY32. We conducted
cytotoxicity comparisons in HAP1 CES2- cells because
CES1 is not expressed in HAP1 and because the haploid
system is easily amenable to CRISPR KO. Negligible
differences in cytotoxicity for POMHEX and VCY32 in
HAP1 CES2- cells seem to provide additional support that
CES1, rather than CES2, is the major enzyme responsible
for removing the first POM promoiety on these
compounds (Figure 23).
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Figure 23. POMHEX is highly unstable
in mouse and human plasma. 4 mM of
POMHEX was dissolved in either 80%
mouse (A) or human serum with 20% D2O
and assayed at the indicated time points.
Chemical shifts (left to right ppm):
POMHEX (27), HemiPOMHEX (15),
PO43-(0). (B) Degradation of POMHEX to
HemiPOMHEX in human plasma (HP) or
mouse plasma (MP).

3.5 Conclusions
In sum, we have generated a panel of structurally diverse phosphonoamidate prodrugs of the
Enolase inhibitor HEX that widen the scope of second leave groups possible for phosph(on)ate
prodrugs. Our data show that low MW aliphatic amines are suitable promoieties that can be cleaved
intracellularly at with seemingly greater efficiency than that observed for benzylamine (Figure 20,
entry 3 vs. 11) (97). Preliminary mechanistic studies suggest that, unlike for amino acid esters on
McGuigan prodrugs, these aliphatic and benzylic amines are not cleaved via HINT1. While a
hydrophobic long chain alkylamine (CDP22) demonstrated good potency against ENO1-deleted
cells in vitro, we found that there was no apparent correlation between potency and logP of the
POM-esterified phosphonoamidate prodrugs (Figure 20). We have also shown that, for established
second promoieties such as benzylamine, fluorine substitution is well-tolerated, pointing to the
feasibility

of

applying

18F-labeling

methods

to

study

pharmacodynamics

for

any

phosphoramidase-labile pro-drug. Collectively, these data demonstrate the feasibility of using low
MW aliphatic amines as second promoieties in phosph(on)ate-containing drugs.

3.6 Experimental
General synthetic procedures. 1H,

13C, 31P,

and

19F

NMR spectra were recorded on a Bruker

Avance 300 MHz spectrometer in either CDCl3 or D2O, unless otherwise indicated. Chemical
shifts were measured in ppm relative to CDCl3 (δ=7.24 for 1H and δ=77.0 for 13C) or D2O (δ=4.80
for 1H). NMR characterizations are reported in the following order: chemical shift, multiplicity (s
= singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet), and coupling
constant (J, reported in Hertz). Where appropriate, 2-dimensional experiments (HSQC) and
decoupled NMR experiments (1H with 31P decoupling) were used to support assignments. BnHEX
was initially synthesized according to previously published procedures (29); subsequent syntheses
were contracted to Wuxi AppTec, Shanghai, China. FLM37 was synthesized as described
previously (47). Other starting materials were purchased at the highest commercial quality from
Sigma Aldrich and were used without additional purification. Centrifugations were performed
using an Eppendorf Centrifuge 5810R. Mass spectra were obtained on a Waters Acquity UPLC
H-Class Plus system (A/B: a = 30% MeCN in water, b = 0.1% formic acid in water) using an
electrospray ion source. HPLC purification of the final compound was performed on an Agilent
Technologies 1260 infinity LC system using C18 reverse phase preparative column (Phenomenex,
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Luna® 5 µm C18(2) 100 Å; LC column 250 x 21.2 mm, ax). All final compounds were determined
to be at least 95% pure by LC analysis.
31P

NMR degradation assay. 4 mM POMHEX (in DMSO) were dissolved in either 80% mouse

plasma 20% D2O or 80% human plasma, 20% D2O in an NMR tube. Samples were run at 202
MHz, ns=500, 25ºC.

In vitro cytotoxicity assay. Cell culture experiments were conducted using the D423-MG cell line.
1p36 homozygous deletion in D423 includes the genes from CAMTA1 to SLC25A33; this
includes ENO1. Isogenic ENO1 ectopically rescued lines were described previously (pCMV
ENO1 5X) (4, 6, 29). An ENO1-intact cell line (LN319) was used as a control for sensitivity to
enolase inhibitors. HAP1 CRISPR KO cells (HINT1-, PAPSS-, or CES2-) were purchased from
Horizon. Cells were routinely cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum. Cell viability was determined by crystal violet staining, as previously
described (4, 6, 29). The cell lines used were D423 (ENO1-deleted), D423 ENO1 (overexpressing
ENO1) and LN319 (control). Glioma cells were seeded in 96-well plates and treated with varying
concentrations of the inhibitors described above for 5-7 days. Cells were then washed with PBS,
fixed with 10% formalin and stained with 0.05% crystal violet. Washed and dried plates were dyeextracted using 10% acetic acid, and absorbance was measured at 595 nm using Omegastar Plate
Reader (BMG Labtech). Crystal violet staining was then performed as described above.
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Scheme 2. Synthesis of structurally diverse phosphonoamidates. Conditions: (a) NHR1R2, PPh3,
DIAD, CH2Cl2, 30 min, 0°C-RT. (b) POM-Cl, MeCN, 50°C, 2 h. (c) H2, Pd/C, MeOH/THF, 2 h, RT.
(d) Cs2CO3, MeOH, RT, 1 h. Pro-drug moieties in blue represent a second pro-drug leave group while
those in red represent a first pro-drug leave group. To screen efficacy of the amine as a second pro-drug
leave group, the BnHEX phosphonoamidate was first esterified with a known, esterase-labile
pivaloyloxymethyl (POM) group and then de-benzylated to liberate the crucial hydroxamate moiety.
CDP22 was not esterified with a POM moiety. VCY33 was generated from VCY32 via ester cleavage
with Cs2CO3 in MeOH.

General procedure (G1, Scheme 2a) for the synthesis of phosphonoamidates from BnHEX.
All coupling reactions described for BnHEX were performed as described in Chapter 2.

General procedure (G2, Scheme 2b) for the synthesis of POM esters from BnHEX
phosphonoamidates. All esterification reactions with POM-Cl follow the same general procedure.
BnHEX phosphonoamidate was dissolved in CHCl3. To this solution DIPEA (2 eq.) was added
followed by POM-Cl (2 eq.). The solution was stirred at 50ºC for 2h. The crude reaction mixture
was then transferred to a 50 mL Falcon tube, where 2 volumes of H2O was added. The reaction
was vortexed and centrifuged twice (4000 rpm, 4°C) each for 2 minutes. The organic layer was
then isolated, washed with brine, dried over Na2SO4, evaporated and lyophilized to a colorless oil,
unless otherwise specified.
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General procedure (G3, Scheme 2c) for the debenzylation of BnHEX phosphonoamidate
POM esters. Pd (10%) on carbon (1:1 w/w) was suspended in anhydrous MeOH/THF (3:2 v/v) in
an appropriate reaction vial or round bottom flask with a septum. Two balloons were filled with
H2, one of which was attached to the septum to purge for 3 min. Then the second balloon was
attached and the suspension was left to stir at RT for 30 min to saturate it with H 2. BnHEX
phosphonoamidate POM ester was dissolved in 200-500 μL MeOH or THF and added to the
stirring suspension which was purged for 3 min by removing 1 balloon. Then the balloon was
reattached and the suspension was left to stir at RT for another 2 h. The reaction mixture was
filtered with a 0.22 μm sterile filter and filtrate was evaporated and purified via HPLC to obtain a
colorless solid, unless otherwise specified.
Synthesis of KY9 (Figure 17, entry 4).
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(pyridin-2-ylmethyl)phosphonamidic

acid

(4a).

Following the procedure G1, the following quantities were used: DIAD (68.17 μL, 350.59 μmol)
and triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL). BnHEX (1, 50 mg,
175.29 μmol) and pyridin-2-ylmethanamine (37.83 μL, 350.59 μmol) in anhydrous DCM (1 mL).
The product was lyophilized to an orange oil. Yield: 48.60 mg (74%). Analysis by ESI+ (Expected
[M+H]+ = 376.36. Observed [M+H]+ = 376.35). 1H NMR (300 MHz, CDCl3) δ 8.38 (d, J=4.73 Hz,
1H), 7.83 (t, J=1.77 Hz, 1.92 Hz, 1H), 7.37-7.49 (m, 7H), 4.90 (d, J=2.02 Hz, 2H), 3.43-3.58 (m,
2H), 2.79-2.91 (dt, J=21.84 Hz, 1H), 2.06-2.14 (m, 1H), 1.91-1.99 (m, 2H), 1.70-1.81 (m, 1H). 31P
NMR (121 MHz, CDCl3) δ 20.60 (1P).

(((1-(benzyloxy)-2-oxopiperidin-3-yl)((pyridin-2-ylmethyl)amino)phosphoryl)oxy)-methyl
pivalate (4b). Following the procedure G2, the following quantities were used: POM-Cl (37.86
μL, 258.95 μmol), DIPEA (45.17 μL, 258.95 µmol), 2a (48.6 mg, 129.47 µmol) in CHCl3 (0.5
mL). Yield: 41.83 mg (66%). Analysis by ESI+ (Expected [M+H]+ =490.51. Observed [M+H]+
=490.41). 1H NMR (300 MHz, CDCl3) δ 8.81 (d, J=4.77 Hz, 1H), 8.24-8.27 (t, J=7.80 Hz, 7.87
Hz, 1H), 7.90-7.92 (d, J=7.99 Hz, 1H), 7.69-7.71 (t, J=6.44 Hz, 6.75 Hz, 1H), 7.33-7.40 (m, 5H),
5.61-5.68 (m, 2H), 4.90 (d, J=2.22 Hz, 2H), 4.64-4.80 (t, J=9.91 Hz, 9.91 Hz, 2H), 3.35-3.37 (m,
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2H), 3.12-3.20 (dt, J=23.65 Hz, 1H), 2.09-2.15 (m, 1H), 1.94-2.05 (m, 2H), 1.69-1.75 (m, 1H),
1.18 (s, 9H). 31P NMR (121 MHz, CDCl3) δ 29.81 (1P), 29.11 (1P).

(((1-hydroxy-2-oxopiperidin-3-yl)((pyridin-2-ylmethyl)amino)phosphoryl)oxy)-methyl
pivalate (KY9). Following the procedure G3, the following quantities were used: 4b (41.83 mg,
82.60 µmol), MeOH (3 ml), THF (2 ml). Analysis by ESI+ (Expected [M+H] + = 400.38. Observed
[M+H]+ =400.48). Yield: 31.4 mg (92%) 1H NMR (300 MHz, CDCl3) δ 8.74 (d, J=4.48 Hz, 1H),
8.17-8.22 (t, J=7.93 Hz, 8.37 Hz, 1H), 7.83-7.85 (m, 1H), 7.62-7.67 (t, J=6.53 Hz, 6.94 Hz, 1H),
5.62-5.64 (d, J=7.04 Hz, 2H), 4.61-4.71 (m, 2H), 3.64 (s, 2H), 3.14-3.27 (dt, J=25.08 Hz, 1H),
1.99-2.19 (m, 2H), 1.78-1.91 (m, 2H), 1.18 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 160.89 (d, J=4.03
Hz, 1C), 123.50 (d, J=3.68 Hz, 1C), 81.67 (d, J=7.61 Hz, 1C), 40.96 (s, 1C), 26.84 (s, 1C), 22.07
(d, J=5.68 Hz, 1C), 21.67 (d, J=7.44 Hz, 1C). 31P NMR (121 MHz, CDCl3) δ 26.16 (1P), 26.59
(1P).

Synthesis of CDP24 (Figure 17, entry 5)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(2-fluorobenzyl)phosphonamidic

acid

(5a).

Following the procedure G1, the following quantities were used: DIAD (265.50 μL, 1340 μmol)
and triphenylphosphine (351.27 mg, 1340 μmol) in anhydrous DCM (3 mL). BnHEX (1, 191.00
mg, 669.62 μmol) and 3- fluorophenylmethane amine (152.78 μL, 1340 μmol) in anhydrous DCM
(1 mL). Yield: 170.05 mg (62%). Analysis by ESI+ (Expected [M+H] + = 393.37. Observed
[M+H]+ = 393.42). 1H NMR (300 MHz, CDCl3) δ 7.15-7.34 (m, 9 H), 4.79 (s, 2H), 4.09 (s, 2H),
3.22-3.37 (m, 2H), 2.62-2.74 (dt, J=21.5 Hz, J=7.5 Hz, 1H), 2.06-2.12 (m, 1H), 1.80-1.85 (m, 2H),
1.55-1.63 (m, 1H). 31P NMR (121 MHz, CDCl3) δ 19.32 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((2-fluorobenzyl)amino)phosphoryl)oxy)-methyl
pivalate. Following the procedure G2, the following quantities were used: POM-Cl (119.25 μL,
815.56 μmol), DIPEA (142.25 μL, 815.56 µmol). 5a (160.05 mg, 407.78 µmol) in CHCl3 (1 mL).
Yield: 112 mg (70%). Analysis by ESI+ (Expected [M+H]+ = 507.52 Observed [M+Na]+ =529.04).
1

H NMR (300 MHz, CDCl3) 7.27-7.41 (m, 10H), 5.52-5.64 (m, 2H), 4.85 (s, 2H), 3.21-3.31 (m,
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2H), 2.74-3.03 (m, 1H), 2.02-2.12 (m, 1H), 1.82-1.99 (m, 2H), 1.59-1.68 (m, 1H), 1.12 (s, 9H).
31P

NMR (121 MHz, CDCl3) δ 29.23 (1P), 29.26 (1P).

((((2-fluorobenzyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)methyl

pivalate

(CDP24). Following the procedure G3, the following quantities were used: 5b (21.17 mg, 41.79
µmol), MeOH (3 ml), THF (2 ml). Yield: 17 mg (97%). Analysis by ESI+ (Expected [M+H]+ =
417.16. Observed [M+H]+ =417.43). 1H NMR (300 MHz, MeOD) 7.02-7.46 (m, 1H), 5.51-5.64
(m, 2H), 4.24-4.40 (m, 2H), 3.60-3.67 (m, 2H), 2.88-3.15 (m, 1H), 2.16-2.29 (m, 1H), 1.91-2.15
(m, 2H), 1.81-1.91 (m, 1H), 1.21 (s, 9H). 13C NMR (75 MHz, MeOD) 176.97 (s, 1C), 162.55 (s,
1C), 160.11 (s, 1C), 129.66 (d, J=4.50 Hz, 1C), 129.33 (d, J = 8.25 Hz, 1C), 126.94 (d, J=5.25 Hz,
1C), 124.34 (d, J=3.75 Hz, 1C), 115.55 (s, 1C), 81.06 (s, 1C), 48.67 (s, 1C), 43.53 (s, 1C), 41.7142.43 (d, J=54.00 Hz, 1C), 38.69 (s, 1C), 26.80 (s, 3C), 21.71 (m, 2C).

31P

NMR (121 MHz, MeOD)

δ 30.04 (1P), 29.13 (1P). 19F NMR (282 MHz, MeOD) δ -118.85 (s, 1F).

Synthesis of CDP12 (Figure 17, entry 6)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(3-fluorobenzyl)phosphonamidic

acid

(6a).

Following the the procedure G1, the following quantities were used: DIAD (265.50 μL, 1340 μmol)
and triphenylphosphine (351.27 mg, 1340 μmol) in anhydrous DCM (3 mL). BnHEX (1, 191.00
mg, 669.62 μmol) and 3- fluorophenylmethane amine (152.78 μL, 1340 μmol) in anhydrous DCM
(1 mL). Yield: 160.05 mg (61%). Analysis by ESI+ (Expected [M+H] + = 393.37. Observed
[M+H]+ = 393.42). 1H NMR (300 MHz, CDCl3) δ 7.18-7.38 (m, 9 H), 4.87 (s, 2H), 4.03 (s, 2H),
3.27-3.38 (m, 2H), 2.62-2.74 (dt, J=22.20 Hz, J=6.9 Hz, 1H), 2.07-2.13 (m, 1H), 1.79-1.88 (m,
2H), 1.55-1.59 (m, 1H). 31P NMR (121 MHz, CDCl3) δ 19.30 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((3-fluorobenzyl)amino)phosphoryl)oxy)-methyl
pivalate (6b). Following the procedure G2, the following quantities were used: POM-Cl (119.25
μL, 815.56 μmol), DIPEA (142.25 μL, 815.56 µmol). 6a (160.05 mg, 407.78 µmol) in CHCl3 (1
mL). Yield: 112 mg (70%). Analysis by ESI+ (Expected [M+H] + = 400.38. Observed [M+H]+
=400.44). 1H NMR (300 MHz, CDCl3) 7.34-7.47 (m, 10H), 5.58-5.70 (m, 2H), 4.92-5.01 (m, 2H),
3.34-3.42 (m, 2H), 3.01-3.13 (dt, J=21.00 Hz, J=6.0 Hz, 1H), 2.17-2.28 (m, 1H), 1.89-2.15 (m,
2H), 1.68-1.77 (m, 1H), 1.25 (s, 9H). 31P NMR (121 MHz, CDCl3) δ 31.18 (1P), 30.91 (1P).
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((((3-fluorobenzyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)methyl

pivalate

(CDP12). Following the procedure G3, the following quantities were used: 6b (112 mg, 221.12
µmol), MeOH (6 ml), THF (4 ml). Analysis by ESI+ (Expected [M+H]+ = 417.16. Observed
[M+H]+ =417.43). Yield: 90 mg (97%). 1H NMR (300 MHz, MeOD) 7.20-7.27 (m, 1H), 7.05-7.11
(m, 2H), 6.95-6.85 (t, J=8.29 Hz, 8.90 Hz, 1H), 5.56 (m, 2H), 4.09-4.16 (t, J=10.08 Hz, 10.08 Hz,
2H), 3.49-3.53 (t, J=5.76, 5.78 Hz, 2H), 3.02-3.16 (dt, J=25.13 Hz, 1H), 1.99-2.11 (m, 2H), 1.861.97 (m, 1H), 1.73-1.84 (m, 1H), 1.10 (s, 9H). 13C NMR (75 MHz, MeOD) 176.89 (s, 1C), 164.66
(s, 1C), 162.23 (d, J=1.43 Hz, 1C), 143.39 (d, J=3.21 Hz, 3.21 Hz, 5.14 Hz, 1C), 129.82-129.93 (d,
J=8.16 Hz, 2C), 113.59 (d, J=5.25 Hz, 2C), 81.37 (d, J=7.5 Hz, 1C), 50.95 (s, 1C), 43.53 (s, 1C),
41.88-43.16 (d, J=96 Hz, 1C), 25.84 (s, 3C), 21.51-22.03 (m, 2C).

31P

NMR (121 MHz, MeOD) δ

31.18 (1P), 30.91 (1P). 19F NMR (282 MHz, MeOD) δ -114.08 (s, 1F), -114.19 (s, 1F).

Synthesis of VCY19 (Figure 17, entry 7)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(4-fluorobenzyl)phosphonamidic

acid

(7a).

Following the procedure G1, the following quantities were used: DIAD (68.17 μL, 350.59 μmol)
and triphenylphosphine (43.87 mg, 350.59 μmol) in anhydrous DCM (3 mL). BnHEX (1, 50 mg,
175.29 μmol) 4-fluorophenylmethane amine (40.07 μL, 350.59 μmol) in anhydrous DCM (1 mL).
Yield: 44 mg (64%). Analysis by ESI+ (Expected [M+H]+ = 393.37. Observed [M+H]+ = 393.38).
1H

NMR (300 MHz, CDCl3) δ 7.41-7.54 (m, 5H), 7.10-7.24 (m, 4H), 4.94 (s, 2H), 4.02 (d, J=8.76

Hz, 2H), 3.46-3.60 (m, 2H), 2.77-2.88 (dt, J=21.74 Hz, 1H), 1.90-2.00 (m, 2H), 2.07-2.16 (m, 1H),
1.77-1.83 (m, 1H). 31P NMR (121 MHz, CDCl3) δ 20.78 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((4-fluorobenzyl)amino)phosphoryl)oxy)-methyl
pivalate (7b). Following the procedure G2, the following quantities were used: POM-Cl (33.11
μL, 224.28 μmol), DIPEA (39.12 μL, 224.28 µmol). 7a (44 mg, 112.14 µmol) in CHCl3 (1 mL).
Yield: 40 mg (70%). Analysis by ESI+ (Expected [M+H]+ = 507.52. Observed [M+H]+ =507.54).
1H

NMR (300 MHz, CDCl3) 7.14-7.35 (m, 9H), 5.58-5.70 (m, 2H), 4.89-5.02 (m, 2H), 3.49-3.53

(m, 2H), 2.99-3.13 (m, 1H), 2.17-2.28 (m, 1H), 1.89-2.15 (m, 2H), 1.66-1.74 (m, 1H), 1.19 (s, 9H).
P NMR (121 MHz, CDCl3) δ 31.11 (1P), 30.81 (1P).
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((((4-fluorobenzyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)methyl

pivalate

(VCY19). Following the procedure G3, the following quantities were used: 7b (40 mg, 112.14
µmol), MeOH (3 ml), THF (2 ml). Yield: 41 mg (96%). Analysis by ESI+ (Expected [M+H]+ =
417.39. Observed [M+H]+ = 417.44). 1H NMR (300 MHz, CDCl3) 6.95-7.02 (m, 4H), 5.52 (s, 2H),
4.19-4.27 (m, 2H), 3.58-3.63 (m, 2H), 2.84-3.08 (m, 1H), 1.95-2.25 (m, 3H), 1.78-1.89 (m, 1H),
1.16 (s, 9H). 13C NMR (75 MHz, CDCl3) 177.40 (s, 1C), 163.91 (d, J=1.43 Hz, 1C), 135.96 (dd,
J=3.21 Hz, 3.21, 5.14 Hz, 1C), 129.22-129.32 (d, J=8.16 Hz, 2C), 115.52 (d, J=3.14, 2C), 81.50
(d, J=5.96 Hz, 1C), 49.53 (s, 1C), 43.91 (s, 1C), 41.03-42.72 (d, J=128.22 Hz, 1C), 27.03 (s, 3C),
21.51-22.15 (m, 2C). 31P NMR (121 MHz, CDCl3) δ 27.23 (1P), 26.08 (1P). 19F NMR (282 MHz,
CDCl3) -116.33 (s, 1F), -116.27 (s, 1F).

Synthesis of CDP13 (Figure 17, entry 8)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(3,4-difluorobenzyl)phosphonamidic

acid

(8a).

Following the procedure G1, the following quantities were used: DIAD (276.11 μL, 1.40 mmol)
and triphenylphosphine (367.82 mg, 1.40 mmol) in anhydrous DCM (3 mL). BnHEX (1, 200 mg,
245.41 μmol) and (3,4-difluorophenyl) methane amine (165.89 μL, 1.40 mmol) in anhydrous
DCM (1 mL). Yield: 104 mg (52%). Analysis by ESI+ (Expected [M+H] + = 411.36. Observed
[M+H]+ = 411.42). 1H NMR (300 MHz, CDCl3) δ 7.21-7.25 (m, 8H), 4.77 (s, 2H), 3.91 (s, 2H),
3.21-3.35 (m, 2H), 2.50-2.62 (m, 1H), 1.90-1.92 (m, 1H). 1.75-1.79 (m, 1H), 1.46-1.50 (1H, m);
31P

NMR (121 MHz, CDCl3) δ 18.95 (1P).

(((1-(benzyloxy)-2-oxopiperidin-3-yl)((3,4-difluorobenzyl)amino)phosphoryl)oxy)-methyl
pivalate (8b). Following the procedure G2, the following quantities were used: POM-Cl (71 μL,
487.38 μmol), DIPEA (85.01 μL, 487.38 µmol), 8a (100 mg, 243.69 µmol) in CHCl3 (1 mL). Yield:
112 mg (70%). Analysis by ESI+ (Expected [M+H]+ = 525.20. Observed [M+H]+ =525.24). 1H
NMR (300 MHz, CDCl3) 7.26-7.34 (m, 5H), 6.95-7.04 (m, 3H), 5.58-5.70 (m, 2H), 4.92-5.01 (m,
2H), 3.29-3.37 (m, 2H), 2.75-2.88 (m, 1H), 2.05-2.13 (m, 1H), 1.81-2.00 (m, 2H), 1.59-1.73 (m,
1H), 1.14 (s, 9H). 31P NMR (121 MHz, CDCl3) δ 29.53 (1P), 23.31 (1P).
((((3,4-difluorobenzyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy-)methyl
pivalate (CDP13). Following the procedure G3, the following quantities were used: 8b (85 mg,
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221.12 µmol), MeOH (6 ml), THF (4 ml). Yield: 67 mg (96%). Analysis by ESI+ (Expected
[M+H]+ = 435.15. Observed [M+H]+ =435.47). 1H NMR (300 MHz, CDCl3) 7.21 (m, 1H), 7.11
(m, 2H), 6.63 (bs, 1H), 5.60 (m, 2H), 4.28 (m, 2H), 3.61-3.64 (t, J=3.14 Hz, 4.17 Hz, 2H), 2.973.09 (dt, J=23.84 Hz, 1H), 2.19-2.28 (m, 1H), 1.99-2.12 (m, 2H), 1.80-1.92 (m, 1H), 1.18 (s, 9H).
NMR (75 MHz, CDCl3) δ 176.98 (s, 1C), 159.87 (d, J=1.92 Hz, 2C), 151.46 (s, 1C), 123.15

13C

(s, 1C), 117.47 (d, J=17.00 Hz, 1C), 116.20 (d, J=18.00 Hz, 1C), 81.06 (d, J=7.50 Hz, 1C), 48.56
(s, 1C), 38.76-40.54 (d, J=134.60 Hz, 1C), 32.15-32.25 (t, J=3.75 Hz, 4.04 Hz, 1C), 26.78 (s, 3C),
21.71 (d, J=12.00 Hz, 1C), 21.40 (d, J=4.56 Hz, 1C). Note: some quaternary carbons not observed.
31P

NMR (121 MHz, CDCl3) δ 29.95 (1P), 28.79 (1P). 19F NMR (282 MHz, CDCl3) δ -137.78 (d,

J=20.79 Hz, 1F), -137.83 (d, J=21.62 Hz, 1F), -140.40 (d, J=21.17 Hz, 1F), 140.43 (d, J=21.33 Hz,
1F).

Synthesis of CDP14 (Figure 17, entry 9)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(2,4-difluorobenzyl)phosphonamidic

acid

(9a).

Following the procedure G1, the following quantities were used: DIAD (96.64 μL, 490.82 μmol)
and triphenylphosphine (128.74 mg, 490.82 μmol) in anhydrous DCM (3 mL). BnHEX (1, 70 mg,
245.41 μmol) and (2,4-difluorophenyl) methane amine (58.55 μL, 490.82 μmol) in anhydrous
DCM (1 mL). Yield: 54.7 mg (61%). Analysis by ESI+ (Expected [M+H] + = 411.12. Observed
[M+H]+ = 411.38). 1H NMR (300 MHz, CDCl3) δ 6.68-7.71 (m, 8H), 4.84 (m, 2H), 4.09 (s, 2H),
3.29 (m, 2H), 2.65 (m, 1H), 2.01 (m, 2H). 1.55 - 1.76 (2H, m); 31P NMR (121 MHz, CDCl3) δ
18.98 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((2,4-difluorobenzyl)amino)phosphoryl)oxy)-methyl
pivalate (9b). Following the procedure G2, the following quantities were used: POM-Cl (30.4 μL,
208.11 μmol), DIPEA (36.30 μL, 208.11 µmol), 9a (42.7 mg, 104.06 µmol) in CHCl3 (0.5 mL).
Yield: 35 mg (66%). (Expected [M+H]+ = 525.20. Observed [M+H]+ =525.24). 1H NMR (300
MHz, CDCl3) 7.26-7.34 (m, 5H), 6.66-6.73 (m, 3H), 5.52-5.68 (m, 2H), 4.15-4.37 (m, 2H), 3.213.37 (m, 2H), 2.75-3.07 (m, 1H), 2.04-2.10 (m, 1H), 1.76-1.97 (m, 2H), 1.57-1.69 (m, 1H), 1.16
(s, 9H). 31P NMR (121 MHz, CDCl3) δ 29.68 (1P), 29.33 (1P).
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((((2,4-difluorobenzyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)-methyl
pivalate (CDP14). Following the procedure G3, the following quantities were used: 9b (35 mg,
66.73 µmol), MeOH (3 ml), THF (2 ml). Yield: 28.2 mg (97%). Analysis by ESI+ (Expected
[M+H]+ = 435.15. Observed [M+H]+ =435.40). 1H NMR (300 MHz, CDCl3) 7.42 (m, 1H), 6.86
(m, 2H), 6.12 (bs, 1H), 5.56-5.60 (dd, J=12.77 Hz, 2H), 4.33 (m, 2H), 3.63 (m, 2H), 2.96-3.09 (dt,
J=22.80 Hz, 1H), 2.17-2.26 (m, 1H), 1.98-2.10 (m, 2H), 1.79-1.90 (m, 1H), 1.17 (s, 9H). 13C NMR
(75 MHz, CDCl3) δ 177.11 (s, C), 159.65 (d, J=1.92 Hz, 1C), 130.49 (m, 1C), 111.65 (s, 2C),
80.96 (d, J=7.5 Hz, 1C), 49.25 (s, 1C), 40.70-42.41 (d, J=128.25 Hz, 1C), 38.08 (t, J=3.75 Hz,1C),
26.81 (s, 3C), 21.35-21.71 (m, 2C). Note: some quaternary carbons not observed. 31P NMR (121
MHz, CDCl3) δ 29.94 (1P), 28.79 (1P). 19F NMR (282 MHz, CDCl3) δ -111.55 (d, J=7.29 Hz, 1F),
-111.66 (d, J=7.41 Hz, 1F), -115.2 (d, J=7.74 Hz, 1F), -115.18 (d, J=7.77 Hz, 1F).

Synthesis of CDP19 (Figure 17, entry 10)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(2,6-difluorobenzyl)phosphonamidic acid (10a).
Following the procedure G1, the following quantities were used: DIAD (96.64 μL, 490.82 μmol)
and triphenylphosphine (128.74 mg, 490.82 μmol) in anhydrous DCM (3 mL). BnHEX (1, 70 mg,
245.41 μmol) and (2,6-difluorophenyl) methane amine (58.55 μL, 490.82 μmol) in anhydrous
DCM (1 mL). Yield: 54.7 mg (61%). Analysis by ESI+ (Expected [M+H] + = 411.12. Observed
[M+H]+ = 411.38).1H NMR (300 MHz, CDCl3) δ 7.28-7.70 (m, 9 H), 4.90-4.94 (m, 2H), 4.004.03 (d, J = 6.0 Hz, 2H), 3.26-3.32 (m, 2H), 2.56-2.68 (dt, J= 22.20 Hz, J=6.9 Hz, 1H), 1.97-1.99
(m, 1H), 1.71-1.86 (m, 2H), 1.55-1.56 (m, 1H). 31P NMR (121 MHz, CDCl3) δ 17.47 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((2,6-difluorobenzyl)amino)phosphoryl)oxy)-methyl
pivalate (10b). Following the procedure G2, the following quantities were used: POM-Cl (30.4
μL, 208.11 μmol), DIPEA (36.30 μL, 208.11 µmol), 7a (50 mg, 104.06 µmol) in CHCl3 (0.5 mL).
Yield: 40 mg (63%). (Expected [M+H]+ = 525.20. Observed [M+Na]+ =547.00). 1H NMR (300
MHz, CDCl3) 7.27-7.36 (m, 5H), 7.12-7.19 (m, 1H), 6.78-6.85 (m, 2H), 5.47-5.68 (m, 2H), 4.82
(s, 2H), 4.35-4.38 (m, 2H), 3.24-3.29 (m, 2H), 2.73-3.01 (m, 1H), 2.43-2.50 (m, 1H), 2.04-2.10
(m, 1H), 1.81-1.95 (m, 2H), 1.59-1.65 (m, 2H), 1.13 (s, 9H). 31P NMR (121 MHz, CDCl3) δ 29.10
(1P), 28.88 (1P).
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((((2,6-difluorobenzyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)-methyl
pivalate (CDP19). Following the procedure G3, the following quantities were used: 10b (35 mg,
66.73 µmol), MeOH (6 ml), THF (4 ml). Yield: 27.1 mg (93%). Analysis by ESI+ (Expected
[M+H]+ = 435.38. Observed [M+H]+ =435.40). 1H NMR (300 MHz, CDCl3) δ 7.23 (m, 2H), 6.856.90 (t, J= 7.51 Hz, 8.09 Hz, 1H), 5.51-5.57 (dd, J=13.24 Hz, 2H), 4.40 (m, 2H), 3.63 (m, 2H),
2.99-3.10 (dt, J=23.86 Hz, 1H), 2.17-2.26 (m, 1H), 1.97-2.11 (m, 2H), 1.80-1.90 (m, 1H), 1.17 (s,
9H).

13C

NMR (75 MHz, CDCl3) δ 176.98 (s, 1C), 159.61 (d, J=1.92 Hz, 2C), 129.58 (s, 1C),

111.65 (s, 2C), 81.03 (d, J=6.44 Hz, 1C), 48.43 (s, 1C), 38.76-40.54 (d, J=134.60 Hz, 1C), 32.1532.25 (t, J=3.75 Hz, 4.04 Hz, 1C), 26.78 (s, 3C), 21.71 (d, J=12.00 Hz, 1C), 21.40 (d, J=4.56 Hz,
1C). Note: some quaternary carbons not observed.

31P

NMR (121 MHz, CDCl3) δ 29.28 (1P),

28.61 (1P). 19F NMR (282 MHz, CDCl3) -115.33 (s, 2F).

Synthesis of CDP18 (Figure 17, entry 11)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(cyclohexylmethyl)phosphonamidic acid (11a). To a
solution of triphenylphosphine (275.87 mg, 1.05 mmol) in DCM (6 mL), DIAD (204.50 μL, 1.05
mmol) was added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX (150
mg, 525.88 mmol), cyclohexane methylamine (136.85 μL, 1.05 μmol), and DBU (157.29 μL, 1.05
mmol) in DCM (2 mL) was prepared and added dropwise to the betaine solution. The reaction
mixture was allowed to warm to room temperature over 30 minutes. Then, 1 volume of water was
added to the crude mixture. After vigorous shaking and partitioning via centrifugation (2 min at
4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to clear oil. Yield: 142.35 mg
(83%). Analysis by ESI+ (Expected [M+H]+ = 381.42. Observed [M+H]+ =381.50). 1H NMR (300
MHz, CDCl3) δ 7.37-7.44 (m, 5H) 3.61-3.65 (m, 2H), (m, 1H), 2.15-2.25 (m, 1H), 1.97-2.12 (m,
2H), 1.83-1.93 (m, 1H), 1.62-1.74 (m, 6H), 1.32-1.44 (m, 1H), 0.79-0.94 (m, 3H). 31P NMR (121
MHz, CDCl3) δ17.41 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((cyclohexylmethyl)amino)phosphoryl)oxy)-methyl
pivalate (8b). Following the procedure G2, the following quantities were used: POM-Cl (108.56
μL, 749.69 µmol), DIPEA (115.35 μL, 749.69 µmol), 11a (142.35 mg, 374.84 µmol) in CHCl3 (1
mL). Yield: 113.26 mg (66%). (Expected [M+H]+ = 525.20. Observed [M+H]+ =525.24). 1H NMR
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(300 MHz, CDCl3) 7.27-7.40 (m, 5H), 5.53-5.64 (m, 2H), 4.86-4.89 (m, 2H), 3.20-3.35 (m, 2H),
2.88-2.97 (m, 1H), 2.75-2.88 (m, 2H), 2.04-2.10 (m, 1H), 1.82-1.97 (m, 2H), 1.50-1.78 (m, 8H),
1.29-1.40 (m, 1H), 1.15 (s, 9H), 0.83-0.98 (m, 4H). 31P NMR (121 MHz, CDCl3) δ 29.99 (1P),
29.56 (1P).
((((Cyclohexylmethyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)-methyl
pivalate (CDP18). Following the procedure G3, the following quantities were used: 11b (113.26
mg, 228.97 µmol), MeOH (6 ml), THF (4 ml). Yield: 88.10 mg (95%). Analysis by ESI+ (Expected
[M+H]+ = 405.45. Observed [M+H]+ =405.44). 1H NMR (300 MHz, CDCl3) δ 5.54-5.64 (m, 2H),
3.61-3.65 (m, 2H), 2.88-2.97 (m, 1H), 2.15-2.25 (m, 1H), 1.97-2.12 (m, 2H), 1.83-1.93 (m, 1H),
1.62-1.74 (m, 6H), 1.32-1.44 (m, 1H), 1.19 (s, 9H), 0.79-0.94 (m, 3H). 13C NMR (75 MHz, CDCl3)
177.18 (s, 1C), 160.29 (d, J=1.19 Hz, 1C), 92.29 (s, 1C), 81.35-81.44 (d, J=7.52 Hz, 1C), 40.6242.34 (d, J=130.41 Hz, 1C), 30.67 (d, J=1.28 Hz, 1C) 27.00 (s, 3C), 26.00 (s, 2C), 25.98 (s, 1C),
25.96 (s, 1C), 21.85-21.89 (d, J=2.72 Hz, 1C), 21.67-21.73 (d, J=5.09 Hz, 1C).

31P

NMR (121

MHz, CDCl3) δ 30.65 (1P), 29.94 (1P).

Synthesis of VCY32 (Figure 17, entry 12)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(cyclopropylmethyl)phosphonamidic acid (12a). To
a solution of triphenylphosphine (275.87 mg, 1.05 mmol) in DCM (15 mL), DIAD (204.50 μL,
1.05 mmol) was added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX
(150 mg, 525.88 mmol), cyclopropyl methyl amine hydrochloride (74.80 mg, 1.05 mmol), and
DBU (156.98 μL, 1.05 mmol) in DCM (2 mL) was prepared and added dropwise to the betaine
solution. The reaction mixture was allowed to warm to room temperature over 30 minutes. Then,
1 volume of water was added to the crude mixture. After vigorous shaking and partitioning via
centrifugation (2 min at 4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to a clear
solid. Analysis by ESI+ (Expected [M+H]+ =339.34. Observed [M+H]+ = 339.38). Yield: 49.50
mg (83%). 1H NMR (300 MHz, CDCl3) δ 7.32-7.51 (m, 5H), 4.70-4.74 (d, J=2.1 Hz, 2H), 3.10
(m, 2H), 2.67-2.75 (m, 1H), 2.44-2.50 (m, 1H), 2.02-2.06 (m, 1H), 1.89-1.94 (m, 2H), 1.69-1.75
(m, 1H), 1.08-1.12 (m, 1H), 0.76-0.86 (m, 1H), 0.23-0.27 (m, 2H), 0.01-0.02 (m, 2H). 31P NMR
(202 MHz, CDCl3) δ 19.54 ppm (1P).
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(((1-(benzyloxy)-2-oxopiperidin-3-yl)((cyclopropylmethyl)amino)phosphoryl)oxy)-methyl
pivalate (12b): Following the procedure G2, the following quantities and conditions were used:
POM-Cl (43.20 μL, 292.60 µmol), DIPEA (51.04 μL, 292.60 µmol), 12a (49.50 mg, 146.30 µmol)
in CHCl3 (1 mL). Yield: 46.20 mg (69%). 1H NMR (300 MHz, CDCl3) δ 7.32-7.51 (m, 5H), 5.515.61 (m, 2H), 3.59 (m, 2H), 2.79-2.90 (m, 1H), 2.77-2.83 (m, 1H), 2.08-2.18 (m, 1H), 2.08-2.13
(m, 2H), 1.79-1.82 (m, 1H), 1.15 (s, 9H), 0.41 (m, 1H), 0.12 (m, 1H). 31P NMR (121 MHz, CDCl3)
δ 31.51 (1P), 31.12 (1P).
((((Cyclopropylmethyl)amino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)-methyl
pivalate (VCY32). Following the procedure G3, the following quantities were used: 12b (46.20
mg, 102.10 µmol), MeOH (3 ml), THF (2 ml). Yield: 33.3 mg (90%). Analysis by ESI+ (Expected
[M+H]+ = 363.36. Observed [M+H]+ = 363.39). 1H NMR (300 MHz, CDCl3) δ 5.54-5.59 (m, 2H),
3.59 (m, 2H), 2.92-2.98 (dt, J=18.06 Hz, 1H), 2.78-2.82 (q, J= 6.81 Hz, 7.07 Hz, 7.07 MHz, 1H),
2.14-2.20 (m, 1H), 2.07-2.13 (m, 2H), 1.77-1.85 (m, 1H), 1.16 (s, 9H), 0.44 (m, 1H), 0.17 (m, 1H).
13C

NMR (75 MHz, CDCl3) δ 177.12 (s, 1C), 160.77 (d, J=5.46 Hz, 1C), 81.23 (d, J=2.76 Hz, 1C),

49.98 (s, 1C), 45.87 (d, J=0.95 Hz, 1C), 42.36-41.35 (d, J=127.79 Hz, 1C), 38.87 (s, 1C), 27.03 (s,
3C), 22.03 (d, J=4.83 Hz, 1C), 21.64 (d, J=4.83 Hz, 1C), 13.38 (d, J=6.46 Hz, 1C), 3.62 (s, 1C),
3.60 (s, 1C). 31P NMR (121 MHz, CDCl3) δ 30.15 (1P), 28.65 (1P).

Synthesis of VCY33
N-(cyclopropylmethyl)-P-(1-hydroxy-2-oxopiperidin-3-yl)phosphonamidic acid (VCY33).
VCY32 (35.00 mg, 96.59 µmol) and CsCO3 (31.9 mg, 96.59 µmol) were dissolved in MeOH (0.5
ml). The reaction mixture was stirred at RT for 1 h, then evaporated, purified via HPLC and
lyophilized to obtain a white solid. Yield: 23.3 mg (97%). Analysis by ESI+ (Expected [M+H] + =
249.23. Observed [M+Na]+ = 271.89). Yield: 21.85 mg (91%) 1H NMR (300 MHz, D2O) δ 3.383.51 (m, 2H), 2.49-2.74 (m, 3H), 1.95-2.05 (m, 1H), 1.82-1.92 (m, 2H), 1.66-1.75 (m, 1H), 0.830.94 (m, 1H), 0.37-0.40 (m, 2H), 0.04-0.09 (m, 2H). 13C NMR (75 MHz, D2O) δ 163.18 (s, 1C),
52.38 (s, 1C), 46.47 (s, 1C), 40.94-42.40 (d, J=34.5 Hz, 1C), 21.06 (s, 1C), 17.01 (s, 1C), 11.9912.11 (d, J=10.5 Hz, 1C), 2.71 (d, J=2.25 Hz, 2C). 31P NMR (121 MHz, D2O) δ 24.26 (1P).
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Synthesis of VCY34 (Figure 17, entry 13)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-cyclobutylphosphonamidic acid (13a). To a solution
of triphenylphosphine (919.56 mg, 3.51 mmol) in DCM (20 mL), DIAD (681.66 μL, 3.51 mmol)
were added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX (500 mg,
1.75 mmol), cyclobutylamine (299.34 μL, 3.51 mmol), and DBU (523.27 μL, 3.51 mmol) in DCM
(2 mL) was prepared and added dropwise to the betaine solution. The reaction mixture was allowed
to warm to room temperature over 30 minutes. Then, 1 volume of water was added to the crude
mixture. After vigorous shaking and partitioning via centrifugation (2 min at 4°C, 4000 rpm), the
aqueous layer was isolated and lyophilized to a clear solid. 49.50 mg (83%). Analysis by ESI+
(Expected [M+H]+ =339.34. Observed [M+H]+ = 339.41). 1H NMR (300 MHz, CDCl3) 7.45-7.55
(m, 5H), 4.96 (s, 1H), 3.26-3.30 (t, J=5.55 Hz, 6.01 Hz, 2H), 2.68-2.79 (dt, J=21.36 Hz, 1H),
2.19-.27 (m, 2H), 2.05-2.11 (m, 1H), 1.79-1.91 (m, 4H), 1.51-1.62 (m, 2H). 31P NMR (121 MHz,
CDCl3) 19.47 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((cyclobutyl)amino)phosphoryl)oxy)-methyl

pivalate

(10b): Following the procedure G2, the following quantities and conditions were used: POM-Cl
(43.20 μL, 292.60 µmol), DIPEA (51.04 μL, 292.60 µmol), 13a (50 mg, 144.83 µmol) in CHCl3
(0.5 mL). Yield: 46.1 mg (69%). Analysis by ESI+ (Expected [M+H] + =453.50. Observed
[M+Na]+ = 475.02). 1H NMR (300 MHz, CDCl3) δ 7.28-7.40 (m, 5H), 5.52-5.57 (m, 2H), 3.773.96 (m, 1H), 3.23-3.35 (m, 2H), 2.70-2.93 (m, 1H), 2.22-2.29 (m, 2H), 2.02-2.11 (m, 1H), 1.831.96 (m, 2H), 1.48-1.69 (m, 1H), 1.19 (s, 9H). 31P NMR (121 MHz, CDCl3) δ 27.53 (1P), 27.08
(1P).
(((Cyclobutylamino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)methyl

pivalate

(VCY34). Following the procedure G3, the following quantities were used: 13b (46.20 mg, 102.10
µmol), MeOH (3 ml), THF (2 ml). Yield: 33.6 mg (90%). Analysis by ESI+ (Expected [M+H] + =
363.36. Observed [M+H]+ = 363.98). 1H NMR (300 MHz, CDCl3) δ 5.55-5.57 (d, J= 5.32 Hz, 2H),
3.78-3.91 (m, 1H), 3.57 (t, J=4.76 Hz, 6.89 Hz, 2H), 2.90-2.98 (dt, J=14.04 Hz, 1H), 2.26 (m, 2H),
2.10 (m, 2H), 1.99 (m, 2H), 1.89 (m, 2H), 1.60 (m, 2H), 1.15 (s, 9H). 13C NMR (75 MHz, CDCl3)
δ 179.81 (s, 1C), 177.09-177.19 (d, J=7.21 Hz, 1C), 81.20-81.30 (d, J=7.85 Hz, 1C), 50.15 (s, 1C),
46.56 (d, J=3.64 Hz, 1C), 41.19-41.88 (d, J=128.81 Hz, 1C), 38.79 (s, 2C), 26.92 (s, 1C), 22.02 (s,
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1C), 21.94 (d, J=4.50 Hz, 1C), 21.69 (d, J=5.22 Hz, 1C).

31P

NMR (121 MHz, CDCl3) δ 28.31

(1P), 27.47 (1P).

Synthesis of CDP21 (Figure 17, entry 14)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N,N-dimethylphosphonamidic

acid

(14a).

To

a

solution of triphenylphosphine (91.96 mg, 350.59 mmol) in DCM (2.5 mL), DIAD (68.17 μL,
350.59 mmol) were added with stirring at 0°C for 30 min. Separately, a solution containing
BnHEX (50 mg, 175.29 mmol), dimethylamine hydrochloride (28.59 mg, 350.59 mmol), and
DBU (53.37 mg, 350.59 mmol) in DCM (1 mL) was prepared and added dropwise to the betaine
solution. The reaction mixture was allowed to warm to room temperature over 30 minutes. Then,
1 volume of water was added to the crude mixture. After vigorous shaking and partitioning via
centrifugation (2 min at 4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to clear
oil. Yield: 47 mg (86%). Analysis by ESI+ (Expected [M+H] + = 313.13 Observed [M+H]+ =
313.20). 1H NMR (300 MHz, CDCl3) δ 7.28-7.46 (m, 5H), 5.50-5.60 (m, 2H), 3.23-3.50 (m, 2H),
2.98-3.02 (m, 1H), 2.68-2.73 (d, J=9.0 Hz, 6H), 2.20-2.23 (m, 1H), 2.02-2.06 (m, 1H), 1.89-1.92
(m, 1H), 1.55-1.64 (m, 2H). 31P NMR (121 MHz, CDCl3) δ 31.69 (1P), 29.85 (1P), 29.13 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)(dimethylamino)phosphoryl)oxy)methyl

piva-late

(14b): Following the procedure G2, the following quantities and conditions were used: POM-Cl
(43.59 μL, 300.99 µmol), DIPEA (52.50 μL, 300.99 µmol), 14a (47 mg, 150.49 µmol) in CHCl3
(1 mL), 40ºC. Yield: 42.36 mg (66%). Analysis by ESI+ (Expected [M+H]+ = 427.20 Observed
[M+Na]+ = 449.18) 1H NMR (300 MHz, CDCl3) δ 7.37-7.47 (m, 5H), 5.58-5.70 (m, 2H), 4.925.01 (m, 2H), 3.34-3.42 (m, 2H), 3.01-3.13 (m, 1H), 2.82 (d, J=9.8 Hz, 6H), 2.17-2.28 (m, 1H),
1.89-2.15 (m, 2H), 1.67-1.77 (m, 9H). 31P NMR (121 MHz, CDCl3) δ 31.96 (1P), 30.13 (1P).
(((dimethylamino)(1-hydroxy-2-oxopiperidin-3-yl)phosphoryl)oxy)methyl pivalate (CDP21).
Following the procedure G3, the following quantities were used: 14b (113.26 mg, 228.97 µmol),
MeOH (3 ml), THF (2 ml). Yield: 33 mg (98%). Analysis by ESI+ (Expected [M+H] + = 337.15
Observed [M+Na]+ = 358.95). 1H NMR (300 MHz, CDCl3) δ 5.54-5.64 (m, 2H), 3.56-3.71 (m,
2H), 2.99-3.09 (m, 1H), 2.71-2.74 (d, J=9.8 Hz, 6H), 1.83-2.37 (m, 2H), 2.00-2.20 (m, 2H), 1.621.74 (m, 9H). 13C NMR (75 MHz, CDCl3) 177.15 (s, 1C), 160.12 (d, J=1.19 Hz, 1C), 80.05-81.07
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(d, J=6.0 Hz, 1C), 50.79 (s, 1C), 38.17-39.84 (d, J=123 Hz, 1C), 38.80 (s, 1C), 36.39-36.47 (d,
J=5.25 Hz, 2C), 26.90 (s, 3C), 22.49 (d, J=2.72 Hz, 1C), 21.39 (d, J=2.72 Hz, 1C). 31P NMR (121
MHz, CDCl3) δ 30.99 (1P), 29.14 (1P).

Synthesis of CDP23 (Figure 17, entry 15)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-methylphosphonamidic acid (15a). To a solution of
triphenylphosphine (183.91 mg, 701.17 μmol) in DCM (5 mL), DIAD (136.33 μL, 701.17 μmol)
was added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX (100 mg,
350.59 μmol), methylamine hydrochloride (47.34 mg, 701.17 μmol), and DBU (106.75 μL, 701.17
μmol) in DCM (1 mL) was prepared and added dropwise to the betaine solution. The reaction
mixture was allowed to warm to room temperature over 30 minutes. Then, 1 volume of water was
added to the crude mixture. After vigorous shaking and partitioning via centrifugation (2 min at
4°C, 4000 rpm), the aqueous layer was isolated and lyophilized to clear oil. Yield: 57.8 mg (55%)
Analysis by ESI+ (Expected [M+H]+ = 299.12 Observed [M+H]+ =299.14) 1H NMR (300 MHz,
CDCl3) δ 7.16-7.40 (m, 5H), 4.63 (s, 2H), 3.39-3.44 (m, 2H), 2.77-2.83 (m, 2H), 2.44-2.55 (m,
1H), 2.34-2.38 (d, J = 12 Hz, 3H), 1.80-1.84 (m, 2H), 1.62-1.69 (m, 1H), 1.42-1.55 (m, 1H), 1.321.39 (m, 1H). 31P NMR (121 MHz, CDCl3) δ 24.49 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)(methylamino)phosphoryl)oxy)methyl pivalate (15b):
Following the procedure G2, the following quantities and conditions were used: POM-Cl (112.24
μL, 775.11 µmol), DIPEA (135.20 μL, 775.11 µmol), 15a (57.8 mg, 193.78 µmol) in CHCl3 (1
mL), 40ºC. Yield: 54.57 mg (68%). Analysis by ESI+ (Expected [M+H] + = 413.18 Observed
[M+Na]+ = 435.17) 1H NMR (300 MHz, CDCl3) δ 7.37-7.54 (m, 5H), 5.63-5.75 (m, 2H), 4.885.01 (m, 2H), 3.29-3.43 (m, 2H), 2.94-3.12 (m, 1H), 2.83 (d, J=12.2 Hz, 6H), 2.12-2.24 (m, 1H),
1.88-2.11 (m, 2H), 1.63-1.81 (m, 9H). 31P NMR (121 MHz, CDCl3) δ 31.74 (1P), 31.70 (1P).
(((1-hydroxy-2-oxopiperidin-3-yl)(methylamino)phosphoryl)oxy)methyl pivalate (CDP23).
Following the procedure G3, the following quantities were used: 15b (113.26 mg, 228.97 µmol),
MeOH (3 ml), THF (2 ml). Yield: 41 mg (98%). Analysis by ESI+ (Expected [M+H] + = 323.14
Observed [M+ Na]+ = 344.91). 1H NMR (300 MHz, CDCl3) δ 5.60-5.69 (m, 2H), 3.86 (brs, 1H),
3.66-3.70 (m, 2H), 2.92-3.03 (dt, J = 6.0 Hz, J = 16.8 Hz, 1H), 2.71-2.74 (dd, J = 5.4 Hz, J=12.3
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Hz, 3H), 2.08-2.25 (m, 2H), 1.87-1.96 (m, 1H), 1.5 (s, 9H). 13C NMR (75 MHz, CDCl3) 177.05
(s, 1C), 160.11 (d, J=5.25 Hz, 1C), 81.01-81.10 (d, J=6.75 Hz, 1C), 48.32 (s, 1C), 41.69 (s, 1C),
40.98 (s, 1C), 40.00 (s, 1C), 38.74 (s, 1C), 26.89 (s, 3C), 21.64 (s, 1C), 21.50 (s, 1C). 31P NMR
(121 MHz, CDCl3) δ 29.93 (1P).

Synthesis of CDP25 (Figure 17, entry 16)
P-(1-(benzyloxy)-2-oxopiperidin-3-yl)-N-(1-isopropoxy-1-oxopropan-2-yl)phosphonamidic
acid (16a). To a solution of triphenylphosphine (183.91 mg, 701.17 μmol) in DCM (5 mL), DIAD
(136.33 μL, 701.17 μmol) was added with stirring at 0°C for 30 min. Separately, a solution
containing BnHEX (100 mg, 350.59 μmol), L-alanine isopropylester hydrochloride (117.54 mg,
701.17 μmol), and DBU (106.75 μL, 701.17 μmol) in DCM (1 mL) was prepared and added
dropwise to the betaine solution. The reaction mixture was allowed to warm to room temperature
over 30 minutes. Then, 1 volume of water was added to the crude mixture. After vigorous shaking
and partitioning via centrifugation (2 min at 4°C, 4000 rpm), the aqueous layer was isolated and
lyophilized to clear oil. Yield: 57.8 mg (55%) Analysis by ESI+ (Expected [M+H] + = 399.17
Observed [M+Na]+ = 399.21) 1H NMR (300 MHz, CDCl3) δ 5.64-5.73 (m, 2H), 5.10-5.14 (m,
2H), 4.01-4.67 (m, 1H), 3.65-3.69 (m, 2H), 2.97-3.35 (m, 1H), 2.20-2.29 (m, 1H), 1.97-2.82 (m,
2H), 1.83-1.97 (m, 2H), 1.42-1.49 (m, 1H), 1.22-1.29 (m, 1H).

31P

NMR (121 MHz, CDCl3) δ

23.59 (1P).
(((1-(benzyloxy)-2-oxopiperidin-3-yl)((1-isopropoxy-1-oxopropan-2yl)amino)phosphoryl)oxy)methyl pivalate (16b): Following the procedure G2, the following
quantities and conditions were used: POM-Cl (112.24 μL, 775.11 µmol), DIPEA (135.20 μL,
775.11 µmol), 13a (57.8 mg, 193.78 µmol) in CHCl3 (1 mL), 40ºC. Yield: 54.57 mg (68%).
Analysis by ESI+ (Expected [M+H]+ = 513.21 Observed [M+Na]+ =535.02) 1H NMR (300 MHz,
CDCl3) δ 7.28-7.36 (m, 5H), 5.56-5.68 (m, 2H), 4.88 (s, 2H), 4.46-4.52 (m, 1H), 4.10-4.19 (m,
1H), 3.27-3.31 (m, 2H), 2.79-2.94 (m, 1H), 2.03-2.09 (m, 1H), 1.88-1.99 (m, 2H), 1.60-1.68 (m,
1H), 1.23 (d, J = 3.3 Hz, 3H), 1.19 (s, 9H), 1.17 (d, J = 2.7 Hz, 6H). 31P NMR (121 MHz, CDCl3)
δ 29.45 (1P), 27.22 (1P).
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(((1-hydroxy-2-oxopiperidin-3-yl)(methylamino)phosphoryl)oxy)methyl pivalate (CDP25).
Following the procedure G3, the following quantities were used: 16b (41.48 mg, 83.87 µmol),
MeOH (3 ml), THF (2 ml). Yield: 41 mg (98%). Analysis by ESI+ (Expected [M+H]+ = 423.42
Observed [M+Na]+ = 445.00). 1H NMR (300 MHz, CDCl3) δ 5.61-5.74 (m, 2H), 5.00-5.07 (m,
2H), 4.01-4.67 (m, 1H), 3.65-3.69 (m, 2H), 2.97-3.35 (m, 1H), 2.20-2.29 (m, 1H), 1.97-2.82 (m,
2H), 1.83-1.97 (m, 2H), 1.42-1.49 (m, 1H), 1.22-1.29 (m, 1H). 13C NMR (75 MHz, CDCl3) 177.00
(s, 1C), 173.76 (d, J=3.25 Hz, 1C), 160.40 (s, 1C), 116.93 (s, 1C), 113.13 (s, 1C), 81.50 (d, J=7.50
Hz, 1C), 69.25 (s, 1C), 50.29 (s, 1C), 49.68 (s, 1C), 42.97 (s, 1C), 41.22 (s, 1C), 38.75 (s, 1C),
26.89 (s, 3C), 21.66 (s, 1C). 31P NMR (121 MHz, CDCl3) δ 29.06 (1P).

Synthesis of CDP22
N-dodecyl-P-(1-hydroxy-2-oxopiperidin-3-yl)phosphonamidic acid (17a). To a solution of
triphenylphosphine (96 mg, 350.59 mmol) in DCM (4 mL), DIAD (68.17 μL, 350.59 mmol) were
added with stirring at 0°C for 30 min. Separately, a solution containing BnHEX (50 mg, 175.29
mmol), dodecylamine (74.69 μL, 350.59 μmol), and DBU (52.33 μL, 350.59 mmol) in DCM (1
mL) was prepared and added dropwise to the betaine solution. The reaction mixture was allowed
to warm to room temperature over 30 minutes. The crude mixture was evaporated and the resulting
yellowish solid triturated with MeCN multiple times to obtain the pure title compound. Yield: 44.1
mg (55%) 1H NMR (300 MHz, CDCl3) δ 7.37-7.44 (m, 5H), 3.55-3.63 (m, 2H), 2.85-2.93 (m,
4H), 2.12-2.17 (m, 1H), 1.96-2.03 (m, 2H), 1.76-1.81 (m, 2H), 1.56-1.66 (m, 2H), 1.41-1.51 (m,
2H), 1.18 (m, 36H), 0.79-0.83 (t, J=6.0 Hz). 31P NMR (121 MHz, CDCl3) δ 31.14 (1P), 22.54 (1P).
N-dodecyl-P-(1-hydroxy-2-oxopiperidin-3-yl)phosphonamidic acid (CDP22). Following the
procedure G3, the following quantities were used: 17b (44.1 mg, 97.22 µmol), MeOH (3 ml), THF
(2 ml). Yield: 32.1 mg (92%). Analysis by ESI+ (Expected [M+H]+ = 363.24. Observed [M+H]+
=362.98). 1H NMR (300 MHz, CDCl3) 3.55-3.63 (m, 2H), 2.85-2.93 (m, 4H), 2.12-2.17 (m, 1H),
1.96-2.03 (m, 2H), 1.76-1.81 (m, 2H), 1.56-1.66 (m, 2H), 1.41-1.51 (m, 2H), 1.18 (m, 36H), 0.790.83 (t, J=6.0 Hz).13C NMR (75 MHz, CDCl3) 167.23 (s, 1C), 50.66 (s, 1C), 42.54 (s, 1C), 39.97
(s, 1C), 32.88 (d, J = 7.5 Hz, 1C), 31.93 (s, 2C), 29.25-29.70 (m, 12C), 29.02 (s, 1C), 27.74 (s,
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2C), 26.78 (s, 2C), 23.44 (s, 1C), 22.70 (s, 2C), 14.12 (s, 2C).
31.14 (1P), 22.54 (1P).
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31P

NMR (121 MHz, CDCl3) δ

CHAPTER 4. NITROHETEROCYCLE PRODRUGS OF AN ENOLASE
INHIBITOR EXHIBIT INCREASED POTENCY UNDER HYPOXIC
CONDITIONS
A continuation of Case Study 1.
This chapter has been published in (permission granted)
Yan VC, Yang KL, Ballato ES, Khadka S, Shrestha P, Arthur K, Georgiou DK, Washington M, Tran T,
Poral AH, Pham C-D, Yan MJ, Muller FL. 2020. Bioreducible Phosphonoamidate Pro-drug Inhibitor of
Enolase: Proof of Concept Study. ACS Med Chem Lett 11:1484–1489.

4.1 Abstract
Glycolysis inhibition remains aspirational in cancer therapy. We recently described a promising
phosphonate inhibitor of enolase for cancers harboring homozygous deletions of ENO1. Here, we
describe the application of a nitroheterocycle phosphonoamidate pro-drug pair to capitalize on
tumor hypoxia. This bioreducible prodrug exhibits greater-than 2-fold potency under hypoxic
conditions compared to normoxia and exhibits robust stability in biological fluids. Our work
provides strong in vitro proof-of-concept for using bioreduction as a prodrug delivery strategy in
the context of enolase inhibition.

4.2 Hypothesis
Nitroheterocycle promoieties are viable first promoieties on phosphonate drugs that are
preferentially removed under low oxygen conditions.

4.3 Introduction
GBM is a highly aggressive form of brain cancer, with few patients surviving beyond 2.5 years
(135). Targeting vulnerabilities in cellular metabolism represents a promising, emergent strategy
in precision oncology. We previously described one such vulnerability in glycolysis, in which the
gene encoding for the enzyme enolase, ENO1, undergoes homozygous deletion in a subset of
GBMs (4, 5). Cancers harboring the homozygous deletion ENO1 remain metabolically active and
viable through redundant action of its paralogue, ENO2. Inhibition of ENO2 in ENO1-deleted
cancers results in cancer-specific killing, leaving non-malignant tissue unperturbed (6, 29).
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A central challenge to developing a
therapeutically relevant enolase inhibitor
concerns the highly polar nature of
glycolysis metabolites, resulting in highly
polar inhibitor structures. To this end, we
recently reported the design and synthesis of
a phosphonate-containing ENO2-inhibitor,
termed “HEX” (29) Because phosphonates
are negatively charged at physiological pH,
a

pivaloyloxymethyl

derivative,

(POM)

“POMHEX,”

was

prodrug
initially

synthesized to improve cell permeability
(29). While POMHEX shows excellent,
preferential potency against ENO1-deleted
cells in vitro and can eradicate ENO1deleted tumors in preclinical murine models,
it suffers from poor pharmacokinetics.
Rapid, extracellular cleavage of the first
POM group by high concentrations of
carboxylesterases exposes the negatively
charged

phosphonate

monoester—

reintroducing cell and BBB permeability

Scheme 3. Bioactivation and synthesis of
bioreducible phosphonoamidate pro-drugs. (A)
Mechanism of bioactivation. (B) Reaction
conditions: 1.) BnNH2, DBU, PPh3/DIAD (2 equiv.
ea.), 1 h, 2.) POMCl (1.5 equiv.), MeCN, 50°C, 1
h, 3.) H2, 10% Pd/C, THF/MeOH, 2 h. (C) Reaction
conditions: 1.) BnNH2, DBU, PPh3/DIAD (2 equiv.
ea.), 1 h 2.) H2, 10% Pd/C, THF/MeOH, 2 h, 3.)
Ac2O, MeCN, 50°C, 1 h, 4.) 2-(bromomethyl)-5nitrofuran (2 equiv.), MeCN, 50°C, 12 h. For full
synthesis procedures, see Section 4.6.

issues (29).

The most optimal prodrug delivery system avoids premature extracellular cleavage and enables
selective release of the active agent within the tumor. A common feature of many tumors,
especially GBM, is the presence of highly hypoxic regions (136) in which median oxygen levels
may be as low as ~2%, as compared to ~7% in normal tissue (137). At present, hypoxia is
visualized clinically using agents such as 18F-AZA and histologically via pimonidazole (138, 139).
Common to both probes is the inclusion of a nitroaromatic moiety, which can be reduced under
hypoxic condition through nitroreductases (NADH dehydrogenases), to reveal the active agent
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(140). Taking the necessity for two pro-drug groups to protect phosphonate drugs into account,
were herein provide proof-of-concept for the feasibility of using both a nitroaromatic and
benzylamine moieties for delivery of a phosphonate glycolysis inhibitor (Scheme 3).

4.4 Results and Discussion
The polyprotic nature of phosphates warrants the attachment of two prodrug protecting groups for
efficient cell permeation. While nitroreductases can facilitate the removal of the first prodrug
moiety, hydrolysis of the second pro-drug is limited to enzymes that can tolerate the presence of
an anionic substrate. We recognized phosphoramidases (97) as a class of enzymes fulfilling this
requirement and thus sought to synthesize mixed phosphonoamidate esters. To the best of our
knowledge, the only similar example in the literature of a similar pro-drug is the alkylating agent
TH-302 (141, 142), wherein nitrogen mustards and nitroimidazole moiety are attached to the
phosphate to form the bioreducible phosphoramidate. However, where the active alkylating agent
of TH-302 preserves the P-N phosphoramidate bond, we sought to generate a labile amine prodrug so that the active enolase inhibitor may be released. The most prominent example in the
literature using phosphoramidases for prodrug bioactivation is the McGuigan (ProTide®) prodrugs
(118), which use N-linked amino acid alkyl esters in phosphate/phosphonate nucleotide analogues.
Another example of a phosphoramidase-labile pro-drug is the liver-specific anti-viral nucleotide
IDX-184 (97), in which the phosphate is protected by both a thioester and a benzylamine. Due to
the interdependent bioactivation mechanism of the amino acid ester the context of glioma cells.
Given that IDX-184 is a liver-specific anti-viral pro-drug (132), it was initially unclear whether
benzylamine would be an effective delivery moiety in the context of glioma. We thus began our
study by preparing a cell-permeable, esterase-labile phosphonoamidate pro-drug (Scheme 3b,
FLM37) and examining its efficacy as a pro-drug moiety in vitro.

Benzyl-protected HEX (BnHEX), was prepared according to previously published procedures
(29). First, BnHEX was coupled with benzylamine using a novel mono-amidation procedure we
developed (129) to generate the intermediate phosphonoamidate (Scheme 3b). To establish the
efficacy of using benzylamine as a pro-drug moiety in the context of glioma cells, we first
generated the esterase-labile POM ester through reaction with the free phosphonoamidate
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intermediate (Scheme 3b, step 2). Finally, we performed reductive hydrogenation to liberate the
hydroxamate, generating the POM/benzylamine test compound (Scheme 3b, FLM37).

Figure 24. Benzylamine is a viable pro-drug group in the context of glioma. (A) Proposed mechanism of
bioactivation for FLM37. (B). Proliferation assay comparing the activity of FLM37 (bottom) to the esterase
prodrug POMHEX (middle) and the free phosphonate HEX (top) in vitro. Cells were incubated with inhibitor
for 5 days before being fixed, stained with crystal violet and quantified spectroscopically at 590 nm. Cell
density is plotted as a function of inhibitor concentration. FLM37 exhibits more than 30-fold greater potency
compared to HEX, indicating the ability for glioma cells to cleave benzylamine.
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We and others have documented the ability for the POM group to undergo rapid hydrolysis by
ubiquitously expressed esterases in cells (29, 143). Thus, we can infer that the predominant in vitro
potency effects observed from FLM37 treatment arise from the lability of benzylamine (Figure
24a). Congruent with our general therapeutic framework, we tested FLM37 on a panel of 3 cell
lines: D423 (ENO1-deleted), D423 ENO1 (ENO1 overexpressing), and LN319 (WT control).
Cells were treated with FLM37 for 5 days. FLM37 demonstrated select toxicity against ENO1deleted cells in the nanomolar range, indicating the ability for benzylamine to be cleaved in glioma
cells to release the active ENO2 inhibitor, HEX (Figure 24b). Compared to the esterase pro-drug
POMHEX, FLM37 exhibited less potency against ENO1-deleted cells but was still significantly
more potent compared to the free phosphonate, HEX (Figure 24b).
Having established the feasibility of using benzylamine as a second pro-drug group, we then
sought to synthesize the nitroaromatic phosphonoamidate prodrugs. Returning to the benzylprotected phosphonoamidate intermediate (Scheme 3c), we performed reductive hydrogenation to
remove the benzyl ether on the hydroxamate; this was then re-protected with an acetyl group.
Though circuitous, we found these deprotection-reprotection steps to be necessary due to the
incompatibility of hydrogenation with the nitroaromatics. Due to the nucleophilic nature of the
hydroxamate, direct reaction with the nitroaromatics was not possible without addition to the
hydroxamate.

To examine the relationship between standard reduction potential and sensitivity to hypoxia, we
compared the nitrofuran phosphonoamidate pro-drug (Scheme 3c, VCY15) to TH-302, a
nitroimidazole-containing alkylating agent known to exhibit greater potency under hypoxic
conditions (144). VCY15 was prepared by simple Sn2 reaction with the phosphonoamidate
intermediate and 2-(bromomethyl)-5-nitrofuran (Scheme 3c). Previous studies have shown that
nitroreductases facilitate the removal of nitroaromatics under hypoxic conditions through a 4electron reduction mechanism (140). It thus followed that the ease of reduction between VCY15
and TH-302 would depend on the standard reduction potentials of the nitroheterocycles. We
hypothesized that the fold-change in potency between normoxic and hypoxic conditions would
correlate with the standard reduction potentials of the nitrofuran and nitroimidazole, respectively.
Nitrofurans have been reported to have a standard reduction potential of -257 mV (145) while
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nitroimidazoles have a reported standard reduction potential of -398 mV (145). Accordingly, both
VCY15 and TH-302 would show improved potency under low oxygen conditions, with the latter
exhibiting a more dramatic potency increase under hypoxia.

Figure 25. Nitroaromatic benzylamine pro-drug exhibits greater potency under hypoxic
conditions. (A) VCY15 contains a bioreducible nitrofuran pro-drug moiety that exhibits greater
potency at 1% O2 against a panel of 3 glioma cell lines. In contrast, POMHEX exhibits a decrease in
potency at 1% O2 across the same set of cell lines. (B) Representative plates for cells treated with
VCY15 at 21% O2 and 1% O2 after a 5-day treatment course. (C) IC50 values for cells treated with
either POMHEX, TH-302, or VCY15 and corresponding fold-changes for ENO1-deleted cells (n=4).
Bioreducible pro-drugs increase in potency at 1% O2.

To test this hypothesis, we performed in vitro cell culture experiments under both normoxia (21%
O2) and hypoxia (1% O2). We note that while the physiological oxygen concentration (“physioxia”)
is about 7% O2 (146), we saw no significant difference in cytotoxicity measurements between 21%
O2 and 7% O2 (Figure 25). All three compounds were tested against the same three cell lines
aforementioned. Cells were incubated with either VCY15, TH-302 (positive control), or POMHEX
(negative control) at 21% O2 or 1% O2. After 5 days, cells were then fixed, stained with crystal
violet, and quantified spectroscopically. As anticipated, VCY15 showed selectivity for D423 cells,
indicating selective inhibition of enolase through release of the active agent, HEX. Importantly,
VCY15 also showed markedly improved potency under hypoxic conditions compared to
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POMHEX, which contains no bioreducible moieties (Figure 25a-c). At 21% O2, VCY15 showed
an average an IC50 of 299 nM and 136 nM at 1% O2 against D423 cells. Concurrent with our
predictions, the potency changes from normoxia to hypoxia correlated with the standard redox
potentials of each nitroaromatic pro-drug. From 21% to 1% O2, VCY15 (nitrofuran) exhibited a 2fold increase in potency against D423 cells while TH-302 exhibited an 8-fold increase in potency
against the same cell line (Figure 25c). In support of the hypoxia-mediated activation for VCY15,
we found that POMHEX exhibited a 2-fold decrease in potency at 1% O2 compared to normoxia.

It is generally understood that sensitivity to
glycolysis inhibition should increase under
hypoxia (147), as capacity for ATP
production by oxidative phosphorylation
decreases. However, as ENO2 is a HIFtranscription factor that is inducible by
hypoxia (147), it is highly upregulated
under low oxygen conditions. Prior studies
have shown that, compared to ENO1 which
exhibits a 2-fold increased induction under
hypoxia, ENO2 exhibits a greater-than-5fold increase across a broad panel of glioma
cell lines (147). As the sensitivity of ENO1deleted cells to Enolase inhibition is
dependent on residual ENO2 activity (4),
upregulation of ENO2 under mild hypoxic
conditions paradoxically decreases the

Figure 26. Nitroaromatic benzylamine prodrugs exhibit robust stability in human plasma.
31
P NMR scans (121 MHz) of esterase-labile prodrug, POMHEX (left, red) and VCY15 (right, blue)
were taken in 80% human plasma with 20% D2O
for signal lock; ns = 1000. Where POMHEX
degrades to its hemi-ester form after 4 hours,
VCY15 remains stable for over 22 hours.

sensitivity of ENO1-deleted cells to Enolase
inhibitors. Within this context, the sensitivity of ENO1-deleted cells to VCY15 is thus particularly
impressive. That sensitivity to VCY15 is increased at 1% O2 while that of POMHEX is decreased,
suggests that the net increase in nitrofuran pro-drug bioactivation from 21% O2 to 1% O2 is actually
higher than the 2-fold inferred by the IC50 shift alone. Combined, these results suggest a correlation

79

between cytotoxicity and pro-drug sensitivity to O2; this corresponds with earlier studies on
various nitroaromatic derivatives conjugated to alkylating agents (148) or radiosensitizers (149).

Finally, we sought to examine the stability of these nitroheterocycle pro-drugs in human plasma.
We reasoned that VCY15 should experience little to no degradation, as nitroreductases are found
exclusively within the cell and intracellular phosphoramidases require the presence of a negative
charge for hydrolytic activity. To examine stability, we assayed VCY15 at various timepoints in
human plasma using

31P

NMR (Figure 26). In sharp contrast to POMHEX, which begins to

hydrolyze to its monoester form in less than 30 minutes (Figure 26, left), all nitroheterocycle
prodrugs were stable for over 22 hours (Figure 26, right), as indicated by a constant peak at ~32
ppm.

4.5 Conclusions
We have prepared a bioreducible prodrug inhibitor of enolase containing a nitrofuran and
benzylamine that confers improved specificity and stability towards cancer cells. Our data suggest
that this delivery mechanism may be specific to tumors, in which extended hypoxia is a unique
characteristic (45). Further in vivo studies are ongoing. While nitroaromatic prodrugs have
previously been reported in other drug delivery contexts, this combination of a nitroaromatic and
benzylamine is, to the best of our knowledge, the first of its kind. Benzylamine has previously
been reported to be a suitable pro-drug substrate for phosphoramidases in the context of liver
diseases (150), however, its efficacy in the context of GBM has not been disclosed in the literature.
Our laboratory is actively investigating the tunability of the nitroaromatic prodrug in relation to its
hypoxia sensitivity. Preliminary data have shown that nitrothiophene pro-drug (standard reduction
potential of -277 mV (145)) and nitroimidazole phosphonoamidate pro-drugs of HEX are also
hypoxia-labile moieties. Initial comparison between VCY15 and the nitrothiophene and
nitroimidazole derivatives concur with our observed relationship between standard reduction
potential and fold-change in potency between normoxic and hypoxic conditions (151). Given the
challenge of synthesizing this class of compounds, further optimization and in vitro assessments
are ongoing.

4.6 Experimental
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General synthetic procedures. All solvents and reagents were purchased from Sigma-Aldrich at
the highest commercially available purity and were used without further purification. 1H, 13C, and
31P

NMR spectra were recorded on a Bruker Avance 500 MHz or 300 MHz spectrometer, as

indicated. BnHEX was initially synthesized according to previously published procedures (29);
subsequent syntheses were contracted to WuXi AppTec, Shanghai, China. Final compounds were
purified via HPLC (Phenomenex Luna-C18. 0-3 min 10% Buffer B, 21-24 min 100% Buffer B,
27-30 min, 10% Buffer B; Buffer A= H2O + 0.1% TFA, Buffer B= MeCN + 0.01% TFA). See
Scheme 3 for a representative synthesis scheme.

Cell viability assay. Cell culture experiments were performed using the D423-MG cell line. The
D423-MG cell lines is 1p36 homozygous deleted from CAMTA1 to SLC25A33; this includes ENO1.
Isogenic ENO1 ectopically rescued lines were described previously (pCMV ENO1 5X) (4).
An ENO1-intact cell line (LN319) was used as a control for sensitivity to enolase inhibitors. Cells
were regularly cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum. Cell viability was determined by crystal violet staining, as previously described (6,
29, 134, 152) .The cell lines used were D423 (ENO1-deleted), D423 ENO1 (overexpressing ENO1)
and LN319 (control). Glioma cells were seeded in 96-well plates and treated with varying
concentrations of the inhibitors described above for 7 days. Cells were then washed with PBS,
fixed with 10% formalin and stained with 0.05% crystal violet. Washed and dried plates were dyeextracted using 10% acetic acid, and absorbance was measured at 595 nm using Omegastar Plate
Reader (BMG Labtech). To test the efficacy of the synthesized under hypoxic conditions, 1 x
104 cells were plated in 96-well plates, treated with inhibitor and incubated for 3 days in a hypoxia
station (Don Whitley Scientific, Shipley, UK) set at 1% O 2 and 5% CO2. Crystal violet staining
was then performed as described above.

Synthesis of FLM37
N-benzyl-P-(1-(benzyloxy)-2-oxopiperidin-3yl)phosphonamidic acid (1). Intermediate 1 was prepared using
methods describes in Chapter 2 (129). To a solution of
triphenylphosphine (275.87 mg, 1.06 mmol) in DCM (15 mL),
DIAD (204.50 μL, 1.06 mmol) were added with stirring at 0°C
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for 30 min. Separately, a solution containing BnHEX (150 mg, 527.74 mmol), benzylamine
(115.18 μL, 1.06 mmol), and DBU (157.54 μL, 1.06 mmol) in DCM (2 mL) was prepared and
added dropwise to the betaine solution. The reaction mixture was allowed to warm to room
temperature over 30 minutes. Then, 1 volume of water was added to the crude mixture. After
vigorous shaking and partitioning via centrifugation (2 min at 4°C, 4000 rpm), the aqueous layer
was isolated and lyophilized to a clear solid. Analysis by ESI+ (C19H23N2O4P Expected
[M+H]+=375.38. Observed [M+H]+=375.35). 1H NMR (500 MHz, D2O) δ 7.32-7.53 (m, 10 H),
4.91-4.96 (m, 2H), 4.02-4.11 (m, 2H), 3.46-3.57 (m, 2H), 2.80-2.87 (dt, J=21.52 Hz, J=21.70 Hz,
1H), 2.07-2.13 (m, 1H), 1.92-1.98 (m, 2H), 1.72-1.79 (m, 1H).

13C

NMR (125.7 MHz, D2O) δ

167.97 (d, J=4.72 Hz, 1C), 141.25 (d, J=7.36 Hz, 1C), 134.52 (s, 1C), 129.92 (s, 2C), 129.15 (s,
1C), 128.73 (s, 2C), 128.60 (s, 2C), 127.59 (s, 1C), 127.00 (s, 1C), 75.54 (s, 1C), 50.11 (s, 1C),
45.28 (s, 1C), 43.64 (d, J=111.12 Hz, 1C), 22.33 (d, J=3.65 Hz, 1C), 21.65 (d, J=7.23 Hz, 1C). 31P
NMR (202 MHz, D2O) δ 20.91

(((Benzylamino)(1-(benzyloxy)-2-oxopiperidin-3yl)phosphoryl)oxy)methyl pivalate (2). To a solution of (1) (36.50
mg, 97.24 μmol) in anhydrous MeCN (1 mL), chloromethyl pivalate
(21.02 μL, 145.86 μmol) and DIPEA (2 μL, 11. 51 μmol) were
added. The reaction was allowed to stir for 15 h at 50°C. Then, the
crude mixture was concentrated under reduced pressure to a yellow oil and purified via reversephase HPLC (Agilent G1361A 1260 Infinity) using a stepwise gradient (5-90% Buffer B over 10
minutes, 90-100% Buffer B over 7 minutes, 100% Buffer B over 8 minutes, 100-5% Buffer B over
5 minutes; Buffer A: dH2O with 0.1% TFA, Buffer B: CH3CN + 0.1% TFA). The desired
compound was obtained after 10 minutes and lyophilized to a white powder. Analysis by ESI+
(C25H33N2O6P Expected [M+H]+ =490.51. Observed [M+H]+ =490.41). 1H NMR (500 MHz,
CDCl3) δ 8.81 (d, J=4.77 Hz, 1H), 8.24-8.27 (t, J=7.80, 7.87 Hz, 1H), 7.90-7.92 (d, J=7.99 Hz,
1H), 7.69-7.71 (t, J=6.44, 6.75 Hz, 1H), 7.33-7.40 (m, 5H), 5.61-5.68 (m, 2H), 4.90 (d, J=2.22 Hz,
2H), 4.64-4.80 (t, J=9.91, 9.91 Hz, 2H), 3.35-3.37 (m, 2H), 3.12-3.20 (dt, J=23.65 Hz, 1H), 2.092.15 (m, 1H), 1.94-2.05 (m, 2H), 1.69-1.75 (m, 1H), 1.18 (s, 9H). 13C NMR (125 MHz, CDCl3) δ
177.48 (d, J=7.39 Hz, 1C), 163.53 (d, J=4.81 Hz, 1C), 156.93 (d, J=4.22 Hz, 1C), 145.22 (s, 1C),
143.48 (s, 1C), 130.13 (s, 2C), 130.03 (s, 1C), 129.42 (s, 1C), 129.03 (s, 2C), 126.04 (s, 1C),
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125.18 (s, 1C), 81.58-81.64 (d, J=7.40 Hz, 1C), 76.40 (s, 1C), 43.73-44.77 (d, J=132.02 Hz, 1C),
43.05 (s, 1C), 22.43-22.47 (d, J=4.61 Hz, 1C), 21.91-21.94 (d, J=4.32 Hz, 1C); quaternary sp3
carbon not observed. 31P NMR (202 MHz, CDCl3) δ 29.81 (s, 1P), 29.11 (s, 1P) (isomers).
(((Benzylamino)(1-hydroxy-2-oxopiperidin-3yl)phosphoryl)oxy)methyl pivalate (3, FLM37). Palladium on
carbon (10 wt. %, 100 mg) was mixed with THF (2 mL) and MeOH (3
mL) with stirring. Hydrogen in a balloon was then allowed to flow
through the reaction for 1 minute with venting. Then, a second balloon
with hydrogen was added to the reaction and the mixture was allowed to stir and saturate with
hydrogen for 1 hour. Next, to a separate vial, (2) was dissolved in MeOH (2 mL) and injected into
the hydrogen-charged flask. The reaction stirred at room temperature for 1 hour. Then, the
palladium was filtered, and the reaction was concentrated under reduced pressure to a pale-yellow
oil. The crude product was purified via reverse-phase HPLC (Agilent G1361A 1260 Infinity) using
a stepwise gradient (1-60% Buffer B over 25 minutes, 60-100% Buffer B over 10 minutes, 100%
Buffer B over 5 minutes, 100-0% Buffer B over 1 minutes; Buffer A: dH2O with 0.1% TFA, Buffer
B: CH3CN + 0.1% TFA). Product-containing fractions were combined and lyophilized to a paleyellow solid. Analysis by ESI+ (C18H27N2O6P Expected [M+H]+ =399.40. Observed [M+H]+ =
399.35). 1H NMR (500MHz, CDCl3) δ 7.22-7.39 (m, 5H), 5.59-5.66 (dd, J=12.32Hz, 2H), 5.545.59 (ds, J=12.66Hz, 2H), 4.29-436 (t, J=11.71Hz, 2H), 4.25-4.32 (t, J=11.29Hz, 2H), 3.01-3.10
(dt, J=22.99Hz, 1H), 2.86-2.95 (dt, J=22.79Hz, 1H), 2.08-2.13 (m, 2H), 1.83-2.08 (m, 2H), 1.20
(s, 9H), 1.19 (s, 9H).

C NMR (125.7MHz, CDCl3) δ 177.26 (s, 1C), 177.23 (s, 1C), 160.33-

13

160.43 (d, 1.29Hz, 1C), 160.17-160.31 (d, J=2.96Hz, 1C), 139.94 (d, J=2.72Hz, 1C), 139.4-139.52
(d, 2.53Hz, 1C), 127.27-1128.70 (m, 5C), 81.26-81.45 (d, J-3.11Hz, 1C), 80.87-81.05 (d,
J=3.60Hz, 1C), 48.67 (s, 1C), 40.89-41.21 (d, J=31.86Hz, 1C), 26.81-26.90 (s, 3C), 21.43-21.85
(m, 2C). 31P NMR (202 MHz, CDCl3) δ 28.76 (s, 1P), 29.63 (s, 1P) (isomers)
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Synthesis of VCY15
N-benzyl-P-(1-hydroxy-2-oxopiperidin-3-yl)phosphonamidic
acid (4). A solution of 10% Pd/C (200 mg) in anhydrous
THF/MeOH (2:3) was stirred at 25C. A balloon of H2 was added
and the solution vented for 10 minutes. A second balloon of H 2 was
then added, and the solution stirred for 1 h. Then, this slurry was transferred to a vial containing
BnFLM38 (250 mg, 668 mmol) and was allowed to stir for 1 h. The reaction was filtered and
concentrated to a yellow oil. Analysis by ESI+ (C12H16N2O6P Expected [M+H]+=285.25 Observed
[M+H]+=285.30).

P-(1-acetoxy-2-oxopiperidin-3-yl)-N-benzylphosphonamidic
acid (5). To a solution of (4) (65 mg, 229 mol) in anhydrous MeCN
(500 uL), Ac2O (65 L, 668 mol) was added. The reaction stirred
for 3 h at 25C. Then, the reaction was concentrated and lyophilized
for 2 days. Analysis by ESI+ (C14H18N2O6P Expected [M+H]+=327.29 Observed [M+H]+=327.32).
13C

NMR (75 MHz, CDCl3) δ168.01 (s, 1C), 161.65 (d, J=6.32 Hz, 1C), 141.92 (d, J=6.96 Hz,

1C), 128.22 (s, 2C), 127.55 (s, 2C), 126.54 (s, 1C), 51.63 (s, 1C), 43.24 (s, 1C), 36.42-35.29 (d,
J=170.11 Hz, 1C), 25.48 (s, 1C), 25.14 (5.93 Hz, 1C), 22.13 (d, J=7.06 Hz, 1C). 31P NMR (121
MHz, CDCl3) δ 17.50 (s, 1P).
3-((benzylamino)((5-nitrofuran-2-yl)methoxy)phosphoryl)-2oxopiperidin-1-yl acetate (6, VCY15). To a solution of (5) (73
mg, 224 mmol) in anhydrous acetonitrile, 2-(bromomethyl)-5nitrofuran (138.26 mg, 671 mmol) were added. The reaction was
allowed to stir at 50C for 20 h. The solvent was then removed and
the reaction was purified via reverse-phase HPLC (1-60% Buffer B over 25 minutes, 60-100%
Buffer B over 10 minutes, 100% Buffer B over 5 minutes, 100-0% Buffer B over 1 minutes; Buffer
A: dH2O with 0.1% TFA, Buffer B: CH3CN + 0.1% TFA). Product-containing fractions were
combined and lyophilized to a yellow solid. Analysis by ESI+ (C19H22N3O8P Expected
[M+H]+=452.37. Observed [M+H]+=452.42). 1H NMR (300 MHz, CDCl3) 7.26-7.23 (m, 6H),
7.17-7.12 (d, J=3.82 Hz, 1H), 6.49 (d, J=7.12 Hz, 2H), 4.89 (m, 2H), 4.36 (d, J=3.22 Hz, 2H), 4.22
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(d, J=5.92 Hz, 2H), 3.62 (m, 2H), 3.04 (dt, J=23.40, 7.58 Hz, 1H), 2.13 (s, 3H), 1.96 (s, 2H), 1.18
(s, 2H).

13C

NMR (75 MHz, CDCl3) δ 170.19 (s, 1C), 167.26 (d, J=15.44 Hz, 1C), 153.35 (d,

J=9.55 Hz, 1C), 152.60 (s, 1C), 140.09 (d, J=2.07 Hz, 1C), 128.83-127.24 (m, 5C), 112.62-111.99
(m, 2C), 57.39 (s, 1C), 51.37 (s, 1C), 44.46 (s, 1C), 43.61 (d, J=62.07 Hz, 1C), 22.52 (d, J=6.32
Hz, 1C), 20.67 (d, J=2.58 Hz, 1C), 18.2 (s, 1C).
29.37 (s, 1P) (isomers).
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31P

NMR (121 MHz, CDCl3) δ 29.49 (s, 1P),

CHAPTER 5. PRODRUG IDENTITY INFLUENCES CELL- AND TISSUESPECIFIC LOCALIZATION
Part of this chapter has been published in (permission granted)
Yan VC, Butterfield HE, Poral AH, Yan MJ, Yang KL, Pham C-D, Muller FL. 2020. Why Great Mitotic
Inhibitors Make Poor Cancer Drugs. Trends in Cancer 6:924–941.

7.1 Hypothesis
The rate of prodrug removal is largely influenced by the expression of the corresponding prodrug
activating enzyme in a given tissue or cell type. Prodrugs will be preferentially activated in tissues
and cell types with high expression of prodrug activating enzyme.

7.2 Introduction
Two prodrug motifs dominate the landscape of FDA-approved drugs: bis-ester (Farquhar)
prodrugs (Section 1.2.1) and McGuigan prodrugs (Section 1.2.2). While alternative prodrugs
(Section 1.2.3) have been developed and explored, most have remained in preclinical development
(16); efforts on this front are nonetheless ongoing (16, 153). Amongst the phosph(on)ate prodrug
motifs that have been published, the most popular motif is the McGuigan prodrug; this is largely
due to the success of FDA-approved drugs such as SOF and TAF. In the latter case, the
development of TAF was seen as an improvement over its bis-ester predecessor, TDF (154). As a
result, the McGuigan prodrug motif has been applied to a number of phosph(on)ate-containing
drugs and molecules (117)—seemingly without serious consideration of whether such a strategy
is appropriate in the context of a given pathology. The prevalence of McGuigan prodrugs in
pathological contexts that would seem to disfavor such an approach (102) is perhaps illustrative of
how the phosph(on)ate prodrug field overlooks: 1.) the relationship between prodrug structure and
expression of the corresponding bioactivating enzyme(s) in the cell type of a given pathology and
2.) the PK properties of the intact prodrug and the effects of extracellular plasma enzymes on
prodrug metabolism. This oversight is exacerbated by modern (over)reliance and misconception
that cell culture models are reliable indicators of a phosph(on)ate prodrug’s efficacy in vivo. While
my critique on the over-application of McGuigan prodrugs serves as a convenient, modern, and
relevant example of some of the field’s oversights, it is not the only class of phosph(on)ate prodrug
that is illustrative of—what I perceive to be—a gap between chemists and biologists. In this section,
I briefly discuss 2 examples of different phosphate prodrugs indicated for 2 different diseases to
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illustrate the relationship between promoiety structure and cell- and tissue-specific metabolism
towards the active pharmacophore. These examples provide concrete insight into situations when
phosphate prodrugs work well and afford (a sufficient level) of specificity for the target cell
population. In the next chapter, I will describe a situation where scientific disregard of the
relationship between bioactivation of the McGuigan prodrug RDV and localization to the cell
population of interest results in suboptimal delivery of the active pharmacophore to the SARSCoV-2-infected pneumocytes. The seemingly contrarian rationale that I will present in the next
chapter with the RDV/GS-441524 paradigm is a foil to that of SOF, described here in Section 7.4.1.

7.3.1 Case Study 2: Cyclophosphamide achieves a therapeutic window through
preferential formation of the active metabolite in tumors versus normal tissue.
While conventional cytotoxic chemotherapies do not often receive much of a spotlight in an era
preferring molecular targeted therapies, chemotherapy can succeed sufficiently well to impart
clinically meaningful—if not even transformative results at times (155, 156). Combinations of
various chemotherapies have been central to cancer treatment, with a considerable number of
patients across a range of cancers being effectively cured by such combinations (157, 158). While
this is not well appreciated in the cancer research community, many key chemotherapeutic drugs
from diverse classes are prodrugs; their therapeutic windows arise from preferential bioactivation
in cancerous versus normal tissues. A classic and elegant example of this theme is captured by the
bioactivation of cyclophosphamide (Figure 27).

Cyclophosphamide is an intricate prodrug of a nitrogen mustard (159): the nitrogen derivative of
the sulfur mustards used during WWII. Direct application of nitrogen mustards to patients
suffering from cancer such as lymphomas and leukemias yielded hints of anti-neoplastic activity
in model systems and in the clinic (160–165), but intolerable adverse effects (156, 166–170)
precluded further clinical utility. Structurally, the severity of these adverse events may be
attributed to the electrophilic, aliphatic nature of the first clinically-deployed mustards (168–170).
To temper the indiscriminate toxicity of the aliphatic nitrogen mustard (Figure 24), a concerted
effort to reduce the electrophilicity of the mustard was made in the 1950s. It was then that the very
first pro-drug iterations of the nitrogen mustard arose, with the FDA approving chlorambucil in
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Figure 27. Cyclophosphamide mechanism of bioactivation. ALDH oxidizes the aldophosphamide
intermediate to a negatively charged carboxylate, which is inactive. In cancer cells lacking ALDH,
beta-elimination of the aldophosphamide occurs. A narrow therapeutic window between many rapidly
proliferating normal tissue and cancerous tissue arises from the presence versus absence of
ALDH(1A1).

1957. Unlike the previously administered aliphatic nitrogen mustards, chlorambucil contained an
aromatic pro-drug group, which reduced electrophilicity and—by extension—its reactivity with
DNA. More sophisticated efforts to modulate the reactivity of the mustard while increasing
specificity for tumors followed after the inception of perhaps the most iconic nitrogen mustard
pro-drug, cyclophosphamide. Cyclophosphamide is a DNA cross-linking agent that exhibits
selectivity for cancer cells over rapidly proliferating cells such as the bone marrow by exploiting
differences in aldehyde dehydrogenase (ALDH) expression to yield a narrow but sufficient
therapeutic window to impart its therapeutic effects (171). The mechanism of bioactivation begins
with hydroxylation of the carbon alpha to the amine by cytochrome P450 in the liver to generate
the carbinolamine. The instability of this pseudo-enol renders its hydrolysis and subsequent
tautomerization to the aldophosphamide species. Because many cancer cells exhibit diminished
expression of ALDH1A1 (172–175) they are unable to oxidize the free aldehyde to the
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corresponding carboxylate. In normal tissue and especially stem cells, high expression of
ALDH1A1 (172) (and consequent conversion to the anionic carboxylate prevents effectively
nullifies the acidity of the proton on the alpha carbon, thereby preventing beta-elimination (which
is favored in a Lewis basic environment which may also be favored in cancer cells) and subsequent
trapping of the phosphoramide mustard in cells. In contrast, this oxidation of the free aldehyde is
diminished in cancer cells due to downregulated ALDH. Trapping of the aldophosphoramide
mustard and beta-elimination to yield active nitrogen mustard are thus sufficiently cancer-specific
to yield a narrow therapeutic window between prolific normal and cancerous tissue. Sufficient
target-specific killing is contingent upon loss of ALDH expression in cancer, allowing activation,
but retention of ALDH in stem cells, yielding protection (173). Contrary to the non-specific
characteristic of rapid rates of proliferation, lowered ALDH expression is an attribute specific to
cancer cells. This leaves many rapidly proliferating, non-malignant cells unperturbed. Cells
expressing high levels of ALDH, such as bone marrow-derived stem cells and skin cells, are able
detoxify the aldophosphoramide intermediate into the inactive carboxylate-cyclophosphamide
species (58, 59).

7.3.1 Case Study 3: Sofosbuvir is an orally administered McGuigan prodrug
for the treatment of HCV.
As introduced in Section 1.5, SOF is an iconic, orally administered prodrug nucleotide analogue
of the McGuigan class that is FDA-approved for the treatment of HCV (42). The active NTP of
SOF is a UTP analogue; the nucleoside of SOF is a uracil analogue. While the active nucleoside
triphosphate (NTP) is a somewhat potent inhibitor the NS5B polymerase, with a K i of 0.42 ± 0.04
µM (14, 60, 61), the nucleoside of sofosbuvir (RO2433, uridine analogue) is inefficiently
phosphorylated by intracellular nucleoside kinases (deoxycytidine kinase dCK, uridine kinase
UCK, or thymidine kinase TK) to the corresponding monophosphate (Figure 9) (61). As described
in Section 1.2.2, McGuigan prodrugs such as SOF are bioactivated through CES1/CTSA and
HINT1, which are highly expressed in the liver (Figure 9). Because SOF is administered orally
and must go through first pass metabolism through the liver, there is high hepatic extraction of
intact SOF; its McGuigan promoieties are quickly removed and the resulting nucleoside
monophosphate is trapped within hepatocytes (65). The monophosphate is then subject to
phosphorylation by nucleotide kinases to the active triphosphate inhibitor; alternatively, it could

89

be dephosphorylated to the inactive nucleoside (RO2433), which can diffuse out of the cell and
into circulation (33, 34, 88). Inactivation of the intact prodrug to the parent nucleoside RO2433 is
essentially innocuous to visceral organs for two reasons: 1.) the majority of SOF undergoes rapid
hepatic extraction (65, 88) and 2.) the parent nucleoside is very inefficiently metabolized to the
corresponding monophosphate (14, 60) For a liver-specific pathology such as HCV, this paradigm
is ideal as any remaining release of RO2433 is essentially innocuous due to its inability to be
efficiently converted to the bioactive NTP in visceral organs.
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CHAPTER 6. GS-441524 IS THE PARENT NUCLEOSIDE OF
REMDESIVIR WITH MORE FAVORABLE PHARMACOKINETIC
PROPERTIES FOR COVID-19 TREATMENT
A foil to sofosbuvir
Part of this chapter has been published in (permission granted)
Yan VC, Muller FL. 2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid19 Treatment. ACS Med Chem Lett 11:1361–1366.
Yan VC, Muller FL. 2020. Captisol and GS-704277, but not GS-441524, are credible mediators of
remdesivir’s nephrotoxicity. Antimicrob Agents Chemother 64:01920–1920.

8.1 Abstract
While RDV has garnered much hope for its moderate anti-COVID-19 effects, its parent nucleoside,
GS-441524, has been overlooked. Pharmacokinetics analysis of RDV evidences premature serum
hydrolysis to GS-441524 (41, 67, 85); GS-441524 is the predominant metabolite in circulation,
following IV administration of RDV. In contrast to RDV, which is a McGuigan prodrug (Section
1.2.2) that is preferentially bioactivated in tissues such as the liver, GS-441524 is activated by
enzymes that are broadly expressed in all tissue types and exhibits an excellent safety profile (66,
89, 92, 176, 177). Given the pneumocyte-centric nature of COVID-19, we contend that GS-441524
is superior to RDV due to its synthetic simplicity (35, 66, 73) , in vivo safety and efficacy, and
ability to be administered orally.

8.2 Hypothesis
In contrast to RDV, GS-441524 is bioconverted by enzymes that are broadly expressed across celland tissue-types in the body, including the pneumocytes. Thus, direct administration of GS-441524
would be more effective than RDV due to its safety and distribution profile in vivo.

8.3 Introduction
RDV has been FDA-approved for the treatment of COVID-19 (38) on the basis of one
NIH/NIAID-sponsored placebo controlled, randomized control trial (RCT; ACTT-1 Trial)
demonstrating a reduction in average hospitalization time from 15 days to 11 days in patients with
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severe COVID-19 (178). However, preliminary results from a larger RCT (not placebo-controlled)
conducted by the WHO (Solidarity Trial) have thus far not found a significant difference in
mortality between patients treated with RDV versus local standard-of-care (SOC) (179); it should
be noted that the primary endpoints of ACTT-1 and Solidarity are different. Nonetheless, these
preliminary results from the Solidarity Trial have caused many to question the efficacy of RDV
(180). These issues have been exacerbated by RDV’s obligatory IV administration requiring an
inpatient setting (38), inability to be dosed higher due to liver and kidney-related DLTs (181, 182),
and difficult synthesis (35, 77, 183)—all of which hamper its broad translational applicability.

We recently described in a general audience publication the advantages that the parent nucleoside
of RDV, GS-441524, has over remdesivir itself for the treatment of COVID-19 (90). Investigation
into the metabolism of remdesivir evidences premature serum hydrolysis of its phosphate prodrug,
followed by dephosphorylation. As a result, the major metabolite circulating in the bloodstream is
the parent nucleoside, GS-441524, even though RDV (monophosphoramidate prodrug) was the
species initially administered. Accounting for this broader pharmacokinetic (PK) rationale, we
herein provide a detailed analysis of the literature that supports the use of GS-441524 over
remdesivir for the treatment of COVID-19.

8.4 Results and Discussion
8.4.1 The phosphate prodrug on remdesivir is not intended for pneumocyte-specific delivery.
Remdesivir is a structural analogue of adenosine monophosphate (AMP) that interferes with the
SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) (78). The anionic phosphate moiety on
remdesivir is masked by McGuigan prodrug moieties (117), (phenol and L-alaninate ethylbutyl
ester, Section 1.2.2) to enhance cell permeability. In principle, these prodrug moieties would be
removed intracellularly—first by esterases (cathepsin A/carboxylesterase 1) and then by
phosphoramidases (HINT1) (32) to release the monophosphorylated nucleotide. This would then
be phosphorylated twice to give the active NTP (32, 78) (Figure 26), which is substratecompetitive with ATP for incorporation by viral RdRp and inhibition of viral RNA synthesis via
chain termination at the i+3 position (78) or via template-dependent inhibition (79).

The

McGuigan phosphate prodrug was partly developed to overcome the perceived rate-limiting first
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Figure 28. McGuigan prodrugs on remdesivir are preferentially bioactivated in the liver. (A)
Labile prodrug moieties on remdesivir with corresponding bioactivation enzymes. (B) Relative tissue
mRNA expression of initial prodrug bioactivating enzymes for RDV (CES1/CTSA/HINT1) adapted
from the HPA dataset on the Human Protein Atlas reported as median-centered protein-coding
transcripts per million (pTPM). Overall, McGuigan prodrug bioactivating enzymes are more highly
expressed in the liver than in the lungs. (C) Immunohistochemistry (IHC) images from the Human
Protein Atlas indicating expression for ProTide bioactivating enzymes. Brown regions indicate
enzyme expression while blue regions indicate absent expression. For the lung, pneumocytes—cells
frequently infected by COVID-19—are characterized by a threadlike appearance. Expression in the
liver is generally higher compared to lung for all enzymes. For CTSA, darkly stained regions are
associated with macrophages. IHC images for the skin are included to show lack of enzyme expression.

phosphorylation step towards the active tri-phosphorylated species (184). Bioactivation of the
prodrug first involves CSE1 and CTSA, followed by HINT1 (Figure 10) (32, 131, 185). Protein
expression data from the Human Protein Atlas show that these enzymes (CES1, CTSA, HINT1-3)
all have high expression in the liver, with minimal expression in alveolar type 2 (AT2) in the lung
(186) (Figure 26). For the HINT family of phosphoramidases, there is some slight variation in
each isoform’s tissue-specific expression (Figure 26b, c); however, all 3 isoforms show high
expression in the GI tract, liver, and kidneys. From the pattern of bioactivation for McGuigan
prodrugs, it follows that the most significant accumulation active NTP will be in cell types with
high expression of CES1/CTSA/HINT1-3, such as the liver. Preferential bioactivation of

93

McGuigan prodrugs such as remdesivir could explain the Grade 3/4 adverse events related to liver
and kidney damage in COVID-19 patients treated with remdesivir (187) and grade 2 elevations of
ALT/AST in healthy human volunteers treated with 150 mg of RDV daily for 7 or 14 days (41).
Seeing that the enzymes involved in McGuigan prodrug hydrolysis are hardly expressed in the
lungs undermines its utility in the context of a primarily respiratory disease such as COVID-19.

8.4.2 GS-441524 is the predominant metabolite in the bloodstream when remdesivir is
administered IV.
Hydrolytic enzymes are ubiquitous in serum (188). This is one physiological factor that, especially
for prodrugs (189), prevents direct extrapolation of bioactivation mechanisms observed in vitro to
the in vivo setting. For example, esterases and phosphatases are abundantly present in serum across
species (30, 190). Premature serum hydrolysis of the McGuigan prodrug on RDV is thus
unsurprising (Figure 10b). Multiple studies have demonstrated that the nucleoside, GS-441524,
is the predominant species in serum after RDV is administered (Figure 10b, c) (39, 40, 82) . All
studies that have investigated the PK of RDV in non-human primates (NHP) have concluded that
intact RDV exhibits a short plasma half-life of about 0.4 hours in serum, with “persistence” of the
downstream nucleoside, GS-441524 (Figure 10c) (40, 82). IV injection of remdesivir in NHP
results in GS-441524 being present in serum at concentrations 1,000-fold higher than RDV
throughout a 7-day treatment course (40) (Figure 10b). This recurring phenomenon can first be
explained by the abundance of plasma esterases, as the phosphoramidases (HINT1) involved in
removal of the L-alanine have a strictly intracellular presence (see Human Protein Atlas HINT1).
Inadvertent biotransformation of remdesivir to GS-441524 can be explained by the following
sequence: 1.) esterase removal of the L-alaninate ester, 2.) intramolecular cyclization,
displacement of the phenolate, followed by re-opening of the ring, 3.) cleavage of the phosphate
ester by serum phosphatases or nucleosidases (Figure 10b). The proposed serum bioactivation
mechanism accounts for the general substrate constraints for each class of enzyme. For instance,
CES1 is named as one of the enzymes involved in McGuigan prodrug hydrolysis (32, 33).
However, this does not preclude other esterases from acting on its L-alaninate ester. A study
conducted by Sheahan and colleagues specifically investigated the PK of remdesivir in
carboxylesterase 1c deficient mice (Ces1c-/-) (39). Even in this Ces1c-/- model, the half-life of
remdesivir was still short (T1/2 ~25 minutes), supporting the notion that other esterases are capable
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of performing the initial hydrolysis reaction. Thus, the abundance of hydrolytic enzymes in serum
explains the persistent, multi-species observation that GS-441524 is the predominant metabolite
when remdesivir is administered (39, 40, 82). For the fleeting duration of time that remdesivir is
in the blood (prior to hydrolysis to GS-441524), the expression of bioactivating enzymes for
McGuigan prodrugs suggests that the highest concentrations of NTP formation by remdesivir—
rather than GS-441524—would occur in cell types with high expression of CES1/CTSA/HINT1.
This largely favors the liver over the lungs (Figure 28). Differential expression of prodrug
bioactivating enzymes likely explains the wide range of EC50 values with remdesivir in vitro (75,
84, 191). A study investigating the PK and tissue distribution of RDV following IV injection in
mice (20 mg/kg) found that the AUC0-t of RDV was approximately 5-fold higher in the liver
compared to the lungs, AUC0-t (last observable timepoint) of the monophosphate was
approximately 1,000-fold higher in the liver compared to lungs, and that the AUC0-t of the active
NTP was approximately 1.6-fold higher in liver compared to lungs (192). At first glance, it may
seem that formation of active NTP is only slightly higher in the liver compared to lungs; however,
it is important to consider that the AUC values were taken from T=0 to the last timepoint when the
species of interest was detected. GS-443902 (active NTP) has an intracellular T1/2 of over 35 h in
peripheral blood mononuclear cells (PBMCs) (193) and over 7 days in RBCs (Peter Anderson, CU
Boulder, personal correspondence). Considering that the T1/2 of GS-441524 is >24 h following IV
injection of RDV (41, 85) and that GS-441524 is capable of being converted to GS-443902 (81,
84, 92), the narrower gap between the concentration of active NTP in the liver versus lungs can
likely be explained by the formation of active NTP by GS-441524 in the lungs.

Finally, due to the exceedingly short T1/2 of RDV, the influence of duration of drug exposure to
the cell and tissue-types of interest is poorly modeled in cell culture-based experiments. In stark
contrast to the < 1 h systemic exposure to RDV in vivo, cells in culture are typically subjected to
48-72 h of continuous drug exposure (35, 75, 81, 84). A key experiment conducted by Wang and
colleagues inadvertently revealed the significance of duration of RDV drug exposure in vitro
through pulsed (2 h treatment with drug-containing media, then replace with fresh media and
incubate for 48 h) versus continuous treatment (drug-containing media for 48 h) in VeroE6 cells
infected with SARS-CoV-2 (194). Wang and colleagues showed that, in contrast to cells
continuously exposed to drug media where RDV showed inhibition of viral replication, no

95

inhibition of viral replication was observed in cells given pulsed treatment (194). These results
demonstrate the shortcomings of traditional cell culture experimental approaches when attempting
to extrapolate efficacy to the in vivo situation with phosph(on)ate prodrugs.

8.4.3 GS-441524 is exceptionally effective and well-tolerated against clinical presentations of
feline coronavirus.
There are currently no published studies that have compared the antiviral activities of remdesivir
and GS-441524 in vivo (see Section 8.4.4), with most focusing exclusively on remdesivir. Where
GS-441524 has been investigated in vivo is in the veterinary setting (176, 177, 195). Cats infected
with feline coronavirus (FCoV) present with a serious disease known as feline infectious peritonitis
(FIP). While long considered fatal in its severe manifestations (196), a study conducted by
Pedersen and colleagues showed that GS-441524 is capable of treating cats suffering from FIP
with a 96% cure rate (176). Pedersen noted the “impressive” safety profile of GS-441524, with no
systemic signs of toxicity observed when administered subcutaneously at 4 mg/kg (176). In a more
recent study, Pedersen and colleagues escalated the dose of GS-441524 (5-10 mg/kg) to treat
neurological manifestations of FIP; without accounting for species differences in drug absorption
this translates to about 350-700 mg in a 70 kg human, greatly exceeding the dose currently given
to patients treated with RDV(200 mg loading, then 100 mg) (187, 197). Even at these higher doses,
they found that GS-441524 treatment resulted in the long-term resolution of neurological FIP with
an excellent safety profile: minimal dose-related toxicities were observed (177).

8.4.4 GS-441524 and remdesivir are equally capable of reducing viral titers in the lungs in
pre-clinical models of SARS-CoV-2.
Gilead Sciences has shared data with us from a head-to-head comparison study between GS441524 and RDV in non-human primates (NHP; African green monkeys) infected with SARSCoV-2. NHP were treated IV with either RDV (10 mg/kg loading, then 5 mg/kg daily maintenance),
GS-441524 (7.5 mg/kg) or GS-441524 (20 mg/kg) for 6 days (N=6 per group). NHP were
sacrificed for PD examination in the lungs at 24 h and bronchial alveolar lavage (BAL) was
performed daily to measure viral titers in the upper airway by qPCR. GS-441524 at 20 mg/kg and
RDV were essentially equal in their abilities to reduce viral titers over 5 days. When administered
at 7.5 mg/kg/day, GS-441524 was less effective than RDV but was still able to reduce the viral
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titers to similar levels as RDV in 3/6 of the NHP (compared to 2/6 in untreated CT). No gross
observations were observed in any group. Another study by Li and colleagues examined the
efficacy of GS-441524 in mice transduced with an adenovirus associated virus (AAV) expressing
hACE2 and infected with SARS-CoV-2 (92); this is because mice are not susceptible to infection
via mouse ACE2. AAV-hACE2 mice administered 25 mg/kg/8 days GS-441524 IP demonstrated
100-fold reduction in viral titers at 2 days post infection (dpi) and maintained body weight
compared to untreated controls, highlighting its antiviral efficacy and safety. Both studies provide
in vivo proof-of-principle of the safety and efficacy of GS-441524 against SARS-CoV-2 in vivo.

Due to species differences in drug metabolism and absorption, Gilead had informed us that the
routinely used dosing schedule with RDV in NHP (10 mg/kg loading, then 5 mg/kg maintenance)
approximately translates to the recommended clinical dose in humans (200 mg loading, then 100
mg maintenance) (38). This is particularly intriguing because direct translation of the NHP dose
in a 70 kg human would result in a 700 mg loading, then 350 mg maintenance, which is evidently
prohibitive due to liver DLTs that have already been observed at repeated doses of 150 mg in
healthy human volunteers (41). We suspect that NHPs are capable of tolerating such a dose due to
reduced hepatic extraction of McGuigan prodrugs compared to that observed in humans; this is
because a 15-day study with RDV at 10 mg/kg (starting 3 dpi) did not result in elevations in
ALT/AST (67). PK analysis of RDV following rapid bolus injection in NHP also demonstrates
shows a slightly longer T1/2 in of the intermediate L-Ala metabolite (GS-704277) in plasma (67).
This species difference in drug metabolism between NHP and humans is important because it
likely explains the inability to dose RDV higher in humans, even with its questionable efficacy,
due to liver-related DLTs (41). Inability to dose higher results in the inability to increase
concentrations of both RDV and GS-441524—both of which are able to form active NTP (84).
The significance of increasing the concentration of GS-441524 has been alluded to in the cases
studies where patients with end-stage renal disease (ESRD) have been treated with RDV (86). To
offset the recommendation against using RDV in patients with severe kidney disease, Davis and
colleagues also performed hemodialysis on the 3 patients treated with RDV. All 3 patients
receiving RDV treatment also had other co-morbidities, such as hypertension and diabetes. While
the results from this study should be interpreted cautiously, it is interesting to note that, because
GS-441524 is renally excreted, these 3 patients with ESRD had Cmax concentrations of GS-441524
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in plasma between 5-10-fold higher than that reported in healthy human volunteers (86). Patient 3
achieved a 5 µM Cmax value of GS-441524 in plasma by day 5 of treatment, which is likely due to
accumulation of GS-441524 in plasma. Notably, all 3 patients successfully recovered even while
being part of populations with high morbidity rates (198). Again, such results are observational
but do warrant further investigations into increasing concentrations of active NTP in the
lungs/pneumocytes; this is possible with GS-441524 due to its safety profile (89, 176, 177), but
not with RDV because, again, it is hepatotoxic at higher doses (41).

8.4.5 GS-441524 has the potential to be administered orally
McGuigan prodrugs such SOF can be administered orally because the promoieties are intended to
be rapidly removed in the liver in the context of HCV; however, this is not the case for RDV and
COVID-19, in which RDV is supposed to facilitate the delivery of active NTP to the lungs (AT2
cells). High hepatic extraction of RDV by human hepatocytes (38, 41, 184) would result in
negligible amount of intact RDV that would survive first-pass metabolism to reach the target cell
population. As a result, oral administration of RDV is not feasible. In sharp contrast, GS-441524
is not susceptible to first-pass metabolism and hepatic extraction, making it amenable to oral
administration.

On August 20, 2020, we wrote and co-signed a letter with Public Citizen addressed to Drs. Francis
Collins (NIH Director), Anthony Fauci (NIH/NIAID), Stephen Hahn (FDA), Gary Disbrow
(BARDA), and Daniel O’Day (CEO, Gilead Sciences) to urge further investigation of GS-441524.
In response, Dr. Christopher Austin (Director, NCATS) wrote that NCATS finds the hypothesis
worthy of further investigation and that NCATS will conduct the necessary studies to support
clinical investigation of GS-441524 (199). As of December 11, NCATS has thus far performed
single dose safety and toxicity studies in mice, rats, dogs, and cynomolgus monkeys with GS441524 both IV and PO (Table 3). Range finding studies and confirmatory GLP toxicity studies
are currently ongoing (NCATS OpenData Portal).

It is striking to note the large variation in F% across preclinical species (Table 3). While GS441524 exhibits high oral bioavailability in dogs (85%), the oral bioavailability is significantly
lower in NHP (8.3%). These results are consistent with those later shared with us by Gilead (private
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communication). Systematic comparison of the oral bioavailabilities of various nucleoside
analogues generally show that dogs tend to overestimate whereas NHP tend to underestimate F%
in humans (200). High F% in dogs can likely be attributed to the presence of a paracellular
nucleoside transporter that is absent in other species such as humans and NHP (201). Low F% in
NHP may be explained by the tendency for gastrointestinal (GI) pH in NHP to be in the
neutral/slightly alkaline range for longer durations after food consumption compared to in humans
(202, 203). This key difference between NHP and humans, coupled with the absence of a
paracellular nucleoside transporter in NHP, could explain the general observation that NHP tend
to underpredict the F% of nucleoside analogues and other drugs in humans (204). Considerations
of GI pH in the context of species differences in drug absorption are particularly important for GS441524 due to its odd solubility properties. While GS-441524 is considerably more hydrophilic
than RDV, it is only soluble in water at acidic pH (pH < 1.5-2). At the same time, GS-441524 is
poorly soluble in most organic solvents, somewhat soluble in DMF and NMP (~2 mg/mL) and
readily soluble in DMSO. These rather odd solubility properties make considerations of species
differences in GI pH particularly important when evaluating the F% of GS-441524 in preclinical
species. Interestingly, the F% of GS-441524 are quite similar to the F% of acyclovir (Table 3 vs.
Table 4). These data collectively indicate that, while the oral bioavailability of GS-441524 is
unlikely to be as high as that observed in dogs, it will likely be higher than that projected by NHP.
GS-441524 IV*
Species
Mouse
Rat
Dog
Cynomolgus
monkey

GS-441524 PO**

Cmax
(ng/mL)

Tmax
(h)

AUC
(ng*h/mL)

T1/2
(h)

Cmax
(ng/mL)

Tmax
(h)

AUC
(ng*h/mL)

T1/2
(h)

F
(%)

4340

0.083

2540

3.3

582

1.5

2540

3.9

39

2703

0.083

2888

2.7

193

3.8

2170

3.4

33

4567

0.083

7588

4.0

6010

0.28

8320

4.1

85

4597

0.083

2775

2.4

59.3

2.0

734

7.7

8.3

Table 3. Oral bioavailability of GS-441524 and acyclovir across species. Single dose PK of GS441524 in preclinical species. Studies were conducted by NCATS. *IV doses: 5 mg/kg for mouse, rat;
2 mg/kg for dog, NHP. **PO doses: 10 mg/kg for mouse/rat; 5 mg/kg for dog, NHP.
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Species differences in oral bioavailability of acyclovir
Species

F%

Reference

Human

10-20

FDA (205)

Monkey

3.7

Laskin et al. Clin. Pharm. (1983) (206)

Dog

54-90

Kransy et al. J. Pharm. Exp. Ther. (1981) (207)

Table 4. Oral bioavailability acyclovir across species. Oral bioavailability of acyclovir in preclinical
species is similar to that for GS-441524.

8.5 Conclusions
While RDV has demonstrated some efficacy in patients with advanced COVID-19 (187), its
phosphate prodrug is fundamentally not designed for lung-specific delivery. Enzymes that activate
the McGuigan prodrug are preferentially expressed in tissues such as the liver (Section 1.2.2),
which results in uneven distribution of active NTP formation via remdesivir that disfavors the
pneumocytes. Practically, the structural complexity of the McGuigan prodrug (208) adds
unnecessary synthetic difficulty that hampers mass production and impedes distribution (209).
Above all else, premature hydrolysis of the McGuigan prodrug, followed by dephosphorylation in
serum such that GS-441524 is the predominant metabolite (39, 40, 82) compels studies
investigating its utility in patients with COVID-19. In contrast to the prodrug activating enzymes
that activate RDV, bioactivation of GS-441524 relies on expression of the kinase responsible for
initial phosphorylation (likely adenosine kinase, ADK). According to the Human Protein Atlas,
ADK is moderately expressed across all tissues, suggesting that administration of GS-441524
would result in even distribution across tissues. The remarkable safety profile of GS-441524,
indicated by selectivity indices in vitro (EC50/CC50 ratio) (35, 66, 75) and by clinical observations
in cats (176, 177, 195), suggest that higher dosing and pneumocyte NTP loading could be achieved
with GS-441524 without encountering serious adverse effects. GS-441524 is also a structurally
simple molecule that is easier to synthesize compared to RDV (35), which would ease mass
production and distribution. Especially amidst the documented premature serum hydrolysis of
remdesivir to GS-441524 (39, 40, 82), there are several advantages to using GS-441524 over
remdesivir for patients with COVID-19. Further investigations into the anti-COVID-19 utility of
GS-441524 are thus ongoing and imperative.
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8.6 Experimental
Tissue dependent expression of RDV bioactivating expression. Lung, liver, and skin (negative
CT) stained for CES1, CTSA, and HINT1-3 were compiled from the Human Protein Atlas; Patient
IDs are indicated in Figure 26. Antibodies used: CTSA (CAB024930), CES1 (HPA046717),
HINT1 (HPA044577).

Single dose IV and PO PK of GS-441524. Studies were conducted by NIH/NCATS and made
publicly available through the NCATS OpenData Portal
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